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ABSTRACT
Treatments for Candida albicans systemic infections are limited to three classes
of antifungals, some of which have harmful side effects or increasing instances of
antifungal resistance. These shortcomings illustrate a need for new antifungals.
The phosphatidylserine (PS) synthase, Cho1p, represents a potential drug target
that can address this need. Cho1p is involved in a major phospholipid
biosynthesis pathway and represents a novel drug target for three key reasons:
1) It is required for virulence, indicating that inhibitors of Cho1p would render the
organism incapable of causing infection; 2) it is absent in mammals, so inhibitors
potentially have no toxic side effects; and 3) the enzyme appears to be well
conserved across fungi, indicating that inhibitors could be broadly effective
against many fungal pathogens. In order to take full advantage of Cho1p as a
drug target, we performed several screens of small molecules for ones that
inhibit Cho1p. In one screen we identified SB-224289 that seems to act by
inducing large scale endocytosis. A second screen identified the compound Lee3664 which demonstrates selective toxicity against C. albicans. Further, we
performed a detailed biochemical characterization of Cho1p where we identified
substrate binding sites as well as the Km [subscript M] and apparent Vmax
[subscript max] for each substrate. Computational modeling has produced a
useful model of what Cho1p might look like and has further increased interest in
crystallizing the protein in future work. The results of this dissertation will lead to
more direct approaches for finding Cho1p inhibitors, leading ultimately to more
vi

effective antifungals, as well as a greater understanding of enzymes involved in
phospholipid biosynthesis, which is necessary for virulence in this pathogen.
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INTRODUCTION
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Understanding the roles for lipids in the virulence of microbial pathogens has
long been an area of interest. Virulence is a broad area of study, encompassing
both host and microbe factors, however, within the last decade the role of
microbial physiology in virulence has become more appreciated. Many microbes
have complex life cycles or reside in a variety of locations and must sense their
environment in order to survive and reproduce. This adjustment to environmental
stimuli (e.g. nutrient availability, temperature, pH) plays a large role in the
metabolism and virulence of microbes (Finlay and Falkow 1989, Finlay and
Falkow 1997, Mahan, et al. 2000).
Lipids are one of the four main macromolecules (along with nucleic acids,
proteins, and carbohydrates) essential for cells to function. Depending on their
properties, lipids can have many roles in the cell including control of membrane
structure and fluidity (Cronan 2003, Dowhan 1997), signaling (Shea and Del
Poeta 2006), facilitating membrane-associated functions (Bogdanov and Dowhan
1999, Cronan 2003), virulence (Bhatt, et al. 2007, Jain, et al. 2007, Mirucki, et al.
2014, Upreti, et al. 1984, Wessel, et al. 2006) and drug resistance (Anderes, et
al. 1971, Cronan 2003, Rakotomanga, et al. 2005). A great deal of research has
been conducted to help better understand the role that lipids play in virulence
across species, and even within strains of the same species (Cox and Best 1972,
Disalvo and Denton 1963, Nielsen 1965). Some of the first studies into the
importance of lipids within fungal pathogens compared lipid composition of
different strains of Blastomyces dermatitidis (Disalvo and Denton 1963).
2

Differences in total lipid content were observed, revealing that the more virulent
strains had higher levels of total lipids. However, no correlation was seen
between virulence and increased phospholipids in particular. In contrast, a similar
study on Histoplasma capsulatum revealed no direct correlation between
virulence and lipid content (Nielsen 1965). A later study on the impact of lipid
composition on virulence in Cryptococcus neoformans found that lower virulence
correlated with decreased levels of total lipids and phospholipids, but no major
association between virulence and specific lipids was identified (Upreti, et al.
1984). Over the past few decades, a great deal of research has led to a deeper
understanding of lipids and their roles in virulence.
Within the broad category of lipids are many different subtypes, including
sphingolipids, phospholipids, and sterols. Nearly all of these have been
implicated in virulence across a wide range of pathogens (Davis, et al. 2014a,
Geiger 2010, Goren, et al. 1974, Rella, et al. 2016, Tilney, et al. 2001, Wessel, et
al. 2006). Furthermore, some microbes have been shown to have the ability to
take up host fatty acids which alters the microbe’s membrane, allowing them to
resist antibiotics and other stressors (Giles, et al. 2011, Harp, et al. 2016, Saito,
et al. 2014, Yao and Rock 2017). While there are many reviews describing the
general role of lipids in microbial pathogenesis (Geiger 2010, Mishra, et al. 1992,
Ramakrishnan, et al. 2013, Rella, et al. 2016, Sant, et al. 2016), this review will
focus on a specific subset of aminophospholipids, phosphatidylserine (PS) and
phosphatidylethanolamine (PE), and their role in microbial pathogenesis. PS and
3

PE have been subject to fewer studies than some other classes regarding their
roles in virulence, but a number of more recent reports reveal interesting roles for
PS and PE in a variety of fungal, protozoan, and prokaryotic pathogens,
indicating that these phospholipids and their biosynthetic enzymes should be
considered more carefully.

This introduction will briefly review PS and PE

synthesis, and then cover the role of PS and PE in particular cellular pathogens
as regulators of virulence and the role of host PS/PE as facilitators of virulence.

Phosphatidylserine and phosphatidylethanolamine synthesis in microbes
Phosphatidylserine
PS is a negatively charged phospholipid with a glycerol backbone and two fatty
acid tails (Fig. I.1A). In bacteria and fungi, PS is produced from two substrates:
cytidine diphosphate diacylglycerol (CDP-DAG) and serine (Fig. I.2). Although
the enzymes responsible for this reaction can differ greatly in sequence between
fungi and many prokaryotic microbes (excepting some bacteria like B. subtillis or
Sinorhizobium meliloti whose PS synthase is similar to S. cerevisiae) the
mechanism by which they produce PS is similar (Carman and Han 2011, Carman
and Zeimetz 1996, Cronan 2003, Henry, et al. 2012, Raetz and Dowhan 1990,
Sohlenkamp, et al. 2004, Vance 2015, Vance and Steenbergen 2005a). In
mammals and many parasites like Trypanosoma brucei, PS is produced through
a

base-exchange

reaction.

In

mammals,

head

groups

of

existing

phosphatidylcholine (PC) and PE are cleaved off by two different enzymes, PSS2
4

Figure I. 1 The Structure of Two Amino Phospholipids
(A) phosphatidylserine and (B) phosphatidylethanolamine
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and PSS1 respectively, and replaced with serine to produce PS (Kuge and
Nishijima 1997, Signorell, et al. 2008, Tasseva, et al. 2013, Vance 2015) (Fig.
I.3).

Phosphatidylethanolamine
Phosphatidylethanolamine (PE) is considered a major phospholipid in many
eukaryotic organisms and some prokaryotes. It is an uncharged, non-bilayer
forming phospholipid due to its small head group, which causes a cone-like
shape for its structure (Fig. I.1B). In eukaryotes and most prokaryotes that
contain it, PE is produced by the decarboxylation of PS (Carman and Han 2011,
Cassilly, et al. 2017, Cronan 2003, Dowhan 1997, Kanfer and Kennedy 1964).
However, in many eukaryotes PE can alternatively be made from ethanolamine
via a scavenging pathway known as the Kennedy Pathway (Fig. I.2 and I.3)
(Kennedy and Weiss 1956). In the Kennedy pathway, ethanolamine is taken up
by the cells and phosphorylated to produce phosphoethanolamine, which is then
condensed with CTP to produce CDP-ethanolamine. The third and final step is
condensation of CDP-ethanolamine with diacylglycerol (DAG) to generate PE
and CMP (Gibellini and Smith 2010).
Although the CDP-DAG and Kennedy pathways are the most common
methods employed to generate PE in mammals and fungi, there are alternative
mechanisms that produce PE or its precursors in other microbes. In the bacterial
plant pathogen Xanthomonas campestris, a bifunctional cardiolipin/PE synthase
6

Figure I. 2 Phospholipid Biosynthesis Pathways in C. albicans
C. albicans acquires phospholipids via both an endogenous pathway, the de
novo pathway, and an exogenous pathway, the Kennedy pathway. The
precursors for producing the most common phospholipids are PA and CDP-DAG.
CDP-DAG is then converted to PI, PS, or PG. The endogenously produced PS
can be decarboxylated into PE and then further methylated into PC. In the
Kennedy pathway, exogenous ethanolamine (Etn) and/or choline (Cho) are
brought into the cell and converted into PE and PC. Abbreviations: PA –
phosphatidic acid; CDP-DAG – cytidine diphosphate diacylglycerol; PI –
phosphatidylinositol; PS – phosphatidylserine; PG – phosphatidylglycerol; PE –
phosphatidylethanolamine; CL – cardiolipin; PC – phosphatidylcholine; Etn –
ethanolamine;
Cho
–
choline,
Etn-P-phosphoethanolamine,
Cho-Pphosphocholine,
CDP-Etn-cytidyldiphosphate-ethanolamine,
CDP-Chocytidyldiphosphate-choline, Ser-serine

7

Figure I. 3 Phospholipid Biosynthesis Pathways in
Mammals and Parasites
Mammals acquire phospholipids via both an endogenous
pathway, the de novo pathway, and a scavenging pathway,
the Kennedy pathway. Headgroups of existing PE and PC
can be cleaved and replaced with serine to produce PS. PS
can be decarboxylated to produce PE. PE can then be
methylated three times to produce PC. In the Kennedy
pathway, exogenous ethanolamine (Etn) and/or choline
(Cho) are brought into the cell and converted into PE and
PC. Abbreviations: PS – phosphatidylserine; PE –
phosphatidylethanolamine; PC – phosphatidylcholine; Etn –
ethanolamine; Cho – choline (Figure adapted from Chen et
al., 2010)
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was identified. X. campestris produces PE by the decarboxylation of PS;
however, upon the deletion of PS decarboxylase, growth of the organism was
partially

restored

when

exogenous

ethanolamine

was

supplemented.

Researchers identified a putative cardiolipin synthase gene that, in addition to
making CL from CDP-DAG and phosphatidylglycerol-phosphate, could produce
PE from CDP-DAG and ethanolamine. This process, which may be important in
certain

conditions,

seems

to

be

restricted

to

Xanthomonadales

and

Pseudomonadales orders based on phylogenetic analysis (Moser, et al. 2014).
In the kinetoplast parasites such as Trypanomes and Leishmania, the
Kennedy pathway appears to be the key method of synthesizing PE.

In

Trypanosoma brucei, PE is maintained within the cell in two distinct pools
(Signorell, et al. 2008).

For Leishmania most of the ethanolamine used to

produce PE is not taken up from the environment, but rather produced within the
organism by cleaving sphingosine-1-phosphate to form long chain fatty
aldehydes and phosphoethanolamine. The phosphoethanolamine can be
funneled directly into the second step of the Kennedy pathway where
phosphoethanolamine is converted to CDP-ethanolamine which leads in another
step to PE (Fig. I.3) (Pulido, et al. 2017, Zhang, et al. 2007). This cleavage is
carried out by the enzyme sphinosine-1-phosphate lyase, which is also found in
other microbes such as S. cerevisiae (Dpl1). In yeast, Dpl1 can support growth
of yeast in the absence of PS decarboxylase (psd1∆ psd2∆) and exogenous
ethanolamine, indicating that it can support PE synthesis by the Kennedy
9

pathway in yeast as well. However, under normal conditions, Dpl1 is not a major
source for PE synthesis in this organism (Birner, et al. 2001, Mao, et al. 1997,
Saba, et al. 1997). Yeast also have the ability to take up and acylate lyso-PE to
produce PE or remodel existing PE species (Burgermeister, et al. 2004, Deng, et
al. 2010, Flis and Daum 2013, Riekhof and Voelker 2006, Riekhof, et al. 2007a,
Riekhof, et al. 2007b).
The apicomplexan parasites also have unusual characteristics regarding
PS and PE.

The malaria parasite Plasmodium falciparum can acquire

ethanolamine for the Kennedy pathway by directly decarboxylating serine into
ethanolamine, by means of the serine decarboxylase (SDC) enzyme, an
enzymatic activity shared with plants but not animals or fungi (Fig 3) (Elabbadi, et
al. 1997).
Toxoplasma gondii is an intracellular apicomplexan parasite that
reproduces within a parasitophorous vacuole. In T. gondii, PE is produced via the
Kennedy pathway and via the decarboxylation of PS in the mitochondria
(Hartmann, et al. 2014) as is seen in fungi or mammals. However, T. gondii also
has unusual versions of the canonical base-exchanging PS synthase and PS
decarboxylase enzymes. First, in addition to an internal, membrane-bound PS
decarboxylase, it has a second, soluble PS decarboxylase enzyme (TgPSD1)
that is secreted extracellularly from T. gondii cells and appears to decarboxylate
PS to PE in the parasitophorous vacuole (Hartmann, et al. 2014). This is highly
unusual because both PS decarboxylase and PS synthase are typically
10

membrane bound enzymes with multiple transmembrane domains. There have
been other reports of hyperexpressed PS decarboxylase enzymes dissociating
from the cytoplasmic membrane in bacteria (Tyhach, et al. 1979) and in
Plasmodium falciparum (Baunaure, et al. 2004, Choi, et al. 2016), but TgPSD1 is
the first example of a secreted PS decarboxylase with the enzymatic ability to
convert PS to PE. TgPSD1 has also been detected within the parasitophorous
vacuole. Although its function within this compartment is not entirely clear, it
could potentially help damage the host cell membrane to allow T. gondii to
escape the parasitophorous vacuole when it lyses the cell. Furthermore, the
secreted enzyme may bind liposomes and host membranes to allow for
membrane biogenesis and parasite replication. Thirdly, the secreted enzyme
may suppress PS exposure on the apoptotic host cell, thereby avoiding
phagocytosis, and allowing the parasite to replicate and avoid the immune
system. While these possibilities are likely, the exact reasons for its unique
function still remain to be elucidated (Gupta, et al. 2012). T. gondii also appears
to have the ability to take up host PE (possibly via a permease) when production
of PE is inhibited intracellularly, further increasing the survival and fitness of this
organism (Hartmann, et al. 2014).
In addition to an unusual PS decarboxylase that could affect host PE, T.
gondii also been shown to make an unusual phospholipid that is closely related
to PS called phosphatidylthreonine (PT).

PT is found in small amounts in

mammals and some bacteria (Heikinheimo and Somerharju 2002, Ivanova, et al.
11

2010, Mitoma, et al. 1998, Muller, et al. 2011), but in T. gondii PT is found in
more substantial amounts than PS. PT is synthesized in T. gondii by an enzyme
with close homology to the mammalian PSS base-exchange enzymes (Fig 3),
but it exchanges threonine or serine instead of serine alone (Arroyo-Olarte, et al.
2015, Arroyo-Olarte and Gupta 2016). The PT synthase is predicted to be found
in a few other protozoa including Neospora, Eimeria, Phytophtora, and Perkinsus
(Arroyo-Olarte, et al. 2015, Arroyo-Olarte and Gupta 2016).

PS and PE as Modulators of Virulence
Candida albicans
Candida albicans is a commensal fungus that normally inhabits the gut and skin
of healthy people. However, immunocompromised individuals are at a high risk of
developing bloodstream infections where C. albicans can infect the deep organs
leading to sepsis. C. albicans is known to produce several virulence factors
including hyphae, adhesins, lipases, proteases, and the more recently described
Candidalysin (Moyes, et al. 2016). It is also able to hide itself to a limited extent
from the innate immune system by a process called masking. Yeast cell walls
contain four main components: chitin, mannosylated proteins (mannan), β(1-6)glucan and β(1-3)-glucan. Mannan makes up the majority of the surface layer of
the cell wall, while β-glucans, and chitin are “hidden” beneath. β-(1,3)-glucan is a
pathogen associate molecular pattern (PAMP) that can be detected by the innate
immune receptor Dectin-1 as a signal that the host is infected by a fungal
pathogen (Brown and Gordon 2001) .

Dectin-1 is found on macrophages,
12

dendritic cells, neutrophils, and some other immune cells. The proposed layered
topology, where mannan masks the immunogenic molecule β(1-3)-glucan is a
method of innate immune system evasion by this yeast (Davis, et al. 2014a).
Disruption of this layering (i.e. unmasking) makes it easier for the host to detect
the fungus (Hasim, et al. 2017, Wheeler and Fink 2006, Wheeler, et al. 2008).
It has been shown that the fungal phosphatidylserine (PS) synthase,
Cho1p, is absolutely required for virulence of C. albicans. In a mouse model of
systemic infection, the cho1∆∆ deletion mutant was unable to cause infection,
while mice infected with wild-type or cho1∆/∆::CHO1 reintegrant strains died
within two weeks (Chen, et al. 2010). In addition, cho1∆∆ shows significant
reduction in kidney colonization and is completely cleared from the mice, even
when they are made neutropenic with cyclophosphamide (Y. L. Chen and T. B.
Reynolds, unpublished data). In contrast, mice infected with wild-type C. albicans
showed high kidney burden before succumbing to infection (Chen, et al. 2010).
In addition to a complete loss of PS, the cho1∆∆ mutation also causes a
loss of PE synthesized from PS (Fig 2) (Cassilly, et al. 2017). This suggested
that the avirulence could be caused by loss of PE as well as PS.

A

psd1∆∆ psd2∆∆ double mutation, which eliminates all PS decarboxylase activity,
also causes severe avirulence; however, there is a significantly greater loss of C.
albicans colonization from the kidneys in cho1∆∆ than in psd1∆∆ psd2∆∆ (Davis,
et al., data unpublished). The major difference between cho1∆∆ and psd1∆∆
psd2∆∆ is that only cho1∆∆ has increased β(1-3)-glucan unmasking in its cell
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wall, increasing host immune recognition of this microbe (Davis, et al. 2014a).
Thus, other underlying factors related to loss of PE play a role in the loss of
virulence, but cell wall unmasking driven by the loss of PS correlates with even
faster clearance. The mechanism responsible for cell wall unmasking in the
cho1∆∆ mutant are currently under investigation.
These defects in virulence in the cho1∆∆ and psd1∆∆ psd2∆∆ mutants are
manifest despite the presence of an alternative Kennedy pathway for PE
synthesis (Fig. 2). This brings up questions as to whether Kennedy pathway
synthesized PE is able to compensate for PS-derived PE or if cells are unable to
make sufficient PE by the Kennedy pathway. Furthermore, this also opens the
question of how much of a role the loss of PS alone plays in virulence, in addition
to its effects on cell wall unmasking.
Due to these virulence defects, Cho1p represents a good drug target in C.
albicans (Cassilly, et al. 2016, Chen, et al. 2010). First, as loss of Cho1p renders
C.

albicans

avirulent,

inhibition

of

Cho1p

should

render

C.

albicans

nonpathogenic to the host. Secondly, since the mammalian PS synthase
enzymes are not orthologous with the fungal PS synthase, an inhibitor of Cho1p
should be very specific for fungi without affecting mammalian Pss1p and Pss2p
(Compare Figs I.2 and I.3). Identification of small molecule inhibitors of Cho1p as
potential therapeutics is a priority (Cassilly, et al. 2016).

Finally, Cho1p is

conserved throughout pathogenic fungi, so an inhibitor could be broad spectrum
(Braun, et al. 2005).
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Brucella abortus
Brucella abortus is the causative agent of brucellosis which can be a severe and
chronic infection within humans. This organism is a facultative, intracellular
pathogen that typically resides within a specific compartment in the host cell
called the Brucella-containing vacuole (BCV). From this location, B. abortus can
control the host cell machinery and replicate. Several factors contribute to B.
abortus virulence including immune modulators, smooth lipopolysaccharide
(LPS), and cyclic β-glucans. However, recent studies have shown that the
membrane phospholipid composition is crucial for interaction of the microbe with
the host cells (Bukata, et al. 2008, Comerci, et al. 2006). For example,
phosphatidylcholine (PC)—one of the main phospholipids produced in this
microbe—is necessary for the organism to set up a chronic infection in a murine
model (Comerci, et al. 2006, Conde-Alvarez, et al. 2006). Further studies showed
that PS and PE play significant roles in virulence.
phosphatidylserine synthase (pssA), was produced.

A mutant of the

PS is not considered a

major phospholipid within B. abortus, but this enzyme is crucial for production of
PE (Fig 2) (Bukata, et al. 2008, Thiele and Kehr 1969). The pssA mutant had a
loss of PE and showed increased sensitivity to membrane-perturbing agents like
SDS. The pssA mutant also showed decreased survival intracellularly in tissue
culture cells and showed a marked decrease in maturation of the BCV that
protects the bacteria intracellularly. Finally, a marked decrease in virulence was
found in the pssA mutant as compared to the wild-type within a mouse model of
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infection (Bukata, et al. 2008). Although the exact impact on virulence is not
known, it is thought that PE contributes to BCV formation and thus is necessary
for virulence. Further, by disrupting the structure of the membrane, it is possible
that important protein complexes or virulence determinants are also disrupted
which negatively affects the organism’s ability to survive within host cells.
The pssA gene is important for growth in Escherichia coli, but it has only
been examined for its role in growth in non-pathogenic laboratory strains. As in
B. abortus deletion of pssA causes not only a decrease in PS and PE, but it also
causes a growth defect unless the media is supplemented with divalent cations
like Ca2+ or Mn2+ (Nakajima, et al. 1991). Further investigations into the role for
PS/PE synthesis in the pathogenesis of Gram negative organisms is warranted
as it may be important for virulence in a variety of these often-drug-resistant
pathogens.

Plasmodium
Plasmodium parasites are the causative agents of malaria, which is one of the
most important health problems in the developing world. Finding new treatments
with novel modes of actions to better combat this pathogen is a major area of
current research because of the rising resistance to existing anti-malarial
therapies. Enzymes involved in the production of important malarial lipids, like
the PS decarboxylase (PSD) enzyme, have been suggested as a drug target
since PE is an essential phospholipid within Plasmodium membranes. Indeed,
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inhibition of PSD results in growth arrest of the parasite (Ben Mamoun, et al.
2010, Choi, et al. 2016, Serran-Aguilera, et al. 2016). Recent findings have
shown that the PSD enzyme from Plasmodium falciparum, though both soluble
and membrane-bound in this organism, can complement yeast psd mutants
(Choi, et al. 2016). Furthermore, screening a library of known malaria inhibitors
identified a particular compound, 7-chloro-N-(4-ethoxyphenyl)-4-quinolinamine
(MMV007285), with potent activity against Plasmodium, and the ability to inhibit
the catalytic function of PSD (Choi, et al. 2016).
In addition to PSD, the choline kinase (CK) is crucial for PE synthesis in
Plasmodium, and has been suggested as another drug target (Serran-Aguilera,
et al. 2016). This enzyme is involved in the Kennedy Pathway where choline and
ethanolamine are taken up from the environment and used to produce PC and
PE, respectively (Fig 3). Recent work has found that known anti-cancer
compounds BR23 and BR25 that inhibit human choline kinase cause a dramatic
drop in the levels of PE within P. falciparum but not PC, as these compounds
influence PE synthesis more than PC synthesis in this parasite (Serran-Aguilera,
et al. 2016).

The CK of P. falciparum is involved in both choline and

ethanolamine phosphorylation, but the drugs seem to primarily impact
ethanolamine phosphorylation, rather than choline phosphorylation, explaining
the differential effects on PE and PC synthesis. Treatment with either drug led to
arrested development of the parasite, likely as a result of the loss of membrane
PE, and ultimately were lethal (Serran-Aguilera, et al. 2016). These findings
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demonstrate the importance of PE biosynthesis in survival and pathogenicity of
microbes, and are some of the first studies where small molecule inhibition of an
ethanolamine kinase in a pathogen has led to promising lead inhibitory
compounds.
Finally, although P. falciparum has two different pathways to make PE,
(both CDP-DAG and Kennedy, Fig 2-3), loss of either pathway appears to be
sufficient to compromise its growth. This is surprising, and indicates several
possible explanations: 1) the molecular species of PE made from the two
pathway differ and each is crucial for virulence, 2) localization of PE synthesis for
each pathway differs (PSD is in the mitochondria while the Kennedy pathway
synthesizes PE in the ER) and PE made in one location is not sufficient to make
up for the other, 3) the volume of PE made by either pathway alone is not
sufficient to support virulence (Choi, et al. 2016, Serran-Aguilera, et al. 2016).

Trypanosomes
Trypanosoma brucei is a neglected tropical pathogen that affects both humans
and livestock within specific regions of Africa. Current therapies are inadequate
due to rising drug resistance and high toxicity, creating a need for new drugs.
Like in Plasmodium, phospholipid biosynthetic pathways have been suggested
as excellent targets for therapy in T. brucei. PE represents a good target for
several reasons including its importance in providing the phophoethanolamine
moiety that links GPI anchors to membrane proteins, including variant surface
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glycoprotein (VSG) (Menon, et al. 1993, Menon and Stevens 1992). VSG is a
crucial aspect of T. brucei virulence as it is key in allowing the organism to evade
the immune system and set up chronic infections within the host. Thus, disruption
of proper VSG production and localization represents an excellent drug target in
this organism. Indeed, a conditional knockout of the ethanolamine-phosphate
cytidyltransferase (EPT) in T. brucei revealed that this gene is essential for
growth and crucial in the synthesis of both PE and GPI-anchors (Gibellini, et al.
2009). In addition, ethanolamine analogues are being explored as inhibitors of
the ethanolamine kinase enzyme (Gibellini, et al. 2008).

Toxoplasma gondii
Phosphatidylthreonine (PT) has been shown to be naturally abundant in T. gondii
and play a role in virulences. In a Δtgpts PT synthase mutant, replication of the
parasite was normal, but a marked decrease in plaques and plaque size was
seen upon infection, when compared with a wild-type control. Further, the Δtgpts
mutant showed a decrease in motility, which is a major contributor to virulence
within this organism. As expected, the Δtgpts mutant demonstrated decreased
virulence in a mouse model of infection. These findings implicate PT in the lysis
of host cells, as well as possible egression into new host cells for propagation of
infection, indicating that the parasite has evolved PT specifically for use in its lytic
cycle of infection. Although the exact mechanism of PT in disease is still
unknown, it is likely that PT may affect calcium flux at the plasma membrane and
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calcium homeostasis, which could in turn control motility (Arroyo-Olarte, et al.
2015, Arroyo-Olarte and Gupta 2016).

Host PS and PE are utilized by pathogens for virulence
Host membranes serve as a barrier to microbes, either by preventing entry into
tissues or limiting access to necessary nutrients. It is a common trait for microbes
to manipulate and alter host membranes in order to establish infection and
persist within the host (Ham, et al. 2011, Sarantis and Grinstein 2012). PS is an
important phospholipid in a variety of processes. In mammalian systems,
redistribution of PS is a key indicator that a cell is undergoing apoptosis. Cells
typically maintain an asymmetrical distribution of PS in the plasma membrane,
where most PS faces the cytoplasm (localized to the inner leaflet of the
membrane). Upon receipt of “death signals” for apoptosis from the cell, PS is
flipped to the outer leaflet as a signal to macrophages that a cell is dying.
Macrophages use PS as the “eat me” signal to then engulf the apoptotic cells.
Exposed PS (or even PE) on the host cell, either naturally or as a result of
promoted PS externalization via activity of the microbe (Fujimoto, et al. 1998,
Gao and Abu Kwaik 1999, Goth and Stephens 2001, Murata-Kamiya, et al. 2010,
Semiramoth, et al. 2010, Wandler, et al. 2010), can be recognized and exploited
by microbes. Some microbes, like Chlamydia trachomatis or the influenza virus
enter cells and promote PS-externalization and apoptosis, likely to ensure exit
from the infected cell and further dissemination (Fujimoto, et al. 1998, Goth and
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Stephens 2001). In Helicobacter pylori, the virulence determinant CagA was
shown to bind tightly to PS exposed on host cells via a specific motif. Once
bound, CagA is thought to promote its own uptake into the host cell where it
remains tethered to the membrane via PS and modulates several signaling
pathways (Backert, et al. 2011, Murata-Kamiya, et al. 2010, Wandler, et al.
2010).
In addition, enterohemorrhagic Escherichia coli (EHEC) has been shown
to induce apoptosis and expose both PS and PE on host cell surfaces. EHEC
can then bind to the exposed PE, establishing a tight connection with the host,
followed by subsequent internalization of the microbe, nutrient acquisition, or
delivery of toxins deep into host tissues (Barnett Foster, et al. 2000, Barnett
Foster, et al. 1999). Exposed host PS can also be used as a tool for microbial
dissemination.
Listeria monocytogenes exploits efferocytosis, or the removal of dead cells
and debris via phagocytosis, to facilitate spread from cell to cell. These bacteria
are phagocytosed, but can escape from the phagosome through the activity of
their pore-forming toxin listeriolysin O (LLO). LLO then can promote the release
of bacteria-containing vesicles with exposed PS on the surface which are then
phagocytosed

by

macrophages,

continuing

the

cycle

of

dissemination

(Czuczman, et al. 2014).
Similarly, Mycobacterium tuberculosis also has the ability to escape the
phagosome and can produce the secreted protein EspB which, when processed,
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has been shown to bind phosphatidic acid (PA) and PS. Although the exact
function of this binding is still unknown, it is hypothesized that EspB may interfere
with PA- and PS-mediated signaling in the host (Chen, et al. 2013, Korotkova, et
al. 2015). Based on these examples, it is clear that interaction with host
phospholipids is crucial in many aspects of infection. However, in addition to this
face of virulence, microbial phospholipids have also been shown to be important
in virulence.

PS-Exposure and Apoptotic Mimicry
Many obligate- or facultative-intracellular pathogens employ various methods of
invading host cells. In addition to other various surface determinants, like sugars
(van Zandbergen, et al. 2007), the lipid composition in the microbe’s plasma
membrane can play a role in promoting their uptake by host cells (e.g.
phagocytosis by host macrophages). Phospholipids like PS can play a major
role in this process.

Leishmania
L. braziliensis is known to have multiple virulence factors associated with its
disease and includes cell surface molecules like lipophosphoglycan (LPG) and
carbohydrates. In addition, PS also serves as a ligand for mononuclear
macrophages. L. tropica promastigote forms expose higher levels of PS on their
surface during the infective growth phases (Tripathi and Gupta 2003).
Furthermore, amastigotes of L. amazonensis with higher levels of PS on the cell
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surface had increased infectivity in vivo and in vitro (Wanderley, et al. 2006).
These findings indicate that a higher concentration of PS on the surface of these
organisms increases the chances of being internalized by the host macrophages
(Wanderley, et al. 2006).
The PS exposed on the membrane of the parasite is thought to play a role
in apoptotic mimicry, allowing L. brasiliensis to establish an infection within the
host (de Freitas Balanco, et al. 2001, van Zandbergen, et al. 2007). When PS
exposed on the surface of L. brasiliensis, L. tropica or L. amazonensis is blocked
with annexin V, the infectivity of the parasite in murine peritoneal macrophages is
decreased (de Freitas Balanco, et al. 2001, Farias, et al. 2013, Tripathi and
Gupta 2003, Wanderley, et al. 2006, Wanderley, et al. 2009).
Interestingly, PS exposure seems to have importance even beyond the
initial entry into host macrophages.

L. amazonensis and L. major,

subpopulations of PS-positive and PS-negative promastigotes cooperate to
produce a sustained and successful infection of host macrophages (van
Zandbergen, et al. 2006, Wanderley, et al. 2009). L. amazonensis amastigotes
with high levels of PS exposed on their cell surfaces are able to induce cytokine
production as well as inhibit NO production (Wanderley, et al. 2006). These
findings implicate PS production and exposure as an excellent drug target within
Leishmania.
Similar instances of apoptotic mimicry have also been reported for
Trypanosoma cruzi (Damatta, et al. 2007, Freire-de-Lima, et al. 2000),
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Toxoplasma gondii (Seabra, et al. 2004), and even enveloped viruses (Jemielity,
et al. 2013, Moller-Tank, et al. 2013, Soares, et al. 2008, Vanlandschoot and
Leroux-Roels 2003), demonstrating the prevalence of PS exposure in regulating
infection. Targeting proteins responsible for this PS exposure (Araujo-Santos, et
al. 2003, dos Santos, et al. 2013) or enzymes involved in PS synthesis, could be
a viable option for future therapies across a wide variety of pathogens.

Cryptococcus neoformans
Cryptococcus neoformans is a facultative intracellular fungal pathogen. Recent
studies have demonstrated that beyond secreted virulence factors, there are also
other important proteins within the organism that play a role in virulence. One
such example is Cdc50, which is a lipid flippase responsible for maintaining
asymmetry in the phospholipid bilayer (Huang, et al. 2016). Upon deletion of
Cdc50, C. neoformans becomes more sensitive to fluconazole, caspofungin, and
SDS likely due to a change in membrane integrity. In mice, the cdc50∆ mutant
was unable to cause a robust infection and was cleared from the lungs, further
implicating this protein as a virulence factor. Though the exact mechanism
behind this loss of virulence is currently still under scrutiny, the cdc50∆ mutant
had increased levels of PS exposed to the outer membrane, further supporting
the importance of proper PS localization and membrane integrity for the virulence
of this fungus. These results indicate that loss of Cdc50, and likely a change in
PS localization, can massively disrupt virulence, and fitness of the organism, thus
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representing a drug target within Cryptococcus. In addition, since the cdc50∆
mutant showed greater susceptibility to caspofungin, a common antifungal drug
that Cryptococcus is naturally resistant to, further exploration of phospholipid
flippases or membrane

symmetry could

improve

the

effectiveness

of

echinocandins against the fungus.

PS and PE in Extracellular Vesicles
A potential contributor to virulence in microbes is the use of extracellular vesicles
as delivery systems for virulence factors. This characteristic can be found in C.
albicans, Candida parapsilosis, Sporothrix schenckii, Saccharomyces cerevisiae
(Albuquerque, et al. 2008), Cryptococcus neoformans (Oliveira, et al. 2010,
Rodrigues, et al. 2008), and Paracoccidioides brasiliensis (Manocha, et al. 1980),
and even Gram negative bacteria like E. coli (Hoekstra, et al. 1976, Horstman
and Kuehn 2000), Pseudomonas aeurginosa (Tashiro, et al. 2011), Legionella
pneumophila (Fernandez-Moreira, et al. 2006, Wessel, et al. 2006) and
Haemophilus influenzae (Kulkarni and Jagannadham 2014, Kulp and Kuehn
2010, Roier, et al. 2015, Sharpe, et al. 2011).
A recent study found that the cho1∆∆ mutant of C. albicans displayed
decreased ability to secrete proteases and phospholipases via extracellular
vesicles (Wolf, et al. 2015), indicating the importance of proper phospholipid
balance in this process.
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Lipid profiles from 4 different strains of P. brasiliensis (Manocha, et al.
1980) revealed that the concentration of PC was higher in virulent strains than in
the avirulent strain. Further studies into the lipid composition of fungal
extracellular vesicles, known to harbor various virulence factors, showed some
differences in the lipid composition, which is theorized to play a role in the
virulence of different strains of P. brasiliensis (Vallejo, et al. 2012).
Histoplasma capsulatum is a pathogenic fungus that can cause lifethreatening systemic disease. This organism has many different characteristics
that allow it to grow well within the host environment, including survival in a wide
pH range and nutrient starvation. H. capsulatum also produces various virulence
factors like heat-shock proteins and the cell wall protein YPS3p. Analysis of the
composition of extracellular vesicles reveals that the vesicles were made up of
common plasma membrane phospholipids including PE, PS, and PC
(Albuquerque, et al. 2008). This composition is similar to what is found in
mammalian exosomes which are known to transport important molecules like
bioactive lipids and lipid-degrading enzymes. The biogenesis of exosomes in
mammals is a specific process that requires certain lipids with a characteristic
membrane organization (Laulagnier, et al. 2004, Subra, et al. 2007). Although the
importance of this phospholipid composition has not been studied in H.
capsulatum, it is likely that the specific phospholipids making up the extracellular
vesicles are important in virulence and proper function.
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Significance
Because of this clear significance of aminophospholipids within microbial
virulence, we were interested in focusing on PS synthesis in Candida albicans as
a possible drug target. C. albicans is an opportunistic fungal pathogen that, along
with several other species in the Candida genus, represents the most common
fungal pathogen of humans and has even been shown to cause problems to
astronauts on the international space station (Crabbe, et al. 2013). In most
people, this organism occupies the skin, gut, and vagina as a commensal (Hube
2004); however, it can be a severe threat to immunocompromised individuals
(rendered so by HIV-AIDS, chemotherapy, etc.). In these patients, C. albicans
causes oral thrush, infects skin wounds, and causes life-threatening invasive
bloodstream infections and fungal endocarditis (FE) (Mishra, et al. 2007, Pierrotti
and Baddour 2002). Invasive bloodstream infections and FE—which can arise
from implanted medical devices like long-dwelling intravascular catheters or
prosthetic heart valves (Mishra, et al. 2007, Sun, et al. 2013)—have high
mortality rates, around 30% and 50%, respectively (Baddley, et al. 2008,
Maccallum, et al. 2013, Pierrotti and Baddour 2002). There are three main
classes of antifungals used to treat C. albicans invasive bloodstream infections:
azoles (i.e. fluconazole, itraconazole) which inhibit ergosterol synthesis; polyenes
(i.e. amphotericin B) which target existing ergosterol in the plasma membrane
(Anderson, et al. 2014, Ghannoum and Rice 1999); and echinocandins (i.e.
caspofungin) which target the fungal cell wall (Alem and Douglas 2004,
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Bachmann, et al. 2002, Baddley, et al. 2008, Lyons and White 2000). However,
because of rising drug resistance (azoles, echinocandins), high toxicity
(amphotericin B), and poor oral availability (polyenes, echinocandins) of these
drugs, they are not always effective at safely eliminating the infection (Anderson
2005, Ghannoum and Rice 1999). Lack of effective treatment contributes to high
mortality in individuals with FE or invasive bloodstream infections (Sun, et al.
2013), which creates the need for novel drug targets in the organism as well as
new antifungal compounds (Maccallum, et al. 2013).
Despite this pressing need, little progress has been made in recent
decades to identify new antifungal compounds. The process of drug development
is notoriously slow, but rendered slower in fungi. One main reason for this delay
is the amount of similarity between fungi and humans. Saccharomyces
cerevisiae has long been used as a model organism for understanding eukaryotic
organisms and mammalian processes. Because of this, finding drugs that are
selectively toxic to fungi, while having no side effects on mammalian host cells, is
a monumental hurdle. Even the currently used Amphotericin B suffers from toxic
side effects due to the similarities between fungal ergosterol and mammalian
cholesterol. Thus, it is of utmost importance to identify new or better targets for
antifungal therapies.
Several recent reviews have highlighted the potential of the fungal cell
membrane as an excellent drug target (Rella, et al. 2016, Sant, et al. 2016).
While those reviews aim to provide a general overview of fungal membranes and
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lipids as antifungal targets, the aim of this work was to fully understand PS
synthesis as a drug target within C. albicans.

Screening Approaches for Identifying PS Synthase Inhibitors
Because of the promise of using Cho1p as a drug target, we developed several
approaches for identifying small molecule inhibitors. These approaches largely
hinge on using phenotypic traits of cho1∆∆ as indicators that Cho1p is being
inhibited. Our first method, described in Chapter 2 was based on the anti-fungal
activity of a marine depsipeptide Papuamide A (Pap-A). This compound has
been shown to bind specifically to PS in membranes of liposomes (Andjelic, et al.
2008). Although the exact mechanism of action has not been demonstrated, it is
thought that Pap-A binds PS by inserting a lipophilic tail into cell membranes,
causing a disruption in membrane integrity and subsequent lysis. Indeed, the
cho1∆∆ mutant is completely resistant to Pap-A (Cassilly, et al. 2016, Chen, et al.
2010). As a result, we used Pap-A as an indicator of functional PS synthesis,
hypothesizing that if a small molecule inhibited Cho1p, it would cause the
organism to become resistant to Pap-A. The screening approach and results
from this study can be found in Chapters 2 and 3 and Appendix 3.
A second phenotypic trait that we wished to exploit for our screening was
ethanolamine auxotrophy. Because phosphatidylethanolamine is an essential
phospholipid, the cho1∆∆ cannot survive without ethanolamine provided in the
growth medium. This exogenous ethanolamine can be taken up by the cells and
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used in the Kennedy pathway to circumvent the organism’s requirement for PS
(as a precursor for PE). Thus, cho1∆∆ has a very distinct characteristic of growth
inhibition in minimal medium deplete of ethanolamine, but showing a return of
growth when ethanolamine is supplemented back into the medium. We
hypothesized that small molecules that inhibit Cho1p would cause ethanolamine
auxotrophy in wild-type C. albicans that we could detect based on a lack of
growth in minimal medium. The screening approach and results from this study
can be found in Appendix 1.

Characterization of PS Synthase and PS Trafficking
Although our screening approaches have been beneficial in certain ways, they
have not yet yielded PS synthase inhibitors as we expected. Thus, in addition to
our screening, we were also interested in characterizing the PS synthase
enzyme to provide information that could aid in a more rational drug design
approach. We hypothesized that identifying specific regions on Cho1p that were
crucial for enzyme function could help provide a framework by which we could
design inhibitors to competitively or allosterically inhibit the enzyme. In order to
perform these studies, we began by characterizing Cho1p both in vivo and in
vitro. The results of these studies are described in Chapter 1. Further, we began
biochemical characterization where we mapped the substrate binding sites in
Cho1p. This study is described in Chapter 4.
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In addition to these biochemical characterizations, we were interested in
describing PS dynamics within yeast. Although we wished to perform these
studies in C. albicans, the model yeast S. cerevisiae was more amendable to use
of genetic tools and thus characterization of PS trafficking and dynamics at the
membrane was performed in yeast. The findings from this study can be found in
Appendix 2.
Last, we wished to complete our biochemical characterization by solving
the 3D crystal structure of Cho1p. Although we were unable to complete this
project due to time constraints, we developed several strains of S. cerevisiae
containing Cho1p tagged with 3X FLAG and 6X His which will ultimately allow
purification of the protein via affinity chromatography. These strains will be useful
in future studies to determine the structure of Cho1p. These preliminary
experiments can be found in Appendix 4.
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CHAPTER I
ROLE OF PHOSPHATIDYLSERINE SYNTHASE IN SHAPING THE
PHOSPHOLIPIDOME OF CANDIDA ALBICANS
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Abstract
Phosphatidylserine (PS) synthase (Cho1p) and the PS decarboxylase enzymes
(Psd1p and Psd2p), which synthesize PS and phosphatidylethanolamine (PE),
respectively, are crucial for Candida albicans virulence. Mutations that disrupt
these enzymes, which are part of the cytidyldiphosphate-diacylglycerol (CDPDAG) pathway (i.e. de novo pathway), utilized for phospholipid synthesis,
compromise virulence. Understanding how losses of PS and/or PE synthesis
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pathways affect the phospholipidome of Candida is important for fully
understanding how these enzymes impact virulence. The cho1Δ/Δ and psd1Δ/Δ
psd2Δ/Δ mutations cause similar changes in levels of phosphatidic acid (PA),
phosphatidylglycerol (PG), phosphatidylinositol (PI), and PS. However, only slight
changes were seen in PE and phosphatidylcholine (PC). This finding suggests
that the alternative mechanism for making PE and PC, the Kennedy Pathway,
can compensate for loss of the de novo synthesis pathway. C. albicans Cho1p,
the lipid biosynthetic enzyme with the most potential as a drug target, has been
biochemically characterized, and analysis of its substrate specificity and kinetics
reveal that these are similar to those previously published for Saccharomyces
cerevisiae Cho1p.

Introduction
Fungi of the genus Candida are opportunistic pathogens known to cause
vulvovaginal, oral, and invasive bloodstream infections in humans. Invasive
infections are the most serious, with a mortality rate around 30% (Morrell, et al.
2005, Wisplinghoff, et al. 2004).

Currently, there are three main antifungal

classes used to treat bloodstream infections of C. albicans, the species that
causes the majority of these infections (Pfaller, et al. 2012). These therapies
include azoles (e.g. fluconazole), echinocandins (e.g. caspofungin), and
polyenes (amphotericin B). Unfortunately, these drugs have limited effectiveness
due to documented cases of azole and echinocandin resistance (Mishra, et al.
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2007), the nephrotoxicity of amphotericin B (Ghannoum and Rice 1999, Holeman
and Einstein 1963), and the requirement for intravenous administration of both
amphotericin B and caspofungin. Furthermore, the recent rise in patients that
are immunocompromised puts more people at risk every year (Low and Rotstein
2011), while also dramatically increasing healthcare costs (Mishra, et al. 2007).
As a result, it is of utmost importance to find novel antifungals to treat C. albicans
potently and effectively.
Phospholipids are crucial components of biological membranes in both
prokaryotes and eukaryotes. The phospholipidome of C. albicans is made up
mostly

of

phosphatidylcholine

(PC),

phosphatidylethanolamine

(PE),

phosphatidylserine (PS), phosphatidylinositol (PI), phosphatidylglycerol (PG),
and cardiolipin (CL) (Singh, et al. 2012). C. albicans has a de novo method for
producing phospholipids, which involves the conversion of cytidine diphosphatediacylglycerol (CDP-DAG) into PI, PG, and PS (Fig. 1.1). Although PI, PG, and
PS can be end products; PG and PS can be further modified to form CL and PE,
respectively, and PE can subsequently be methylated to produce PC.

C.

albicans also utilizes exogenously provided ethanolamine and choline to produce
PE and PC via the Kennedy pathway (Chen, et al. 2010, Gibellini and Smith
2010, Henry, et al. 2012).
Previous studies have identified the PS synthase (Cho1p) as a potential
drug target in Candida albicans (Braun, et al. 2005, Chen, et al. 2010). Studies
have been done on the enzymology and lipid profiles associated with PS
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Figure 1. 1 Phospholipid Biosynthesis Pathways in C. albicans.
Canidida albicans phospholipid biosynthesis occurs via both an endogenous
pathway, the de novo pathway and an exogenous pathway, the Kennedy
pathway. The precursors for producing the most common phospholipids are PA
and CDP-DAG. CDP-DAG is then converted into PI, PS or PG. The
endogenously produced PS can then be decarboxylated via Psd1 or Psd2
(Psd1/2) into PE and then further methylated into PC. In the Kennedy pathway,
exogenous ethanolamine (Etn) and/or choline (Cho) are brought into the cell and
converted into PE and PC. PG and CDP-DAG can be combined to generate CL.
Abbreviations: PA, phosphatidic acid; CDP-DAG, cytidine diphosphatediacylglycerol;
PI,
phosphatidylinositol;
PS,
phosphatidylserine;
PG,
phosphatidylglycerol; PE, phosphatidylethanolamine; CL, cardiolipin; PC,
phosphatidylcholine.
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synthase in S. cerevisiae (Bae-Lee and Carman 1984), but little characterization
of the orthologous enzyme or its effects on lipid profiles in C. albicans has been
performed.

Here we report the phospholipidome of the Candida albicans

cho1Δ/Δ and psd1Δ/Δ psd2Δ/Δ strains, as well as the enzyme kinetics of C.
albicans Cho1p, finding both the Km and Vmax to be in close agreement with those
values reported for S. cerevisiae Cho1p (Bae-Lee and Carman 1984). The
studies described in this report set the stage for further characterization of these
enzymes as drug targets.

Materials and Methods
Strains used
The SC5314 (wild-type) strain of C. albicans and mutants used in this study have
been previously described in (Chen, et al. 2010).

These include cho1Δ/Δ

(YLC337), cho1Δ/Δ::CHO1 (YLC344 ), psd1Δ/Δ (YLC280), psd1Δ/Δ::PSD1
(YLC294), psd2Δ/Δ (YLC271), psd2Δ/Δ::PSD2 (YLC290), psd1Δ/Δ psd2Δ/Δ
(YLC375). The media used to culture strains was YPD (1% yeast extract, 2%
peptone, and 2% dextrose).

Lipid Isolation for Mass Spectrometry Analysis
Lipid isolations were adapted from the protocol of (Singh, et al. 2010). Cultures
were grown overnight, shaking at 30° C in 5 mL of YPD. Cultures were then
diluted to 0.4 OD600 in 25 mL of YPD and grown for 6 hours, shaking at 30° C.
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After the 6 hours, cultures were pelleted and washed twice with PBS. The final
pellets were incubated for at least 1 hour at -80° C, then lyophilized overnight.
Dry mass was then recorded for normalization and pellets were suspended in
500 μL to 1 mL of PBS. The resulting thick suspension was then transferred to
Teflon-capped glass tubes (Pyrex) and 1.5 mL of methanol was added. Two
scoops of 150-212 μm sized glass beads (Sigma-Aldrich, St. Louis, MO) were
added to each tube. Cells were lysed by vigorous vortexing for 30 seconds
punctuated by 30 second incubations on ice. 3 mL of chloroform was added and
the solution was vortexed briefly before being transferred to 15 mL glass funnel
filtration system (Millipore, Billerica, MA, USA) with 24 mm glass microfibre filters
(Whatman).

Liquid collected was then poured into a separating funnel and

washed with 900 μL of sterile 0.9% NaCl. The mixture was allowed to sit and
separate for at least 5 minutes, or until adequate separation of the organic and
aqueous layers was observed.

The lower organic layer only was collected

carefully into fresh Teflon-capped glass tubes. The organic layer was then dried
under nitrogen gas until completely dry and stored at -20°C. Immediately before
mass spectrometric analysis, the lipid extracts were resuspended in 300uL of 9:1
methanol:chloroform (v/v).

Mass Spectrometry Lipidomics
Lipid extracts were separated on a Kinetex HILIC column (150 mm x 2.1 mm, 2.6
μm: (Phenomenex, Torrance, CA, USA) connected to a Ultimate 3000 UltraHigh
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Performance Liquid Chromatograph (UHPLC) with autosampler and an Exactive
benchtop Orbitrap mass spectrometer (MS) (Thermo Fisher Scientific, San Jose,
CA) equipped with a electrospray ionization (ESI) probe. The column oven
temperature was maintained at 25°C, and the temperature of the autosampler
was set to 4°C. For each analysis, 10 PL was injected onto the column.
Separations ran for 35 minutes at a UHPLC flow rate of 0.2 mL/min with mobile
phase A and B consisting of 10 mM aqueous ammonium formate pH 3 and 10
mM ammonium formate pH 3 in 93% ACN (v/v), respectively. The gradient
started at 100% B and was altered based on the following profile: t = 0 minutes,
100% B; t = 1 minute, 100% B; t = 15 minutes, 81% B, 29% A; t = 15.1 minutes,
48% B, 52% A; t = 25 in, 48% B, 52% A; t = 25.1 minutes, 100% B, t = 35
minutes, 100% B. The same LC conditions and buffers were used for all MS
experiments described below.
The MS spray voltage was set to 4 kV, and the heated capillary
temperature was set at 350°C. The sheath and auxiliary gas flow rates were set
to 25 units and 10 units, respectively. These conditions were held constant for
both positive and negative ionization mode acquisitions, which were both
performed for every sample. External mass calibration was accomplished using
the

standard

calibration

mixture

and

protocol

from

the

manufacturer

approximately every 2 days. For full scan profiling experiments, the MS was run
with resolution of 140,000 with a scan range of 113-1700 m/z. For lipid
identification studies, HCD fragmentation experiments were run. These
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experiments were performed by alternating between full scan acquisitions and all
ion fragmentation HCD scans. Samples were analyzed in both positive and
negative mode, and full scan settings were the same as listed above. For the all
ion fragmentation scans, the resolution was 140,000 with a scan range of 1131700 m/z. The normalized collision energy was 30eV, and a stepped collision
energy algorithm of 50% was used. Full scan MS data was evaluated using
Maven software (Melamud, et al. 2010), and lipid classes were identified by their
fragments using the Xcalibur software package (Thermo Fisher Scientific, San
Jose, CA) and information from the LIPID MAPS initiative (Fahy, et al. 2007).
Lipid species were verified using retention times, high mass accuracy, and
fragmentation data. Internal standards were not used in this study; therefore, the
relative amounts of each phospholipid species are presented. Inter-class
comparisons are possible, although some approximation of the relative
intensities is inherent due to differing ionization efficiencies among lipids with
different acyl chain lengths. Adequate separation of phospholipids was seen
(data not shown) (Cassilly et al., 2017).

Phosphatidylserine Synthase Assay
This procedure was done as previously described with minor alterations (BaeLee and Carman 1984, Cassilly, et al. 2016, Matsuo, et al. 2007). Cultures were
grown over night and then diluted into 1 L YPD, to approximately 0.1 OD600/mL.
These cultures were shaken at 30°C for 6 to 10 hours.

Cells were then
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harvested by centrifugation at 6,000 xg for 20 minutes.

Pellets were then

transferred to 50 mL conical tubes and washed with water and re-pelleted.
Supernatant was removed and the wet weight of the samples was taken. Cell
pellets were stored overnight in -80°C. The following day, a cold mixture of 0.1 M
Tris-Cl pH 7.5, 5 mM β-mercaptoethanol (BME), 10% glycerol, and protease
inhibitors (phenylmethylsuphonylfluoride (PMSF), leupeptin, and pepstatin) was
added to the frozen pellets (1mL/g [wet weight]) and allowed to thaw on ice.
Cells were lysed using a either a French Press (three passes at approximately
13,000 lb/in2) or using osmotic lysis (Graham, et al. 1994). The homogenate was
centrifuged at 4°C for 5 minutes at 3,000 rpm to clear unbroken cells and heavy
material. Supernatant was then spun again at 27,000 g for 10 minutes at 4°C.
For some experiments, the resulting supernatant was then spun at 100,000 g to
collect the lower density membranes. Pellets were resuspended in 500 μL to 1
mL of 0.1 M Tris-Cl pH 7.5, 5 mM β-mercaptoethanol (BME), 10% glycerol, and
protease inhibitors. This mixture was aliquoted into microcentrifuge tubes and
homogenized to break apart clumps, keeping on ice as much as possible. Total
crude protein concentration was determined using a Bradford Assay.

The

optimal assay mixture contained 50 mM Tris-HCl pH 7.5, 0.1% Triton X-100, 0.5
mM MnCl2, 0.1 mM CDP-DAG (Avanti Polar Lipids, Alabaster, AL) added as a
suspension in 1% to 20% Triton X-100 and 0.4-0.5 mg protein in a total volume
of 0.1 mL. The PS synthase assay was performed by monitoring the
incorporation of 0.5 mM L-serine spiked with 5% by volume [3H]-L-serine (~20
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Ci/mmol) into the chloroform-soluble product at 37°C for a predetermined amount
of time. The reaction was terminated by the addition of 1 mL chloroform:
methanol (2:1). Following a low-speed spin, 800 to 1000 μL of the supernatant
was removed to a fresh tube and washed with 200 μL 0.9% NaCl. Following a
second low-speed spin, 400-500 μL of the chloroform phase was removed to a
new tube and washed with 500 μL of chloroform: methanol: 0.9% NaCl (3:48:47).
Following a third low-speed spin, 200-300 μL was transferred into scintillation
vials (Thermo Fisher Scientific, San Jose, CA). Tubes were left open in the hood
until dried fully. The next day, 2.5 mL scintillation fluid was added to each tube
and run through the scintillation counter.

Statistical analysis
Graphs were made using GraphPad Prism version 6.04. Unpaired t-tests were
used to determine significance between results.

The lipidomics data were

normalized by dry weight prior to statistical analyses.

Results
Phospholipids synthesized in the de novo pathway are dominated by 34:n
species
Phospholipid profiles have previously been generated for the cho1Δ/Δ, psd1Δ/Δ,
and psd1Δ/Δ psd2Δ/Δ mutants using [32P]-labeled phospholipids and thin layer
chromatography (TLC) (Chen, et al. 2010). However, TLC only reveals levels of
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different lipid classes (polar head groups). We wanted to also determine the
differences among the individual species (fatty acid composition) within each
class.

Thus, profiles of the major phospholipid classes were generated via

lipidomics from lipids extracted from wild-type, cho1Δ/Δ, cho1Δ/Δ::CHO1,
psd1Δ/Δ, psd1Δ/Δ::PSD1, psd2Δ/Δ, psd2Δ/Δ::PSD2, psd1Δ/Δ psd2Δ/Δ strains of
C. albicans. The lipids were analyzed by UHPLC-ESI-MS using the protocol
described in methods and materials and adequate separation of standard
phospholipids was seen (data not shown). Profiles of PA, CDP-DAG, PI, PG,
CL, PS, PE, and PC from three biological replicates were generated and are
shown in Figure 1.2. Statistically significant differences for particular species
within each class compared to wild-type were seen (data not shown).
In the cho1Δ/Δ mutant, which lacks PS synthase (the initial step in the de
novo pathway, Fig. 1), PS is essentially absent, as expected (Fig. 1.2).

The

cho1Δ/Δ::CHO1 reintegrant strain exhibited a modest return of PS levels as
compared with the cho1Δ/Δ and wild-type strains. The reintegrant strain has only
one copy of CHO1, so haploinsufficiency is a possible explanation of this result.
However, since the level of PS in the reintegrant is only about 37% of the
wildtype, one allele may be dominant over the other.

C. albicans has well-

documented heterozygosity, which could account for this result (Eckert and
Muhlschlegel 2009).
The distribution of PS species in the wild-type consists predominantly of
34:n species, with 34:2 being the most prevalent (Fig. 1.2). The psd1Δ/Δ mutant,
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Figure 1. 2. The Phospholipid Species Profiles for the Major Classes of
Phospholipids in C. albicans Phospholipid Synthesis Mutants
(A) The phospholipid species profiles are shown for the major phospholipid
classes of phosphatidylserine (PS), phosphatidylethanolamine (PE),
phosphatidylcholine (PC), phosphatidylglycerol (PG), phosphatidylinositol (PI)
and cardiolipin (CL). (B) The species profiles detected are shown for the
precursor lipids phosphatidic acid (PA) and cytidyldiphosphate-diacylglycerol
(CDP-DAG). For each lipid class, a stacked bar graph is used and the species
associated with each color is shown in the legend based on the combined carbon
content and number of unsaturated bonds within the fatty acid component of the
phospholipid. The Y-axis of the graph is the area under the peak for each
species based on spectral profiles. The X-axis is the strains, which are as
follows: wild-type (WT), cho1 (cho1Δ/Δ), psd1 (psd1Δ/Δ), psd1, 2 (psd1Δ/Δ
psd2Δ/Δ), psd2 (psd2Δ/Δ), psd2R (psd2Δ/Δ::PSD2), psd1R (psd1Δ/Δ::PSD1).
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which lacks the dominant PS decarboxylase (predicted to be localized to the
mitochondria) that converts PS to PE, exhibits an overall increase in PS, but
especially of the 34:2 species. A slight increase in PS is seen in the psd2Δ/Δ
mutant, which lacks the alternative PS decarboxylase (predicted to localize to the
Golgi/endosome). The reintegrant strains psd1Δ/Δ::PSD1 and psd2Δ/Δ::PSD2
also show slight increases in levels of PS. The psd1Δ/Δ psd2Δ/Δ mutant, which
lacks all PS decarboxylase activity, has over a 3-fold increase in PS species
overall, but individual species are over-represented by 2 to 5 fold. The 34:n
species, which were the most abundant in wild-type, are also the most abundant
in psd1Δ/Δ psd2Δ/Δ and are over-represented by ~5 fold compared to wild-type.
However, it appears that all species are decarboxylated to some extent, given
that they build up as well.
PE is the direct downstream product of PS decarboxylation (Fig. 1), and
loss of PS was expected to result in a sizeable decrease in PE, but surprisingly
we saw increases in PE levels in most of our mutants (Fig. 1.2). Most of these
changes are not statistically significant in the majority of mutants, including
cho1Δ/Δ (data not shown), although they are for psd1Δ/Δ psd2Δ/Δ. The
maintenance of PE levels by the cho1Δ/Δ and psd1Δ/Δ psd2Δ/Δ mutants is likely
due to growing these cultures in YPD, a rich medium containing ethanolamine
and choline.

Since the cho1Δ/Δ and psd1Δ/Δ psd2Δ/Δ mutants have no

production of PE via the CDP-DAG pathway, it is likely that these mutants
compensate through activity from the Kennedy Pathway in order to synthesize
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PE. The psd1Δ/Δ mutant, which is missing the mitochondrial PS decarboxylase
activity, showed wild-type levels of PE, suggesting that the loss of Psd1p was
rescued by the redundant function of Psd2p. The psd2Δ/Δ strain exhibited an
increase in PE, but this was again not statistically significant.

The

psd2Δ/Δ::PSD2 strain did have significant increases in many phospholipids,
which was unexpected. The psd1Δ/Δ::PSD1 did not show many significant
differences from wild-type. Overall, the majority of PE species in wild-type are of
36:n or 34:n, and even in the psd1Δ/Δ psd2Δ/Δ where the changes were
significant, this only shifted slightly compared to wild-type.
Since the majority of PS is 34:n in wild-type cells, the Kennedy pathway
may account for half of the PE population (34:n) or significant acyl remodeling of
PS-derived PE is used to create other species after, or just prior to,
decarboxylation. However, since a similar distribution of PE is found in wild-type,
cho1Δ/Δ (totally lacks PS), and psd1Δ/Δ psd2Δ/Δ strains (cannot convert PS to
PE), this suggests that most of the 36:n PE is derived from the Kennedy
pathway, and the Kennedy pathway also synthesizes 34:n PE efficiently or
converts 36:n by acyl remodeling.
Previous studies with S. cerevisiae showed an accumulation of PC in the
Sccho1∆ mutant based upon TLC analysis (Atkinson, et al. 1980b). Indeed, our
data show an approximately 1.5 fold increase in the level of PC in both the
cho1Δ/Δ and psd1Δ/Δ psd2Δ/Δ mutants when compared to the wild-type (Fig
1.2).

The

most

obvious

common

relationship

between

cho1Δ/Δ

and
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psd1Δ/Δ psd2Δ/Δ is that both have a complete loss of de novo PE synthesis,
which may indicate that this metabolic alteration causes an increase in PC
synthesis via the Kennedy pathway. In the psd1Δ/Δ psd2Δ/Δ or cho1Δ/Δ
mutants, PC can be synthesized directly from choline and DAG via the Kennedy
pathway or by methylation of Kennedy-pathway-derived PE via the de novo
pathway (Fig. 1.1). However, from this data it is not possible to determine the
level of PC coming directly from Kennedy pathway versus the methylation of
Kennedy pathway derived PE to PC. Interestingly, the cho1Δ/Δ::CHO1 strain,
which has only one allele of CHO1, has wild-type levels of PC. Loss of PS
decarboxylase activity in psd1Δ/Δ or psd2Δ/Δ mutants also has little effect on PC
levels when compared with that of wild-type. Although there is a slight decrease
in PC in the psd2Δ/Δ mutant, it does not appear to be statistically significant.
These findings suggest that the organism strictly controls the production of PC to
at least maintain wild-type levels. The majority of PC species are 36:n and 38:n.
It is possible that the 36:n PC is formed through the de novo methylation of 36:n
PE. The 38:n species are probably produced from the importation of exogenous
choline. However, there are no striking changes within lipid species across
mutant strains to confirm or deny these hypotheses.
Increases in other CDP-DAG derived phospholipids may be caused by an
abundance of substrate in the PS synthase and PS decarboxylase mutants
Phosphatidic acid (PA) is the precursor for CDP-DAG (Gibellini, et al., 2010) that
is used to produce PS, PG, and PI (Fig. 1.1). The cho1Δ/Δ mutant showed a
67

nearly 3 fold increase in PA levels when compared to wild-type (Fig 1.2). These
results were expected because the loss of PS synthesis causes a major
blockage in de novo phospholipid synthesis, which would in turn lead to a buildup of the precursor molecule PA (substrate for CDP-DAG). This is further
supported by the intermediate level of PA in cho1Δ/Δ::CHO1, which correlates
with the partial return of PS production, and thus increased usage of PA. Varying
increases are shown in PA levels within psd1Δ/Δ and psd2Δ/Δ mutants and their
reintegrant strains, again potentially relating back to the build-up of PS in these
strains, which translates into a build-up of PA. This is supported by the large
increase in PA seen in psd1Δ/Δ psd2Δ/Δ, which has no de novo PE production,
and thus represents a blockage in this biosynthetic pathway.
We also aimed to analyze the levels of CDP-DAG within our mutants and
found that we could only detect 32:0 species and that the overall levels of this
precursor lipid were extremely low (Fig. 1.2B). This suggests that there is a high
turnover of CDP-DAG and that it is rapidly used to produce PS, PI, or PG.
Although there was some variability within the CDP-DAG levels, including
increases in most of the mutants tested, none of these changes were statistically
significant when compared to wild-type. However, the change in CDP-DAG levels
within our mutants again could easily be attributed to a back up in the de novo
synthesis (either a halt of PS production or usage) which causes increases in
CDP-DAG levels.
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In addition to the precursors, we also looked at the levels of the other two
phospholipids produced from CDP-DAG, PI and PG, as well as CL, which is
produced from PG (Gibellini, et al., 2010). Both the cho1Δ/Δ and the psd1Δ/Δ
psd2Δ/Δ mutants show increases in PI and PG levels. Where the cho1Δ/Δ PI
levels increase by around 2.5 fold, the psd1Δ/Δ psd2Δ/Δ increase is more
modest. For PG we see an increase in both cho1Δ/Δ and psd1Δ/Δpsd2Δ/Δ, at
approximately 5-fold and 4-fold, respectively. These findings could be a result of
more CDP-DAG being available for the production of PI and PG due to a
blockage of PS synthesis (cho1Δ/Δ) or a build-up in PS (psd1Δ/Δ psd2Δ/Δ). PI
and PG seem to be tightly controlled, however, because in all other mutant and
reintegrant strains, the levels return to wild-type. Finally, levels of CL correspond
well with the changes in PG within our mutant strains. This indicates that some of
the excess PG produced can be further modified to produce CL. These findings
correlate well with studies in S. cerevisiae and confirm our previous results with
TLC (Atkinson, et al. 1980b, Chen, et al. 2010). Interestingly, as with PS, the
most abundant species of PI and PG appear to be 34:n, thus it is possible that
most CDP-DAG destined for PS synthesis is 34:n, but our lipidomics yields of
CDP-DAG were too low to verify this, and it may be 34:n CDP-DAG is so rapidly
processed into other lipids that it is hard to detect at steady-state.
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Phosphatidylserine Synthesis in PS synthase and PS decarboxylase
mutants
The psd1Δ/Δ psd2Δ/Δ mutant exhibits a large increase in PS levels (Fig. 1.2),
which is presumed to be caused by decreased decarboxylation of PS to PE.
However, it is possible that this is due to increased PS synthase activity instead.
This seemed doubtful, but to test this, an in vitro PS synthase assay was
performed on cellular membranes, which were isolated from cell lysates via a
27,000xg centrifugation step. Additional low density membranes were isolated
via a 100,000xg centrifugation step.

However, as highly variable results were

found in the 100,000xg membrane prep, data was generated from the 27,000xg
membranes which provided more consistent results.

The assay was used to

compare the incorporation of [3H]-serine into membranes upon the addition of
CDP-DAG between wild-type, cho1Δ/Δ, cho1Δ/Δ::CHO1, psd1Δ/Δ, psd1Δ/Δ
psd2Δ/Δ, and psd1Δ/Δ::PSD1 strains. Wild-type levels of PS synthase activity
were seen in the psd1Δ/Δ and psd1Δ/Δ psd2Δ/Δ strains, indicating that these
strains have similar enzyme activities as the wild-type organism (Fig. 1.3). Thus,
the excess PS in the psd1Δ/Δ psd2Δ/Δ mutant is likely a product of the loss of
PS decarboxylase activity and build-up of substrate.
As expected from this assay, the cho1Δ/Δ mutant exhibited no PS
synthase activity. However, the cho1Δ/Δ::CHO1 reintegrant strain had only
about 10% of the activity of the wild-type. This compares with the decreased PS
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Figure 1. 3. PS Synthase Activity Across Strains
Cho1p activity within different mutant strains of C. albicans.
Cellular membranes containing Cho1p were isolated and
treated with CDP-DAG and [3H]-serine. Activity is measured
as counts per minute per milligram of protein. Values are
shown as an average of three experiments averaged and
normalized to the wild-type (WT) control. P < 0.0001.
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levels in the reintegrant as measured by lipidomics (Fig. 1.2). Haploinsufficiency
may account for this lower activity.

C. albicans Cho1p enzyme kinetics are similar to those reported for S.
cerevisiae
The wild-type and other strains seemed to have similar PS synthase activity
levels, but it was of interest to know more about the enzyme kinetics of C.
albicans Cho1p, if it is to be considered for potential use as a drug target. The
Km and apparent Vmax of this enzyme was calculated for both serine and CDPDAG (Fig. 4). L-serine, where the CDP-DAG was held constant at 0.1 mM,
yielded a Km of 1.2±0.57 mM and an apparent Vmax of 0.15±0.02
nmole/minute/mg of protein (Fig. 1.4A). For CDP-DAG, where the serine was
held constant at 2.5 mM, a Km of 43.17±19.18 μM and an apparent Vmax of
0.19±0.023 nmole/minute/mg of protein (Fig. 1.4B) was obtained. Interestingly,
the intracellular concentration of serine in S. cerevisiae has been estimated to be
around 2 mM on average (Hans, et al. 2003), which fits well with the Km for
serine. These assays were performed on the crude 27,000xg membranes in
order to determine their kinetics within native membranes. These compare
relatively closely with what has been reported for S. cerevisiae (Bae-Lee and
Carman 1984).
To control for the possibility that any similar substrate molecules to serine
might give a similar activity, which could cast doubt on the accuracy of the assay,
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Figure 1. 4. Enzyme Kinetics for Cho1p
The PS synthase assay was performed with varying concentrations of substrate
over time courses to generate enzyme kinetics for both substrates. (A) The
Michaelis-Menton curve for the l-serine substrate shows a Km of 1.243 ± 0.5715
mM and an apparent Vmax of 0.1514 ± 0.02059 nmole/min/mg of protein. (B) The
Michaelis-Menton curve for the CDP-DAG substrate shows a Km of 43.17 ± 19.18
μM and an apparent Vmax of 0.1919 ± 0.02361 nmole/min/mg of protein.
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we determined whether increasing concentrations of cold

D-serine

or threonine

(similar amino acid) could compete with [ 3H]-L-serine for incorporation into [3H]PS. Only at the highest concentration of 200 mM (400x) did the cold

D-serine

show any competition with L-serine (Fig. 1.5). Threonine showed no statistically
significant competition with L-serine, even at 200 mM (400x). As a control, cold
L-serine

eliminated incorporation of [3H]-L-serine at a 10x concentration (5 mM).

Thus, this assay would not yield a product with these two similar molecules (Dserine or threonine), thus suggesting that the assay is specifically measuring
activity against L-serine.

Discussion
The loss of de novo PE synthesis and/or PS synthesis has striking effects on the
phospholipidome, which are consistent with what we know from fungal
phospholipid metabolism. In particular, the loss of the de novo pathway for PS
and/or PE synthesis appears to increase the synthesis of other CDP-DAGdependent phospholipids like PI and PG (Fig. 1.2). Surprisingly, PE and PC
levels appear to be buffered against change, presumably by the activity of the
Kennedy pathway. The 34:n species are the most prominent forms of PS, and
34:2 in particular is the most actively used substrate by PS decarboxylase
enzymes to synthesize PE, and the 34:2 species is also what builds up in PI and
PG, which may suggest that either Cho1p preferentially uses 34:2 CDP-DAG, or
34:2 CDP-DAG is what it encounters in its subdomains in the ER.
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Figure 1. 5. Cho1p Specificity for L-serine.
The PS synthase assay was performed with 0.5 mM [3H]-serine and 0.1 mM
CDP-DAG. An excess of d-serine (A) or L-threonine (B) was added at varying
concentrations. Only D-serine or L-threonine at concentrations 400-fold that of Lserine show any inhibition in [3H]-PS production. Values are shown as an
average of three experiments averaged and normalized to the wild-type control.
P = 0.0361.
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Finally, our analysis of the enzymology of Cho1p from C. albicans reveals
it is very similar to S. cerevisiae, and that changes in the enzyme activity, for
example in the CHO1 compared to cho1Δ/Δ::CHO1 strains, seem to correlate
with one another rather closely. These analyses set the stage for better
understanding how strategies to inhibit de novo PS or PE synthesis, which are
required for virulence of C. albicans, may impact overall lipid profiles and ability
to cause disease.
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CHAPTER II
SB-224289 ANTAGONIZES THE ANTIFUNGAL MECHANISM OF
THE MARINE DEPSIPEPTIDE PAPUAMIDE A
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Abstract
In order to expand the repertoire of antifungal compounds a novel, highthroughput phenotypic drug screen targeting fungal phosphatidylserine (PS)
synthase (Cho1p) was developed based on antagonism of the toxin papuamide
A (Pap-A). Pap-A is a cyclic depsipeptide that binds to PS in the membrane of
wild-type C. albicans and permeabilizes its plasma membrane, ultimately causing
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cell death. Organisms with a homozygous deletion of the CHO1 gene (cho1ΔΔ)
do not produce PS and are able to survive in the presence of Pap-A. Using this
phenotype (i.e. resistance to Pap-A) as an indicator of Cho1p inhibition, we
screened over 5,500 small molecules for Pap-A resistance and identified SB224289 as a positive hit. SB-224289, previously reported as a selective human
5-HT1B receptor antagonist, also confers resistance to the similar toxin
theopapuamide (TPap-A), but not to other cytotoxic depsipeptides tested.
Structurally similar molecules and truncated variants of SB-224289 do not confer
resistance to Pap-A suggesting that the toxin-blocking ability of SB-224289 is
very specific.

Further biochemical characterization revealed that SB-224289

does not inhibit Cho1p, indicating that Pap-A resistance is conferred by another
undetermined mechanism.

Although the mode of resistance is unclear,

interaction between SB-224289 and Pap-A or TPap-A suggests this screening
assay could be adapted for discovering other compounds which could
antagonize

the

effects

of

other

environmentally-

or

medically-relevant

depsipeptide toxins.

Introduction
Patients with a compromised immune system are prone to develop nosocomial
infections which can be fungal, bacterial, parasitic, or viral in nature. Candida
spp. are pathogenic fungi responsible for the majority of fungal infections arising
within hospitals (Mishra, et al. 2007, Morrell, et al. 2005). Of these, the species
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found most often is Candida albicans (Papon, et al. 2013). This fungus most
commonly causes mucosal infections including vaginal infections and oral thrush,
but it can also cause life-threatening infections.

The most serious of these

include fungal endocarditis and systemic bloodstream infections which have
mortality rates around or greater than 30% (Baddley, et al. 2008, Pfaller and
Diekema 2007).
There are currently three primary classes of antifungals used to treat
invasive Candida infections.

The first line defense includes azoles (e.g.

fluconazole) and echinocandins (e.g. caspofungin).

However, resistance and

tolerance to these drugs can lead to treatment failures (Alexander, et al. 2013,
Dannaoui, et al. 2012, Pfaller 2012, Srinivasan, et al. 2014). The mainstay of
second line defense is the polyene amphotericin B, a drug that must be carefully
administered due to its nephrotoxic potential (Ghannoum and Rice 1999,
Holeman and Einstein 1963).

As a result of drug resistance, poor oral

availability, and toxic side effects including drug-drug interactions (Mukherjee, et
al. 2005), there is a clear need for new antifungal drugs to treat Candida
infections.
Previously, the fungal phosphatidylserine (PS) synthase (Cho1p) was
identified as a promising antifungal drug target for several reasons. First, Cho1p
has been demonstrated to be required for Candida albicans virulence in a mouse
model of systemic infection (Chen, et al. 2010). Mice infected with a strain of C.
albicans where both alleles of the Cho1p gene are deleted (cho1ΔΔ) were able to
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survive indefinitely, whereas mice infected with the wild-type strain succumbed to
infection within two weeks (Chen, et al. 2010). Second, the Cho1p enzyme is
conserved among many pathogenic fungi (Braun, et al. 2005, Chen, et al. 2010).
Last, Cho1p is absent within mammals (Atkinson, et al. 1980b, Braun, et al.
2005, Chen, et al. 2010, Kuge, et al. 1986). Based on these observations, we
hypothesized that high affinity inhibitors of Cho1p should render the organism
unable to cause infection within a host, be active against a broad range of fungal
pathogens, and be highly selective with minimal side effects in mammals.
Based on this hypothesis, we set out to identify inhibitors of this pathway using a
cell based high-throughput screening approach.

The assay is based on the

action of a PS-dependent toxin, papuamide A (Pap-A), which is a cyclic
depsipeptide isolated from marine sponges of the genus Theonella. Pap-A kills
C. albicans and other yeasts by binding to PS in the membrane and forming
pores that disrupt the integrity of the membrane (Andjelic, et al. 2008, Parsons, et
al. 2006). We wished to exploit the PS-specific nature of Pap-A toxicity and
identify compounds that block PS synthesis or alternatively interfere with PS
metabolism, by selecting those small molecules that allow C. albicans survival in
the presence of Pap-A. Thus, the Pap-A killing assay was adapted into a robust
384-well plate screening assay and tested against a reference set of bioactive
compounds including many known drugs.
This screen showed a good statistical window and yielded several
promising hits. However, we found that Pap-A resistance is not specific enough
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to conclude that a compound targets Cho1p, as other mechanisms can be
responsible for this protection phenotype.

In this study we describe the

characterization of a positive hit, SB-224289, which in turn showed interesting
and highly specific behavior that blocks Pap-A mediated cellular poisoning.

Materials and Methods
Strains Used
The SC5314 (wild-type) strain of C. albicans and mutants used in this study have
been previously described (Chen, et al. 2010) and are as follows: cho1∆∆
(YLC337), and cho1∆∆::CHO1 (YLC344). The media used to culture strains was
YPD (1% Bacto yeast extract, 2% Bacto peptone, and 2% dextrose (Thermo
Fisher Scientific, San Jose, CA)) (Guthrie 2002).

Compounds
The 5,760 bioactive compound library is a collated compound set of approved
drugs (675 compounds) and biologically active compounds that have been
documented to interact with wide range of targets (approximately 5095
compounds) including Sigma Aldrich’s Library of Pharmacologically Active
Compounds (LOPAC), Prestwick, and Microsource compound libraries. The
library compounds were all independently verified for purity and identity by
UPLC-MS analysis. Papuamide A was obtained from Flintbox in association with
David Williams from the University of British Colombia, Canada. SB-224289
85

(Cat. # 1221), MG-624 (Cat. # 1356), and valinomycin (VA; Cat. # 3373) were
ordered from Tocris Bioscience. GMC 2-29 (Cat. # 1080) and SB-216641 (Cat. #
1085) were ordered from Axon MedChem. Staurosporine (CGP 41251) was
ordered from Selleckchem. Kahalalide F (KF) was a kind gift from Dr. Fernando
Albericio at the Institute for Research in Biomedicine, Barcelona, Spain.
Theopapuamide (TPap-A) was provided by Dr. Mark Hamann at University of
Mississippi, University, Mississippi, USA. Compounds 2945, 2946, 3047, and
3048 were synthesized as described previously (Gaster, et al. 1998). Details of
the synthesis and compound characterization data are provided the manuscript
(Cassilly et al., 2016).

Papuamide A resistance assay
Strains were grown overnight in liquid YPD shaking at 30°C to saturation, and
cultures were diluted to 2 x 104 cells/ml in YPD. Compounds of interest were
diluted to twice the working concentration by serial dilution in a 96 well plate or by
preparing separately and adding to the wells directly, in a volume of 37.5 μl of
YPD. Then 37.5 μl of cells at 2 x 104 cells/ml in YPD were added. Plates were
incubated at 37°C for 6 hours or 3 hours depending on the experiment, and then
75 μl of YPD containing depsipeptide (Pap-A at 8 μg/ml, VA at 6 μg/ml, KF at 30
μg/ml, or TPap-A at 12 μg/ml) was added to each well, diluting those
concentrations by half. This addition was followed by a 37°C overnight
incubation.
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Cell survival was measured the next day by fluorescence intensity or
optical density. For fluorescence intensity, Alamar Blue (Invitrogen, Waltham,
MA) was added to the wells at a 1:10 dilution. Plates were allowed to incubate
again at 37°C for 30 minutes to 2 hours until color change was apparent.
Fluorescence was then read at excitation 550 nm and emission 590 nm. For
optical density, plates were removed from overnight incubation and absorbance
was read in a plate reader at a wavelength of 600 nm. All measurements were
performed on a Cytation3 BioTek plate reader using Gen 5 software.

High throughput screen for Pap-A resistance
The 5,760 compound library was screened in a total of eighteen 384 well plates
(Nunc) at a final concentration of 50-75 μM. Approximately 0.155 μl of compound
dissolved in DMSO were inoculated into 10 μl of YPD in each well from ~10 mM
stock plates using a BioMek robot with pin tools. Wild-type and cho1∆∆ (positive
control strain) were grown in liquid YPD in a 30°C shaker overnight and cultures
were diluted to 104 cells/ml in YPD, and 10 μl were added to each well of the 384
well plate containing the test compound using a Wellmate. Plates were incubated
for 6 hours at 37°C, and then 10 μl of YPD containing 12 μg/ml Pap-A was added
to give a final concentration of 4 μg/ml in 30 μl of YPD. Plates were then
incubated for another 16 hours at 37°C to allow selection for Pap-A resistance.
The following day, cell survival was measured by adding Alamar Blue (Invitrogen,
Waltham, MA) at a 1:10 dilution using a Wellmate.

Plates were allowed to
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incubate again at 37°C for 2 hours. Fluorescence was then read at excitation
550 nm and emission 590 nm on an Envision plate reader (Perkin Elmer,
Waltham, MA).

In each plate, three of the columns of wells were used as

controls. One column contained no compounds and no cells and served as
background control. The positive control column contained cho1ΔΔ plus Pap-A,
as it showed resistance. An additional control was wild-type with no drugs and no
Pap-A for maximal wild-type growth. The averaged background readings from
the wild-type cells plus compounds in the presence of Pap-A served as the
negative control in each plate.

Phosphatidylserine Synthase Assay
This procedure was done as described in (Bae-Lee and Carman 1984, Matsuo,
et al. 2007) with minor alterations. Cultures were grown overnight and then
diluted to approximately 0.1 OD600/ml in 1 L YPD, and were shaken at 30°C for 6
to 10 hours. Cells were harvested by centrifugation at 6,000 x g for 20 minutes.
Pellets were then transferred to 50 ml conical tubes and washed with water and
re-pelleted. Supernatant was removed and the wet weight of the samples was
taken. Cell pellets were stored overnight in -80°C. The following day, a cold
mixture of 0.1 M Tris-Cl pH 7.5, 5 mM β-mercaptoethanol (BME), 10% glycerol ,
and protease inhibitors 1.7 μg/ml PMSF, 1 μg/ml leupeptin, and 1 μg/ml pepstatin
(RPI, Corp., Mount Prospect, IL, USA) was added to the frozen pellets (1 ml/g
[wet weight]) and allowed to thaw on ice. Cells were lysed using a French press
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(three passes at approximately 13,000 lb/in 2). The homogenate was centrifuged
at 4°C for 5 minutes at 3,000 rpm to clear unbroken cells and heavy material.
Supernatant was then spun again at 27,000 x g for 10 minutes at 4°C. For some
experiments, the resulting supernatant was then spun at 100,000 xg to collect the
lower density membranes. Pellets were resuspended in 500 μl to 1 ml of 0.1 M
Tris-Cl pH 7.5, 5 mM BME, 10% glycerol, and protease inhibitors. This mixture
was aliquoted into microcentrifuge tubes and homogenized to break apart
clumps, keeping on ice as much as possible. Total crude protein concentration
was determined using a Bradford Assay. The optimal assay mixture contained
50 mM Tris-HCl pH 7.5, 0.1% Triton X-100, 0.5 mM MnCl2, 0.1 mM CDP-DAG
(Avanti Polar Lipids, Alabaster, AL) added as a suspension in 1% - 20% Triton X100, and 0.4 - 0.5 mg protein in a total volume of 0.1 ml. SB-224289 and MG624 were added to the reaction mixture at varying concentrations to monitor their
ability to inhibit [3H]-PS production. The PS synthase assay was performed by
monitoring the incorporation of 0.5 mM L-serine spiked with 5% [3H]-L-serine (or
0.02 μM) (Cat# ART 0246, ARC, Inc., St. Louis, MO, USA) into the chloroformsoluble product at 37°C for a predetermined amount of time. The reaction was
terminated by the addition of 1 ml chloroform: methanol (2:1). Following a lowspeed spin, 800 - 1000 μl of the supernatant was removed to a fresh tube and
washed with 200 μl 0.9% NaCl. Following a second low-speed spin, 400 - 500 μl
of the organic phase was removed to a new tube and washed with 500 μl of
chloroform: methanol: 0.9% NaCl (3:48:47). Following a third low-speed spin,
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200 - 300 μl was transferred into scintillation vials (Thermo Fisher Scientific, San
Jose, CA). Tubes were dried under the chemical hood and 2.5 ml Cytoscint-ES
liquid scintillation cocktail (MP Bio, Santa Ana, CA, USA) was added to each tube
and counted in a Packard TriCarb 2900TR Liquid Scintillation Analyzer.

Statistical analysis
Graphs were made using GraphPad Prism version 6.04. Unpaired t-tests were
used to determine significance between results. RISE (Robust Investigation of
Screening Experiments) software was used to analyze data from the high
throughput screen and was used to calculate Z-factors, identify 95th and 99th
quantile data, and identify compounds that yielded hits of greater than 90% of
positive control (cho1∆∆).

Results
Screen for compounds that confer Pap-A resistance
A novel screen was developed with an original goal of identifying compounds that
inhibit the Cho1p PS synthase enzyme. This screen utilizes the unique activity of
Pap-A, a toxin isolated from Theonella spp. of sponges (Ford 1999). Pap-A has
been shown to selectively compromise the integrity of membranes containing PS
(Andjelic, et al. 2008, Parsons, et al. 2006). As a result, Pap-A is toxic to wildtype C. albicans. However, the cho1ΔΔ mutant, which lacks Cho1p, and thus
has no PS in its membranes, is able to survive in the presence of Pap-A
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Figure 2. 1. Resistance to Pap-A Correlates
with Decreases in PS.
The cho1ΔΔ mutant
is
resistant
to
all
concentrations of papuamide A (Pap-A) indicating
a total lack of PS. The cho1ΔΔ::CHO1 reintegrant
strain is more resistant to Pap-A than the wild-type
(WT), but less resistant than the cho1ΔΔ mutant.
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(Fig. 2.1) (Chen, et al. 2010). A reintegrated strain, cho1ΔΔ::CHO1 which has
one allele of CHO1 and intermediate levels of PS (Chen, et al. 2010) shows
intermediate resistance (Fig. 2.1). This feature of Pap-A was employed as a
selection tool in our screen to identify those compounds that inhibit Cho1p. We
hypothesized that some compounds that allow wild-type growth in the presence
of Pap-A would do so by decreasing levels of PS in membranes.
The

screen

was

performed

on

approximately

5,600

diverse

pharmacologically active compounds as representative set of chemical space.
Each plate contained a column for each control: 1) cho1ΔΔ + Pap-A as a positive
control 2) no cells/no Pap-A as a background control 3) wild-type cells with no
drugs or Pap-A for a wild-type growth control. The remainder of the plate was
reserved for compound testing by pin transfer, and served as a control for
background of wild-type cells killed by Pap-A.
The majority of test wells (black open circles in Fig. 2.2), which contained
cells that were killed by Pap-A, read near the no drug/no cell background control
(red circles, Fig. 2.2). Compounds were tested at a final concentration of 50-75
μM for their ability to provide resistance to wild-type C. albicans against a lethal
dose of Pap-A (4 μg/ml). After incubation overnight, the viability indicator Alamar
Blue was added and fluorescence measured at 590 nm as a proxy for survival.
Of the tested compounds, 21 (filled in blue circles) showed viability greater than
or equal to 90% of the cho1ΔΔ positive control (green circles) (Fig. 2.2). These
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Figure 2. 2. Screen of FDA-approved Bioactive Compounds for Those that
Confer Pap-A Resistance
5,760 compounds were screened for their effects on the growth of wild-type C.
albicans (open black circles) in the presence of 4 μg/ml Pap-A. Cell growth was
measured by transformation of the dye Alamar Blue over approximately 3 hours
at 37°C. The cho1ΔΔpositive control cells growth in the presence of Pap-A with
no compounds from the library are represented by green circles. Compounds
that allowed wild-type cells to display >90% (above the blue line) of the growth
of cho1ΔΔ control were designated with filled-in blue circles. Around 95% of the
tested compounds showed growth levels closer to the negative control, wells
which contained no cells or drugs (open red circles). The horizontal lines show
the 99th quantile (purple) where 99% of the compounds exhibited growth and the
95th quantile (yellow) 95% of the compounds lie. The vertical lines divide the
compounds by the 384-well plate in which they were screened which correlate to
plate numbers along the bottom. A full description of the screening method is
found in Materials and Methods.
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21 compounds, were considered first round positive hits and were selected and
tested for reproducibility in providing Pap-A resistance (data not shown).

Of

these 21 first round hits, two compounds reproducibly conferred Pap-A
resistance to the wild-type cells: SB-224289, a serotonin receptor antagonist
(Selkirk, et al. 1998b), and MG-624, a nicotinic acetylcholine receptor antagonist
(Fig. 2.3A).
Dose response curves were performed to determine the lowest
concentrations of SB-224289 and MG-624 that could confer Pap-A resistance.
Serial dilutions starting at 200 μM revealed that SB-224289 could confer
resistance down to 25 μM, while MG-624 was not consistently effective at
producing Pap-A resistance.

We found that effects of SB-224289 at

concentrations above 400 μM could not be determined as this was greater than
its solubility limit in the test media (data not shown). Efforts were focused on SB224289, which showed consistent efficacy at a concentration range from 100 μM
to 25 μM (Fig. 2.3B).

Identification of structural features that enable SB-224289 to confer Pap-A
resistance
In order to determine if Pap-A resistance is a property common to compounds
with a similar structure to SB-224289, we searched the other compounds
screened in our library and found one structural analog, GR127935, which did
not provide Pap-A resistance (Fig. 2.4A, data not shown). Two other structural
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Figure 2. 3. Compounds that Conferred Pap-A Resistance to C.
albicans Wild-type Yeast
(A) Structures of hits identified from the screen. (B) Comparison of the ability of
the hits to confer Pap-A resistance to wild type C. albicans; SB-224289, MG-624,
and DMSO as a control.
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Figure 2. 4. The Full Structure of SB-224289 is Required to Provide Pap-A
Resistance
(A) and (B) show the structures of purchased or synthesized analogs of SB224289, respectively. In (C) and (D) 1x104 cells/ml were treated with a serial
dilution of SB-224289, test compounds or DMSO control, and then allowed to
incubate for 6 hours at 37°C. Pap-A was added at either 4 μg/ml or 5 μg/ml after
6 hours the plate was incubated at 37°C overnight. Alamar Blue was added and
fluorescence signal measured at 590 nm indicating survival of cells.

96

analogs of SB-224289, GMC 2-29 and SB-216641, were tested to assess their
ability to confer Pap-A resistance to wild-type C. albicans (Fig. 2.4A&C). We
found that neither analog rescued cells when compared with the SB-224289
control. This finding prompted us to hypothesize that the areas of structural
dissimilarity between SB-224289 and GR127935, GMC 2-29, and SB-216641—
specifically the spirofuro-indole ring structure unique to SB-224289—may be the
key to conferring Pap-A resistance. We synthesized four SB-224289 ring
structure homologues, 2945, 2946, 3047, and 3048 (Fig. 2.4B), and tested their
ability to provide Pap-A resistance to wild-type C. albicans. Although we
expected protection against Pap-A at similar or even lower concentrations, none
of the synthesized SB-224289 ring structures provided resistance to Pap-A (Figs
2.4B & D). These data indicate that the full molecular structure of SB-224289 is
required for producing Pap-A resistance to wild-type C. albicans.

Exploration of the Mechanism of Action of SB-224289
We hypothesized that SB-224289 inhibited the PS synthase enzyme, Cho1p,
thus reducing levels of PS and allowing wild-type cells to survive despite the
activity of Pap-A. In order to test this hypothesis, we performed a PS synthase
assay to assess the activity of Cho1p with the addition of varying concentrations
of SB-224289.

Upon addition of SB-224289, no changes were seen in the

activity of the Cho1p enzyme as compared to the wild-type control, indicating that
SB-224289 does not directly inhibit the PS synthase enzyme in this in vitro assay
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Figure 2. 5. SB-224289 and MG-624 Do Not Inhibit the Activity of Cho1p.
PS synthase activity shown as counts per minute per milligram of protein,
quantifying 3H-L-serine incorporated into PS. Addition of varying concentrations
of SB-224289 (A) and MG-624 (B) did not have an inhibitory effect on PS
production.
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(Fig. 2.5A). Furthermore, a PS synthase assay was performed with MG-624 at
varying concentrations. Again, no PS synthase inhibition was observed in any
concentration tested (Fig. 2.5B).
To further investigate the mode of action of SB-224289, we assessed the
compound’s ability to inhibit PS synthesis in vivo. If the compound must be
metabolized or modified internally in order to inhibit Cho1p, we should see a
decrease in PS levels only when treating live cells with SB-224289. Previous
studies showed that cho1ΔΔ, which has no PS, shows a distinct phenotype of β
(1-3)-glucan unmasking (Davis, et al. 2014b). Based on this, we performed an
assay to determine if treatment with SB-224289 would cause the β (1-3)-glucan
in the cell wall to become exposed. Cells were treated with SB-224289 for 3
hours and then stained with β (1-3)-glucan antibody. However, epifluorescence
microscopy showed no indication that β (1-3)-glucan was exposed in SB-224289treated cells (data not shown).

PS is also a precursor for the synthesis of

phosphatidylethanolamine (PE), in a pathway where PS is decarboxylated to
form PE.

As a result, the cho1∆∆ mutant, since it lacks PS, requires

ethanolamine in the medium so it can make PE from imported ethanolamine via
the Kennedy pathway. If SB-224289 is a PS synthase inhibitor, then it should
have caused ethanolamine auxotrophy in wild-type C. albicans, however, this
was not the case (data not shown).
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Figure 2. 6. SB-224289 Protects Against Theopapuamide, but Not Other
Depsipeptides.
(A) The structure of several depsipeptides are shown. For each of these
compounds, 1x104 cells/ml were treated with serially diluted concentrations of
SB-224289 (SB) and were incubated for 3 hours at 37°C. Following this
incubation, (B) 3 μg/ml valinomycin (VA), (C) 15 μg/ml kahalalide F (KF), or (D) 6
μg/ml theopapuamide (TA) was added and further allowed to incubate overnight.
Optical density (OD) was read at 600 nm the next day as a measure of cell
survival.
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SB-224289 specifically blocks the activity of Pap-A and not other
membrane disruptors
Naturally-produced depsipeptides share similar structures (Fig. 2.6) and can be
medically relevant

like

the antibiotic

valinomycin

(VA)

produced

from

Streptomyces spp. (Kroten, et al. 2010, Tempelaars, et al. 2011), the emetic
toxin cereulide produced by the foodborne pathogen Bacillus cereus (Agata, et
al. 1995, Andersson, et al. 1998, Kroten, et al. 2010, Zuberovic Muratovic, et al.
2014), and anti-tumor drug prospect kahalalide F (KF) found in sea slugs
(Suarez, et al. 2003).

A previous study found that a serotonin receptor

antagonist, ondansetron hydrochloride, abolished the emetic effect of cereulide in
Asian house shrews (Agata, et al. 1995). Theopapuamide A (TPap-A) is a close
structural relative of Pap-A and was previously shown to have potent antifungal
activity (Plaza, et al. 2009, Ratnayake, et al. 2006). Based on these studies, we
were interested in determining if SB-224289 would block the activities of similar
depsipeptide toxins.
First, we tested if SB-224289 could rescue cells from toxic levels of VA.
We treated C. albicans with serially diluted concentrations of SB-224289,
followed by treatment with 6 μg/ml of VA. We found that no concentration of SB224289 was sufficient to provide protection to cells (Fig. 2.6A).

We further

measured the ability of SB-224289 to mitigate the toxicity of KF and TPap-A (Fig.
2.6B & C). SB-224289 was unable to protect wild-type cells against KF, but we
found that SB-224289 was able to provide protection against TPap-A.
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Discussion
The screen described in this communication was originally intended to identify
inhibitors of the fungal PS synthase. However, the identified hit compound, SB224289, does not inhibit PS synthesis even though it interferes with the lethal
effects of Pap-A on C. albicans cells that contain PS. The evidence that SB224289 does not block PS synthesis comes from several secondary screens
based on the cho1ΔΔ mutant’s characteristic phenotype (Chen, et al. 2010). For
example, the cho1∆∆ mutant is an ethanolamine auxotroph because C. albicans
uses PS as a precursor for production of PE, a vital phospholipid, in one of its
two PE synthesis pathways.

Thus, ethanolamine must be supplemented in the

medium so that the organism can produce PE through the alternative Kennedy
Pathway. We saw no indication that treatment with SB-224289 caused wild-type
C. albicans to become an ethanolamine auxotroph (data not shown), indicating
that it does not interfere with PS synthesis.

A second useful phenotype is

increased exposure of β (1-3)-glucan in the cell wall upon loss of PS. The cause
of this exposure in cho1ΔΔ is currently unknown, but it is very specific to the loss
of PS rather than PE (Davis, et al. 2014b). As with the previous assay, treatment
with SB-224289 does not lead to exposure of ß (1-3)-glucan, thus indicating that
it does not interfere with PS synthesis (data not shown). Finally, SB-224289 did
not interfere with PS synthesis in an in vitro assay (Fig. 2.5A).
The most interesting aspect of the blockade of the lethal effects of Pap-A
on C. albicans by SB-224289 is its specificity.

Seven different analogs
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representing fragments of SB-224289 or the entire molecule fail to rescue C.
albicans from Pap-A-induced cytotoxicity. These results indicate that the activity
of SB-224289 is specific and relies on the entire structure of the molecule (Fig.
2.4), possibly, due to a specific three-dimensional conformation which could only
be adopted by the full SB-224289. In addition, SB-224289 could only inhibit the
toxicity of depsipeptides that were structurally highly similar. For example, we
saw no indication that SB-224289 provided protection to wild-type C. albicans
treated with VA or KF (Fig. 6). However, as expected, SB-224289 was able to
abrogate the cytotoxicity of TPap-A, a close structural relative of Pap-A (Fig. 6)
likely to bind PS as well. Altogether, these data suggest that there might be a
physical interaction between the two compounds that inhibits the toxic effects of
Pap-A. More specifically, structural differences in the tail regions of these related
depsipeptides may confer their selectivity.

It is also possible that SB-224289

impacts cellular physiology in a way that creates a protective response, but it is
unclear what such a mechanism might entail.
Further studies are needed to understand the nature of the interaction
between SB-224289 and Pap-A and the mechanism that leads to protection of C.
albicans cells against Pap-A toxicity. Although SB-224289 is clearly not acting by
inhibiting Cho1p, the selective inactivation of the Pap-A toxin by SB-224289
indicates a path to the discovery of other compounds that can inactivate similar
membrane active toxins. In fact, the assay described herein could be easily
adapted from use with Pap-A to any number of membrane potent toxins to find
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antagonists. The compounds discovered by this approach would be useful for
treatments against environmental toxins that occur during algal blooms that affect
drinking water, food contamination, etc. It could also be useful as a method for
identifying potential drug interactions that would counter-indicate compounds or
combination therapies being considered as potential anti-cancer or anti-microbial
drugs.
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CHAPTER III
SB-224289 DISRUPTS THE PROPER LOCALIZATION OF
PHOSPHATIDYLSERINE, PHOSPHATIDYLINOSITOL (4,5)BISPHOSPHATE, AND THE PLASMA MEMBRANE ATPASE 1 IN
SACCHAROMYCES CEREVISIAE
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Abstract
In previous work, a series of drug screens were performed in order to identify
chemical inhibitors of the fungal phosphatidylserine (PS) synthase, as it
represents an excellent drug target in pathogenic fungi. Preliminary studies on a
promising hit, SB-224289, showed that this compound did not inhibit the PS
synthase as was hypothesized, but acted by an unknown mechanism to provide
resistance to the PS-specific toxin papuamide A. Further studies were conducted
in order to understand the mechanism of action of SB-224289 using fluorescent
microscopy of plasma-membrane-localized probes. Our studies suggest that SB224289 causes a physiological response in the model yeast Saccharomyces
cerevisiae which we hypothesize is a disruption of cellular trafficking (i.e.
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endocytosis). Further, preliminary screening of a lethal concentration of SB224289 against a mutant library of S. cerevisiae identified Rho5 as a possible
target of SB-224289. Although this is speculation and remains to be
experimentally tested, it is possible that SB-224289 interferes with this protein in
some way. A compound that modulates endocytosis, like SB-224289 may, could
prove useful in research on membrane trafficking.

Introduction
Our lab previously performed a drug screen to identify small molecule inhibitors
of the fungal phosphatidylserine (PS) synthase. This enzyme represents an
excellent drug target as it is absent in mammals, and has been shown to be
important for virulence (Cassilly, et al. 2016, Chen, et al. 2010). This drug screen
worked by identifying compounds that allowed Candida albicans to survive in the
presence of the PS-specific toxin papuamide A. Pap-A works by binding PS and
causing lysis and eventual death of cells (Andjelic, et al. 2008, Chen, et al. 2010).
We hypothesized that compounds that allowed survival of C. albicans in the
presence of Pap-A could be PS synthesis or trafficking inhibitors.
From this screen, we identified SB-224289 as possible inhibitor of PS
synthesis in Candida albicans.

We found that certain concentrations of SB-

224289 resulted in cell survival in the presence of this toxin. Initial hypotheses
were formed that SB-224289 inhibited PS synthesis, but these were rejected
because cells treated with the drug did not share the same phenotypic
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characteristics as the cho1ΔΔ mutant control. In addition, no direct evidence was
observed that SB-224289 inhibited the function of the C. albicans PS synthase in
an in vitro enzyme assay. Based on these findings, it was concluded that SB224289 likely interacted with Pap-A to produce resistance to the toxin, but no
data could confirm this suspicion (Cassilly, et al. 2016).
Continued studies of the SB-224289 mechanism of action indicated that
the compound may have a physiological effect on the fungus that was hidden
from our previous methods of experimentation. We made various strains of
Saccharomyces cerevisiae expressing fluorescent probes specific for PS,
phosphatidylinositol 4,5-bisphosphate (PI4,5P2), and plasma membrane ATPase
1 (Pma1), and determined the effect of SB-224289 on these probes. Our findings
show that SB-224289 causes a disruption in the normal plasma membrane
localization of all three fluorescent markers. These results indicate that SB224289 may disrupt normal plasma membrane trafficking in yeast.
In order to test these hypotheses, we performed a screen on the Boone
Mutant Library of S. cerevisiae looking for mutants that were resistant to a lethal
concentration of SB-224289 (Owen Ryan Ph.D. Thesis). From this screen, we
were able to identify possible targets of SB-224289.
Based on our findings, it appears that SB-224289 does not interfere solely
with phospholipid trafficking and localization, as was previous suspected. Rather,
the results indicate that SB-224289 may disrupt the trafficking of some cellular
components within cells. This conclusion is supported by the punctate
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localization of GFP-Pma1p inside the cells treated with SB-224289. These
punctate spots are likely vaculolar, where the protein is transported for
degradation; however, further studies will need to be performed to confirm and
support this hypothesis. Although SB-224289 does not act as an inhibitor of PS
synthesis or trafficking, a compound that disrupts cellular trafficking could still be
useful as a tool in general biological research.

Materials and Methods
Strain Production
Wild-type Σ S. cerevisiae (TRY181) and a cho1Δ deletion mutant (BMY2), which
is unable to produce PS, were used. Using a standard lithium acetate
transformation method we created the strains used in this study (Gietz and
Woods 2002). Transformation of GFP-Lact-C2 into WT and cho1Δ S. cerevisiae:
GFP-Lact-C2 (pGFP-Lact-C2) was transformed into wild-type and cho1Δ using
the URA3 marker to produce ura3Δ his3Δ pGFP-Lact-C2 and ura3Δ his3Δ cho1Δ
pGFP-Lact-C2, respectively. Transformation of mCherry-Lact-C2 into WT and
cho1Δ S. cerevisiae: mCherry-Lact-C2 (pGPD416-mCherry-Lact-C2) was
transformed into wild-type and cho1Δ using the URA3 marker to produce ura3Δ
his3Δ pGPD416-mCherry-Lact-C2 and ura3Δ his3Δ cho1Δ pGPD416-mCherryLact-C2, respectively. Transformation of GFP-2x Ph(PLCδ) into ura3Δ his3Δ
pGPD416-mCherry-Lact-C2 and ura3Δ his3Δ cho1Δ pGPD416-mCherry-Lact-C2
S. cerevisiae: The GFP-2x Ph(PLCδ) was cut from pRS426GFP-2×PH(PLCδ)
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using BamHI and SalI and ligated into pRS423 to produce pRF1. pRS423GFP2×PH(PLCδ) (pRF1) was transformed into ura3Δ his3Δ pGPD416-mCherry-LactC2 and ura3Δ his3Δ cho1Δ pGPD416-mCherry-Lact-C2 using the HIS3 marker
to produce ura3Δ his3Δ pGPD416-mCherry-Lact-C2 pRS426GFP-2×PH(PLCδ)
and

ura3Δ

his3Δ

cho1Δ

pGPD416-mCherry-Lact-C2

pRS426GFP-

2×PH(PLCδ),respectively. Transformation of the CEN plasmid PMA1-GFP into

WT and cho1Δ S. cerevisiae: pCEN PMA1-GFP wild-type and cho1Δ using the
URA3 marker to produce ura3Δ his3Δ pCEN PMA1-GFP and ura3Δ his3Δ cho1Δ
pCEN PMA1-GFP, respectively.
All strains and plasmids used in this study can be found in Tables 3.1 and 3.2,
respectively.

Fluorescent Microscopy
To confirm the presence and assess the localization of all fluorescent probes
used, overnight cultures were diluted back to 0.1 or 0.2 OD600/ml and allowed to
grow for 2-4 hours shaking at 30° C before fluorescent microscopy was
performed on a Leica DMRXA microscope. All images were analyzed using Leica
Application Suite 3.4.

SB-224289 Treatment
Overnight cultures of selected strains were diluted to 0.2 OD600 and allowed to
grow for 3-4 hours. Cultures were then diluted to 0.1 OD600/ml and 100 - 200 μL
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Table 3. 1. Strains Produced in this Study
Strain
Σ (TRY 181)
BMY2

Organism
S. cerevisiae
S. cerevisiae

RF01

S. cerevisiae

RF04

S. cerevisiae

RF09

S. cerevisiae

RF10

S. cerevisiae

RF21

S. cerevisiae

RF18

S. cerevisiae

CDCS41

S. cerevisiae

CDCS42

S. cerevisiae

Genotype
ura3Δ his3Δ
ura3Δ his3Δ cho1 Δ
ura3Δ his3Δ pGFPLact-C2
ura3Δ his3Δ cho1Δ
pGFP-Lact-C2
ura3Δ his3Δ
pGPD416-mCherryLact-C2
ura3Δ his3Δ cho1Δ
pGPD416-mCherryLact-C2
ura3Δ his3Δ
pGPD416-mCherryLact-C2 pRS426GFP2×PH(PLCδ)

ura3Δ his3Δ cho1Δ
pGPD416-mCherryLact-C2 pRS426GFP2×PH(PLCδ)

ura3Δ his3Δ pCEN
PMA1-GFP
ura3Δ his3Δ cho1Δ
pCEN PMA1-GFP

Source
Lab Strain
Lab Strain
This study
This study
This study
This study

This study

This study
This study
This study
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Table 3. 2. Plasmids Used in this Study
Plasmid
Inserts
p200
(pGFP-Lact- GFP-Lact-C2, URA3,
C2)
Cen/Ars, AmpR

Source
Yeung et al.,
2008

pGPD416mCherryLact-C2

mCherry-Lact-C2,
URA3, AmpR

Fairn et al.,
2011

pRS423

HIS3, AmpR

Lab Strain

pRS426GFP- GFP-2x Ph(PLCδ),
2×PH(PLCδ) URA3, AmpR

Addgene
plasmid #
36092

pRF1

GFP-2x Ph(PLCδ),
HIS3, AmpR

This study

pCENPMA1GFP

PMA1-GFP, URA3,
Cen, AmpR

Balguerie et
al., 2002
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of the cells were either treated with 100 μM SB-224289 or an equivalent volume
of DMSO as a negative control. This concentration of SB-224289 was shown to
be non-fungicidal to the tested cell concentration in viable plate counts. All
samples were then incubated at 30˚C shaking for 1 hour followed by fluorescent
microscopy.
SB-224289 Mutant Library Screen
For every Saccharomyces cerevisiae mutant library 96-well plate being tested,
10 ml of YPD was made containing either 50 μM SB-224289 or an equal volume
of DMSO as a negative control. For every library 96-well plate being tested, 100
μl of the corresponding media was added to each well, having one set of plates
for SB-224289 and another set for DMSO. The 96-pin tool inoculator was placed
in 100% ethanol and flamed to sterilize. The pins were then dipped into the stock
S. cerevisiae mutant library plate after cooling. The pins were then dipped into
the test plates to inoculate each well. Inoculated plates were placed in a
stationary 30ºC incubator for 48 hours.
To measure the optical density, each well’s contents were resuspended by
pipeting several times up and down to mix, then measuring the OD600 in a Biotek
Cytation 5 Imaging Reader plate reader. Plates were incubated again at room
temperature and checked again for growth after 72 or 96 hours. If growth was
observed, OD600 was measured again. To ensure that no bacterial contamination
had occurred during the experimental proceedings, all “positive hit mutant
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strains” found in the SB-224289 plates were viewed under a Leica DMRXA
microscope.
Once positive hits were found, the strains were streaked onto YPD and
incubated at 30ºC for 1-2 days. After strains were grown up on YPD plates, liquid
cultures of 5ml YPD with were inoculated and incubated in a shaking incubator at
30ºC overnight. These cultures were diluted back to a 0.01 OD600/ml in 1ml YPD.
A serial dilution of SB-224289 was then performed in a 96-well plate, with the
highest final concentration of SB-224289 being 100 μM. Wild-type (TRY181) S.
cerevisiae was used as a negative control. Plates were incubated at 30ºC for 1-2
days and then optical density was measured, after mixing the wells, at 24, 48,
and 72 hours. All strains that exhibited greater growth than TRY 181 at 50-100
μM SB-224289 concentrations were considered hits and streaked again on YPD
plates.
Results
After previous research with SB-224289 (Selkirk, et al. 1998b), we concluded
that the compound did not inhibit PS synthesis within Candida albicans, as was
hypothesized, but likely had a compound-compound interaction with PapuamideA (Cassilly, et al. 2016). The hypothesis of a compound-compound interaction,
though explanatory for the Pap-A resistance provided by SB-224289, was never
confirmed via experimentation (HPLC runs performed with both compounds were
inconclusive (data not shown)). PS localization can be analyzed in the model
yeast, Saccharomyces cerevisiae using a GFP labeled version of the C2 domain
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of the bovine protein Lactadherin (Lact-C2) that specifically binds PS (Andersen,
et al. 2000, Shi, et al. 2004). We acquired a version of GFP-tagged Lact-C2
(pGFP-Lact-C2) (Yeung, et al. 2008) which we transformed into our TRY181 and
cho1Δ lab strains of Saccharomyces cerevisiae. The strains produced were:
wildtype carrying pGFP-Lact-C2 and cho1Δ carrying pGFP-Lact-C2. Attempts
were made to transform a codon-optimized GFP-Lact-C2 into C. albicans;
however, the probe seemed to be expressed too highly in the chosen strains and
did not show proper or expected localization (data not shown). Because of this
problem, and the fact that many fluorescent probes can be easily used in S.
cerevisiae, all studies done using GFP-Lact-C2 were performed in S. cerevisiae.
GFP-Lact-C2 localizes to the membrane in the wild-type where PS is
enriched. In cho1Δ which is devoid of PS, GFP-Lact-C2 is diffuse throughout the
cell. In an effort to understand the effect of various compounds on PSlocalization, we performed a series of compound treatments followed by
fluorescent microscopy to determine where GFP-Lact-C2 localized as an
indication of what might be happening to PS localization. In these experiments,
we expected that SB-224289 would have no effect on GFP-Lact-C2 localization if
the compound truly acted via an indirect method to inhibit Pap-A toxicity.
However, our findings showed that treatment with 100 μM SB-224289 (shown to
be non-lethal at the cell concentration in this plate assay as assessed by viable
plate counts) caused a dramatic alteration in localization of the GFP-Lact-C2 in
the cell (Fig. 3.1). These results indicated that SB-224289 could have a major
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effect on PS trafficking or turn-over within the cell. In addition, the specificity of
this physiological response is demonstrated by the fact that two structural
analogs of SB-224289—GMC 2-29 and SB-21664—did not produce any
disruption in GFP-Lact-C2 localization (Fig 3.1C). These data were replicated in
wildtype and cho1Δ strains of S. cerevisiae carrying the red-fluorescently-marked
Lact-C2 plasmid (pGPD416-mCherry-Lact-C2) (data not shown).
In order to further understand the extent of SB-224289 activity, we wished
to determine if the compound had an effect on other phospholipid localization.
The Plekstrin homology domain (PH domain) is a domain of approximately 120
amino acids that has been shown to bind PI(4,5)P2 in the membrane of S.
cerevisiae (Lemmon 2007). We hypothesized that localization of the PH domain
fused with GFP (GFP-2x Ph(PLCδ)) would be unaffected by SB-224289 if the
activity of the compound is specific to PS trafficking.
The plasmid pRS426GFP-2×PH(PLCδ) was transformed into wild-type and
cho1Δ strains carrying pGPD416-mCherry-Lact-C2 to produce strains with a red
fluorescent signal showing PS localization and green fluorescent signal showing
PI4,5P2 localization. As expected, in the wild-type we saw localization of the
GFP-2x Ph(PLCδ) at the membrane. Surprisingly, in cho1Δ we saw variable
localization at the membrane, with part of the GFP-2x Ph(PLCδ) present as
diffuse signal in the cytoplasm (Fig. 3.2). This is likely due to problems with
phospholipid trafficking that are produced by the loss of PS. A recent paper
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Figure 3. 1. SB-224289 Disrupts GFP-Lact-C2 Localization to PS
(A) Fluorescent micrographs of GFP-Lact-C2 localization in cho1Δ, wild-type,
or wild-type treated with SB-224289. (B) Quantification of GFP-Lact-C2
localization to the plasma membrane in cho1Δ, wild-type, or wild-type treated
with SB-224289. (C) Structural analogs of SB-224289, GMC 2-29 and SB216641 do not cause a disruption in GFP-Lact-C2 localization.
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described a model where PS is delivered to the plasma membrane in a proteinmediated exchange with PI4P (Moser von Filseck, et al. 2015). It is possible that
the loss of PS causes a disruption in proper localization of PI species, and thus
an alteration in the localization of the GFP-2x Ph(PLCδ), although this has yet to
be confirmed.
We performed treatment of wildtype S. cerevisiae carrying pRS426GFP2×PH(PLCδ) and pGPD416-mCherry-Lact-C2 with 100 μM concentration of SB224289. Our expectation was that if SB-224289 activity was specifically altering
PS localization or trafficking, that we may see no difference or change in GFP-2x
Ph(PLCδ) localization, indicating no change in PI4,5P2 localization or trafficking.
However, we saw diffusion of the GFP-2x Ph(PLCδ) away from the plasma
membrane in cells treated with SB-224289 (Fig. 3.2). These results are similar to
the GFP-Lact-C2 localization studies which may indicate that SB-224289 inhibits
trafficking or turnover of PS at the plasma membrane, and further, has an impact
on some PI species’ localization as well.
In order to determine if SB-224289 activity was specific to phospholipid
trafficking, we wished to determine the effect of SB-224289 on membrane protein
localization. To do this, we selected the highly abundant, membrane-bound
ATPase, Pma1 (Schmitt, et al. 2006). We acquired the plasmid CEN PMA1-GFP
from Dr. Amy Chang and Dr. Annick Breton (Balguerie, et al. 2002, Huang and
Chang 2011) and transformed it into our TRY181 and cho1Δ lab strains. In both
strains, Pma1-GFP is localized to the plasma membrane (Fig. 3.3). Our
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Figure 3. 2. SB-224289 Disrupts GFP-2x Ph(PLCδ)
Localization to PI(4,5)P2
(A) Fluorescent micrographs of GFP-2x Ph(PLCδ) localization
in cho1Δ, wild-type, or wild-type treated with SB-224289. (B)
Quantification of GFP-2x Ph(PLCδ) localization to the plasma
membrane in cho1Δ, wild-type, or wild-type treated with SB224289.
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Figure 3. 3. SB-224289 Disrupts CEN PMA1-GFP
Localization
Fluorescent micrographs of CEN PMA1-GFP localization
in cho1Δ, wild-type, or wild-type treated with SB-224289.

125

hypothesis was that if the SB-224289 activity is specific to phospholipid
trafficking, it would not affect the localization of Pma1-GFP. Interestingly, when
the wildtype and cho1Δ were treated with 100 μM concentration of SB-224289,
we saw a mislocalization of Pma1-GFP into intracellular punctate spots (Fig. 3.3).
These findings led us to hypothesize that SB-224289 causes a disruption in
normal trafficking of cellular material (i.e. endocytosis), instead of having a
specific effect on phospholipid trafficking alone.
In order to test this hypothesis, we attempted to treat Pma1-GFP cells with
100 μM concentration of SB-224289 and then perform a western blot to compare
expression of Pma1 protein to an untreated control. Our expectation was that if
SB-224289 was causing an internalization of Pma1 that it would be degraded in
the vacuole, causing a decrease in signal on the western blot. However, because
of non-specificity of several GFP antibodies tested and the concentration of SB224289 required for treatment, we were unable to detect differences in Pma1GFP expression via western blot (data not shown).
Thus, we took a new approach to identify the pathway(s) targeted by SB224289 activity. To do this, we screened a Whole Genome Mutant Library of S.
cerevisiae against a lethal concentration of SB-224289 (50 μM at this cell
concentration) in a 96 well plate format (Ryan, et al. 2012). Cells that survived
the high dosage of SB-224289 were considered hits and re-screened against a
serial dilution of SB-224289.
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Of 3648 total strains tested, we found 96 resistant strains in the initial
screen, resulting in a positive hit rate of 2.63% (Fig. 3.4). Of these initial hits, 27
mutant strains came out as true positive hits from the serial dilutions, resulting in
a positive hit rate of 28.12% from the initial screen hits, or 0.74% from the total
library. Although this project has not been fully completed and our results are
speculation at this point, one possible target in particular (Rho5p) seemed to be
connected to many of the other possible targets identified (Fig. 3.5) indicating
that it may be inhibited or affected in some way by SB-224289.
Discussion
In this project, we utilized fluorescent markers to examine the effects of SB224289 on localization of PS; PI4, 5P2; and Pma1p. In all cases, SB-224289
caused a re-distribution of the fluorescent probes away from the membrane into
cytosolic or punctate spots (Figs 3.1 – 3.3). These findings demonstrate that SB224289 has a physiological effect on yeast cells as opposed to prior conclusions
that SB-224289 simply produced Pap-A resistance via physical compoundcompound interactions. Based on the membrane probe disruption observed in
our experiments, we hypothesized that SB-224289 might disrupt trafficking, (i.e.
endocytosis) of cellular material.
In order to test this, we performed a large scale S. cerevisiae mutant
library screen against a lethal concentration of SB-224289. We were able to
identify a few possible targets of SB-224289. One target in particular seemed to
have a connection to several of the other identified targets: a GTP-binding
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Figure 3. 4. Screen of Mutant S. cerevisiae Library
Of 3648 total strains tested, 96 were resistant to 50 μM SB-224289, resulting in a
positive hit rate of 2.63%. All mutants treated with SB-224289 are shown in navy
and hits are shown above the arbitrary hit line of 0.5 OD 600. Negative control
strains, treated only with DMSO, are shown in purple.
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Figure 3. 5. Gene Maps Connecting True Hits from the Mutant Screen
(A) All hits from the screen (shown in Table 3.3) are shown mapped with
connections to one another. (B) RHO5 demonstrates a great number of
connections with several other identified targets, supporting the case that this
could be a main target of SB-224289.
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protein, Rho5p. Rho5p regulates a MAP kinase branch of the PKC1-mediated
signal transduction pathway, which is globally important for yeast physiology
(Schmitz, et al. 2002). Thus, it is possible that by targeting Rho5p, SB-224289
could interfere with this pathway and thus cause a disruption in normal celluar
processes. However, because this is unconfirmed, these are only hypotheses
that remain to be tested.
Currently we are in the process of transforming the true positive hit mutant
strains of S. cerevisiae with the GFP-PMA1 and GFP-Lact-C2 probes to
investigate how their localization differs with or without SB-224289 treatment. We
are interested in both of these probes to assess whether SB-224289 continues to
disrupt the localization of all components of the cell membrane by affecting
certain proteins hypothesized as targets of SB-224289 function.
Further, we would like to analyze how SB-224289 might be impacting the
localization of other proteins at the plasma membrane, like Ste2p. A GFP-tagged
version of this lab has been produced in S. cerevisiae (Becker Lab) and we plan
to treat this strain with SB-224289 to determine its effect on Ste2p.
Last, this project would also benefit by futher treating our fluorescentprobe-expressing strains of S. cerevisiae with compounds known to block
endocytosis, like Latrunculin, to determine which facet of cellular trafficking
specifically is affected by SB-224289 treatment.
Although this project does not have a firm conclusion, it furthers research
into the mechanism of action of SB-224289. We also were able to optimize
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conditions for the mutant library screen, to which SB-224289 appeared to be very
sensitive. This screening approach could easily be translated for use against
other compounds with unknown mechanisms of action.
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CHAPTER IV
MAPPING THE SUBSTRATE BINDING SITES IN THE
PHOSPHATIDYLSERINE SYNTHASE IN CANDIDA ALBICANS
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Abstract
The fungal phosphatidylserine (PS) synthase is required for virulence, conserved
in fungi, but does not have a homolog in mammals, and thus represents a
potential drug target in pathogenic fungi, such as Candida albicans. The
substrate-binding sites of Cho1 have not been previously characterized,
therefore we have performed biochemical characterization of this enzyme. Cho1
has two substrates: cytidyldiphosphate-diacylglycerol (CDP-DAG) and serine.
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Previous studies in phospholipid biosynthetic enzymes from a variety of
microorganisms have identified a conserved CDP-alcohol binding motif, known
as the CAPT motif, which is also present within the sequence of C. albicans
Cho1. Sequence alignments between PS synthase and phosphatidylinositol (PI)
synthases from several microbes were used to identify a putative serine binding
site as well. Alanine site directed mutagenesis of both motifs has defined the
crucial residues within both motifs that are required for PS synthesis, but are not
required for protein expression or stability. The results of this project will lead to
more direct and rational approaches for finding Cho1 inhibitors, helping ultimately
to identify more effective antifungals. In addition, these findings provide a greater
understanding of enzymes involved in fungal phospholipid biosynthesis.

Introduction
The phosphatidylserine (PS) synthase enzyme in Candida albicans represents
an excellent drug target for three reasons: 1) It is required for virulence (Chen, et
al. 2010), indicating that inhibitors of this enzyme would render the organism
incapable of causing infection; 2) it is absent in mammals (Braun, et al. 2005), so
inhibitors potentially would have no toxic side effects for the host; and 3) it is
conserved among many fungi, so a drug could potentially be effective against
multiple fungal pathogens.
An important goal then is to discover an inhibitor of Cho1 that can be used
as a lead compound for drug development. In order to better facilitate this, the
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binding sites for the two substrates of Cho1, cytidyldiphosphate-diacylglycerol
(CDP-DAG) and serine need to be described. Small molecule screening is very
effective approach to identify inhibitors of enzymes (Cassilly, et al. 2016), but we
are also interested in taking a more rational approach for identifying inhibitors.
This included biochemically identifying substrate binding motifs. Identification of
these sites in the protein can allow a more directed approach for identifying and
modifying inhibitors via small molecule screening, which could ultimately increase
chances of finding PS synthase inhibitors.
The PS synthase enzyme (originally denoted as: cytidine 5'-diphospho1,2-diacyl-sn-glycerol: L-serine O-phosphatidyltransferase) was first identified in
Saccharomyces cerevisiae in 1980 (Atkinson, et al. 1980a, Atkinson, et al.
1980c, Kovac, et al. 1980). Initial characterization of the yeast PS synthase
included protein purification (Bae-Lee and Carman 1984, Letts, et al. 1983),
determination of Michaelis-Menton kinetics (Bae-Lee and Carman 1984, Carman
and Matas 1981, Carson, et al. 1982, Kovac, et al. 1980), understanding the
regulation of Cho1 (Bae-Lee and Carman 1990, Bailis, et al. 1987, Carson, et al.
1982, Hromy and Carman 1986, Kelley, et al. 1988, Kinney and Carman 1988,
Letts and Henry 1985, Poole, et al. 1986), and identifying the localization of the
enzyme (Kohlwein, et al. 1988, Kuchler, et al. 1986b). Beyond the fungal PS
synthase, characterization of bacterial PS synthases was also performed
(DeChavigny, et al. 1991, Dowhan 2013, Dutt and Dowhan 1977, Dutt and
Dowhan 1981, Dutt and Dowhan 1985, Ge and Taylor 1997, Kanfer and
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Kennedy 1964, Okada, et al. 1994, Raetz and Kennedy 1972, Rilfors, et al.
1999). Within these studies, a distinction between the two subclasses of PS
synthases was formed. Subclass I is present primarily in some Gram negative
bacteria and subclass II is primarily found in Gram positive bacteria and yeast
(Koonin 1996, Matsumoto 1997, Sohlenkamp, et al. 2004, Sung, et al. 1997).
Last, characterization of mammalian PS synthases have also been performed,
although these enzymes share little similarity to any microbial PS synthases, and
indeed function by a completely different mechanism (Kuge and Nishijima 1997,
Ohsawa, et al. 2004, Sturbois-Balcerzak, et al. 2001, Vance and Steenbergen
2005b).
A highly conserved motif, D-(X)2-D-G-(X)2-A-R-(X)2-N-(X)5-G-(X)2-L-D(X)3-D,

was

identified

phosphatidylserine

in

yeast

synthase

phosphatidylinositiol
(CHO1),

and

synthase
the

E.

(PIS1),
coli

phosphatidylglycerophosphate synthase (PGPS) (Gopalakrishnan, et al. 1986,
Nikawa, et al. 1987a, Nikawa, et al. 1987b). This motif was further identified in
yeast cholinephosphotransferase (CPT1) and ethanolaminephosphotransferase
(EPT1) (Hjelmstad and Bell 1990, Hjelmstad and Bell 1991, McMaster and Bell
1994). All of these enzymes bind alcohols and CDP-alcohols, and catalyze the
formation of a phosphodiester bond between the CDP-alcohols and the
secondary alcohol (Hjelmstad and Bell 1990, Hjelmstad and Bell 1991).
Subsequently, threonine and serine residues located within this motif in E. coli
phosphatidylglycerolphosphate

synthase

(PGPS)

and

Bacillus

subtilis
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phosphatidylserine synthase (PSS), respectively, were mutated to proline to
determine the importance of this motif. While not a part of the conserved motif
itself, this amino acid change in both circumstances was non-conservative and
decreased enzyme activity, supporting the hypothesis that this motif is crucial for
enzyme function (Saha, et al. 1996, Usui, et al. 1994), although with the caveat
that proline could be disrupting the secondary structure of the protein. Since
these initial studies, this CDP-alcohol phosphatidyltransferase (CAPT) motif, was
narrowed to D-G-(X)2-A-R-(X)8-G-(X)3-D-(X)3-D, and was identified to be almost
invariably conserved in numerous other lipid biosynthetic enzymes, including
those of Gram positive and Gram negative bacteria, archea, fungi, plants, and
mammals (Dewey, et al. 1994, Dryden and Dowhan 1996, Matsumoto 1997,
Matsuo, et al. 2007, Sohlenkamp, et al. 2004, Tanaka, et al. 1996). In 1998,
Williams et al., characterized the CAPT motif in yeast CPT1 by alanine scanning
mutagenesis which provided detailed importance of each residue within the
conserved motif (Williams and McMaster 1998).
More

recently,

two

enzymes

from

the

CDP-alcohol

phosphatidyltransferase family from Archaeoglobus fulgidus were shown to
contain this motif on helices TM2 and TM3 of the solved crystal structures. In
these studies, the CAPT motif was also widened to include an N-terminal
aspartic acid, making the current, more general motif: D-(X)2-D-G-(X)2-A-R-(X)712-

G-(X)3-D-(X)3-D (Nogly, et al. 2014, Sciara, et al. 2014). This was further

confirmed in the phosphatidylinositol-phosphate synthase from Renibacterium
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salmoninarum where the CAPT motif was again found within TM2 and TM3 of
the solved crystal structure (Clarke, et al. 2015). To our knowledge, these are the
only three CDP-alchohol phosphatidyltransferase enzymes with solved crystal
structures.
Based on the above studies there is sequence homology to guide a
search for the CAPT motif in Cho1, but the motif specific for the other substrate,
serine, is unknown. In fact, for many of the CDP-DAG binding enzymes such as
PI synthase and PGP synthase, the binding sites for the non-CDP substrate are
unclear.

Thus, identification of the serine binding site—or some residues

involved in serine binding, even if it is not the full motif—in Cho1 will facilitate a
better understanding of this class of enzymes which are crucial for phospholipid
biosynthesis in all kingdoms of life.
Previously we described the apparent Km and Vmax for PS synthase, as
well as its role in the phospholipidome of C. albicans. Further, we probed the
specificity of the active site of this protein for L-serine by competition assays with
the closely related amino acids L-threonine and D-serine to an in vitro assay. We
found that only very high concentrations of these substrates could compete with
serine, indicating that the enzyme seems to be fairly specific for L-serine, which
agrees with previous studies in S. cerevisiae and even E. coli (Bae-Lee and
Carman 1984, Cassilly, et al. 2017, Kanfer and Kennedy 1964, Mitoma, et al.
1998). Although these studies provided important preliminary information, they
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did not reveal insights into the active sites themselves. In the present
communication, we map the substrate binding sites for Cho1p.

Materials and Methods
Strains and Media
In this study we used the cho1∆∆ (YLC337) and cho1∆∆::CHO1 (YLC344)
mutants created within the SC5314 (wild-type) strain of C. albicans, which have
been described previously (Chen, et al. 2010). The media used to culture strains
was YPD (1% Bacto yeast extract, 2% Bacto peptone, and 2% dextrose (Thermo
Fisher Scientific)) or minimal medium (0.67% yeast nitrogen base, 2% dextrose)
supplemented with 1 mM ethanolamine where indicated (Guthrie 2002).

Genetic Cloning and Site-Directed Mutagenesis
The plasmid pYLC314 containing the MET3 promoter (PMET3) was generated by
digesting pBluescript SK+ with EcoRI and ligating this to a PCR product carrying
the SAT1 marker and PMET3 generated from pYLC229 that is flanked by EcoRI
sites that were created by primers JCO165 and JCO166 (Chen, et al. 2008). We
also derived a vector from this one that lacks PMET3, but retains the SAT1 marker
by digesting the plasmid with PstI, which cut on either side PMET3, to remove it,
and then religated the vector to itself to create pBluescript-SAT1. The CHO1
gene was amplified from SC5314 genomic DNA using primer CCO54, which sits
1000 bp upstream of CHO1 start site and includes a 5’ XhoI cut site, and CCO55
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which sits at the 5’ end of CHO1 and includes a 3’ 2x HA tag followed by an AatII
cut site. The downstream region of CHO1 was amplified using CCO56, which sits
immediately downstream of the CHO1 stop codon and contains a 5’ AatII cut site
followed by a 1x HA tag before the downstream sequence, and CCO57, which
sits 500 bp downstream of the CHO1 stop site and includes a 3’ HindIII cut site.
Once amplified, both fragments were double digested with their respective
enzyme combinations. The plasmid pBluescript-SAT1 was digested with XhoI
and HindIII and all three fragments were ligated together to create pCDC4.
Site-directed mutagenesis was performed using a primer based method.
Forward and reverse primers approximately 35-40 bp in length were made for
each mutation where the codon of interest was modified as conservatively as
possible to produce alanine (Table 4.1). The plasmids were linearized with MluI
prior to transformation into cho1∆∆ by electroporation. PCR products generated
from isolated genomic DNA from all SDM CHO1 transformant strains using
primers CCO136 and CCO137 were sequenced using CCO105 or CCO20 to
ensure that the genes were reintegrated correctly and that no spurious mutations
had arisen.
To generate PMET3-PIS1, a 3X FLAG tagged version of PIS1 gene was
amplified from pCDC21 using primers TRO1039 and TRO1043 which introduced
BamHI and NotI sites, which were used to clone it into pYLC314 in front of the
PMET3 promoter to produce pCDC27. For insertion of the putative PS synthase
serine-binding motif into the PIS1 sequence, primers CCO141 and CCO142 were
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Table 4. 1. Primers Used in this Study.
Oligonucleotide

Sequence

Mutation

CCO20

GGAATCAAAAGATACTGTG

CCO54

CCO56

aaaactcgagCTGTAGAGCAGTTGGTTG
aaaaGACGTCATAGGGATAGCCGGCATAGTCAGGAACAT
CGTATGGGTAAACGGCCGCTGGTTTAGGAATTTTTAAA
GAT
aaaaGACGTCCCGGACTATGCAGGATCCTATCCATATGA
CGTTCCAGATTACGCTCCGGCCGCCTAGAGATGATTCT
AAAATAGAAT

CCO57

aaaaaagcttCAGAACCAGAATTATTGTTTC

CCO58

GGGGTTATTTTTCGATTTTTTTGctGGTAGAGTTGCAAG

D128A

CCO59

CTTGCAACTCTACCagCAAAAAAATCGAAAAATAACCCC

D128A

CCO60

ATTTTTCGATTTTTTTGATGctAGAGTTGCAAGATTAAG

G129A

CCO61

CTTAATCTTGCAACTCTagCATCAAAAAAATCGAAAAAT

G129A

CCO62

TTTTTGATGGTAGAGTTGCAgctTTAAGAAATAAATCATC

R133A

CCO63

GATGATTTATTTCTTAAagcTGCAACTCTACCATCAAAAA

R133A

CCO64

ATAAATCATCATTAATGGctCAAGAGTTAGATTCATTAG

G142A

CCO65

CTAATGAATCTAACTCTTGagCCATTAATGATGATTTAT

G142A

CCO66
CCO67

TAATGGGACAAGAGTTAGctTCATTAGCTGATTTGGTATC
GATACCAAATCAGCTAATGAagCTAACTCTTGTCCCATTA

D146A
D146A

CCO68

GTTAGATTCATTAGCTGctTTGGTATCATTTGGGGTATC

D150A

CCO69

GATACCCCAAATGATACCAAagCAGCTAATGAATCTAAC

D150A

CCO82

GTTGGGGTTATTTTTCGcTTTTTTTGATGGTAGAGTTG

D125A

CCO83

CAACTCTACCATCAAAAAAAgCGAAAAATAACCCCAAC

D125A

CCO88

GGTTTTATGTGGATTAACAgctTTGGCTAGATTTAATATC

R186A

CCO89

GATATTAAATCTAGCCAAagcTGTTAATCCACATAAAACC

R186A

CCO90

GATTAACAAGATTGGCTgctTTTAATATCTCCGTC

R189A

CCO91
CCO94
CCO95

GACGGAGATATTAAAagcAGCCAATCTTGTTAATC
GGTTTTATGTGGATTAACAAGAgctGCTAGATTTAATATC
GATATTAAATCTAGCagcTCTTGTTAATCCACATAAAACC

R189A
L187A
L187A

CCO96

CAAGATTGGCTAGAgcTAATATCTCCGTCAATAAC

F190A

CCO97

GTTATTGACGGAGATATTAgcTCTAGCCAATCTTG

F190A

CCO105

CTCTCAGTATTGTTCAAAC
CTGATAACATAGCATACATATGCATATAAAATCTAGCCAA
TCTTGTTAATCCACATAAAACCCAATGAGATGATAAATCT
AAACTGACTAGT
ACTAGTCAGTTTAGATTTATCATCTCATTGGGTTTTATGT
GGATTAACAAGATTGGCTAGATTTTATATGCATATGTATG
CTATGTTATCAG

CCO55

CCO141
CCO142
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used for site-directed mutagenesis to produce pCDC28. These plasmids were
linearized with XbaI prior to transformation into C. albicans cho1∆∆ by
electroporation (Chen, et al. 2010). All plasmids and strains can be found in
Tables 4.2 and 4.3, respectively.

Western Blots
Protein isolation and western blotting were performed with some modifications to
previously published methods (Piispanen, et al. 2013) and according to the
manufacturers’ protocols (LI-COR). Cultures were grown overnight in 5 ml YPD,
diluted to 0.1 OD600/ml in 25 ml of YPD and allowed to grow until reaching early
log phase (0.7 – 1 OD600/ml). In the case of PIS1, the strains were grown
overnight in minimal medium containing 1 mM ethanolamine until cultures
reached log phase. Cultures were pelleted, washed with water and frozen
overnight at -80°C. Pellets were then thawed on ice, resuspended in 1X PBS
containing a protease inhibitor cocktail (Roche 4693124001) along with additional
protease inhibitors (phenylmethylsuphonylfluoride (PMSF), leupeptin, and
pepstatin (RPI P20270-5.0, L22035-0.005, P30100-0.005) and broken with 200
μl volume of glass beads (Sigma G1145-500G) in a bead-beater at 4°C for one
minute six times, with one minute pauses in between. Samples were spun at
5,000 rpm for 1 minute to clear debris and transferred to a new tube on ice.
Again, samples were cleared by spinning at 5,000 rpm for 8 minutes. This twice-
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Table 4. 2. Plasmids Used in this Study
Plasmid
pYLC314-TBR

Inserts
R

NAT , Amp

Source

R

Lab Strain

pCDC4

NATR, AmpR , CHO1

Shaner et al., 2004

pCDC15

NATR, AmpR , CHO1D125A

Fairn et al., 2011

pCDC8

NATR, AmpR , CHO1D128A

Lab Strain

pCDC14

NATR, AmpR , CHO1G129A

Addgene plasmid # 36092

pCDC10

NATR, AmpR , CHO1R133A

This study

pCDC12

NATR, AmpR , CHO1G142A

Lab Strain

pCDC11

NAT , Amp , CHO1

D146A

Lab Strain

pCDC9

NATR, AmpR , CHO1D150A

This study

pCDC23

NATR, AmpR , CHO1R186A

This study

pCDC24

NATR, AmpR , CHO1L187A

This study

pCDC22
pCDC25
pYLC314

R

R

R

R

R189A

This study

R

R

F190A

This study

NAT , Amp , CHO1
NAT , Amp , CHO1
R

pMET3, NAT , Amp

R

Joseph Chen, Reynolds Lab
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Table 4. 3. Strains Produced in this Study.
Organism

Marker

Plasmid

Gene/Mutation

Name

C. albicans

Nourseothricin

pCDC4

CHO1-HAx3

CDCS59

C. albicans

Nourseothricin

pCDC15

CHO1-HAx3D125A

CDCS60

C. albicans

Nourseothricin

pCDC8

CHO1-HAx3D128A

CDCS61

C. albicans

Nourseothricin

pCDC14

CHO1-HAx3G129A

CDCS62

C. albicans

Nourseothricin

pCDC10

CHO1-HAx3R133A

CDCS63

C. albicans

Nourseothricin

pCDC12

CHO1-HAx3G142A

CDCS64

C. albicans

Nourseothricin

pCDC11

CHO1-HAx3D146A

CDCS65

C.albicans

Nourseothricin

pCDC9

CHO1-HAx3D150A

CDCS66

C. albicans

Nourseothricin

pCDC23

CHO1-HAx3R186A

CDCS67

C. albicans

Nourseothricin

pCDC24

CHO1-HAx3L187A

CDCS68

C. albicans

Nourseothricin

pCDC22

CHO1-HAx3R189A

CDCS69

C.albicans

Nourseothricin

pCDC25

CHO1-HAx3F190A

CDCS70
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cleared supernatant was moved to fresh tubes on ice and a Bradford assay was
performed to determine protein concentration.
Proteins were separated by SDS-PAGE. 40 μg of protein per sample were
loaded into the wells of a 6% stacking/10% separating gel and run at 35 mAmps,
followed by transfer to PVDF membranes (926-31099 LI-COR) using a blot
module (GE Healthcare Life Sciences 80-6418-96) for one hour at 400 mAmps.
Membranes were dried for one hour at room temperature, blocked using
TBS:Odyssey Blocking Buffer (1:1) (927-50100 LI-COR), and incubated
overnight at 4˚C in TBST:Odyssey Blocking Buffer (1:1) with primary antibodies
according to the tag (HA.11; Covance (Reynolds, et al. 2008) or FLAG 637301;
BioLegend 637301). The following day, after 4 washes in TBST at room
temperature, membranes were incubated with IRDye® 680RD Goat-anti-Rat
(926-68076) or IRDye® 800CW Goat-anti-Mouse (926-32210) secondary
antibodies (LI-COR) at room temperature for at least one hour. Membranes were
then washed 4x with TBST and then imaged using a LI-COR Odyssey scanner.

In vitro PS Synthase Assay
The PS Synthase assay was performed as described previously in (Cassilly, et
al. 2017) with the exception that the 37°C incubation times were increased to 45
minutes.
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Protein Pull Down
Protein was isolated as partially described in (Graham, et al. 1994) by growing
200 ml YPD cultures to approximately 1.5 to 2.5 OD 600/mL. Samples were
centrifuged at 3,300 rpm for 5 minutes, then resuspended in 20 ml YPD
(approximately 18 - 20 OD600/mL). Protease inhibitors (phenylmethylsuphonyl
fluoride, leupeptin and pepstatin), 50 mM HEPES buffer, and 40 mM βmercaptoethanol (BME) was added. Zymolyase (~100 ug/ml) (120493-1 AmsBio)
was added and cultures were shaken at 37°C for 1 hour. Resulting spheroplast
cultures were centrifuged at 3,300 rpm for 5 min. Pellets were washed with
spheroplasting buffer (1 M sorbitol, 20 mM Tris-HCl pH 7.5), then resuspended in
approximately 5 ml resuspension buffer (1 M sorbitol, 10 mM triethanolamine pH
7.5, 1 mM EDTA) and stored at –80°C.
The next day, cells were lysed using osmotic lysis (Graham, et al. 1994).
Pellets were thawed on ice and then 20 ml of lysis buffer (0.1 M sorbitol, 10 mM
triethanolamine pH 7.5, 1 mM EDTA) was added, sitting for 5 min. Dounce
homogenization (>30 strokes) was then used on ice to break cells further.
Homogenate was centrifuged at 4°C for 6 min at 1000 xg to clear unbroken cells.
Supernatant was spun at 27,000× g for 10 min at 4°C and pellets were
resuspended in residual liquid after eluting the supernatant. The thick mixture
was mini-homogenized to break clumps. Last a Bradford assay was performed to
quantify protein.
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The protein pull-down was described in part as in (Hauser, et al. 2007).
2.5 mg of cho1ΔΔ::CHO1-HAx3 and cho1ΔΔ::CHO1 protein was incubated at
37°C with 0.1 mM L-serine and 25 mM cysteine analog for 30 minutes. There
was also an untreated control for both cho1ΔΔ::CHO1-HAx3 and cho1ΔΔ::CHO1.
Following this incubation, the protein was solubilized in RIPA buffer (1X TBS,
0.1% SDS, 1% Triton X-100) overnight, rotating at 4°C. The next day, according
to the manufacturer’s protocol, Anti-HA magnetic beads (Pierce PI88836) were
washed 2x in TBS-T (500 mM Tris Base, 1.5 M NaCl, pH 7.5, 0.05% Tween-20)
using a magnetic stand. The beads were then added to the protein samples and
again incubated overnight, rotating at 4°C. The following day, the samples were
washed with RIPA buffer 4-5x. The samples were then washed 4x with TBS to
remove all detergent. Samples were stored at 4°C or given directly for MS/MS
analysis.

Homology Modeling
The homology model was produced using Molecular Operating Environment
(MOE) software. A Protein Data Bank (PDB) search was performed using the
Cho1 protein sequence, and was found to have at least 25% sequence similarity
to the three published crystal structures in (Clarke, et al. 2015, Nogly, et al. 2014,
Sciara, et al. 2014). Several homology models were produced using each of the
three crystal structures as templates. The final homology model of Cho1p
presented in this manuscript was produced by threading the sequence of Cho1p
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onto AF2299, a CDP-alcohol phosphotransferase, which had approximately
32.4% sequence similarity and 18.7% sequence identity with Cho1p (using the
EMBOSS Stretcher alignment tool).

Statistical Analysis
All statistical analysis was performed on GraphPad Prism 7 using a student’s ttest.

Results
The CDP-alcohol phosphatidyltransferase (CAPT) binding motif (D-G-(X)2-A-R(X)8-G-(X)3-D-(X)3-D) is almost invariably conserved in enzymes binding CDPalcohols even across kingdoms (Table 4.4), indicating the importance of this
motif in the function of these types of enzymes (Okada, et al. 1994). One
exception lies in some Gram negative bacteria, such as E. coli, where this motif
is not present within certain enzymes (e.g. Pss) binding CDP-DAG, indicating
divergence (Matsumoto 1997).
Previously Williams et al., performed detailed site directed mutagenesis on
the CAPT motif in CPT1 cholinephosphotransferase in S. cerevisiae (Table 4.4).
They found that mutation of Gly114, Gly127, Asp131, and Asp135 caused loss of
activity while mutants of Ala117 and Arg118 showed a decrease in activity, and
Asp113 showed wild-type activity (Williams and McMaster 1998). Using S.
cerevisiae Cpt1 as a guide, we tested whether amino acids conserved in the
150

Table 4. 4. CAPT Motif Largely Conserved in Enzymes Binding CDPAlcohols Across Kingdoms

Organism

Enzyme

CDP-Binding Motif

Reference

C. albicans

PS Synthase

DFFDGRVARLRNKSSLMGQELDSLAD

This
research

C. albicans

PI Synthase

DAFDGYAARKFNQGTRFGAVLDMVTD

This
research

C. parapsilosis

PS Synthase

DFFDGRVARLRNKSSLMGQELDSLAD

This
research

C. glabrata

PS Synthase

DFFDGRVARLRNRSSLMGQELDSLAD

This
research

S. cerevisiae

PS Synthase

DFLDGRVARLRNRSSLMGQELDSLAD

Takeda et
al., 2014;
Matsuo et
al., 2007

S. cerevisiae

CPT

DMHDGMHARRTGQQGPLGELFDHCID

Williams et
al., 1998

S. pombe

PS Synthase

DFLDGKVARWRGKSSLMGQELDSLAD

Matsuo et
al., 2007

B. subtilis

PS Synthase

DFFDGMAARKLNAVSDMGRELDSFAD

Okada et al.,
1994

R.
salmoninarum

PIP synthase

DIIDGLMARLLFREGPWGAFLDSYLD

Clarke et al.,
2015

DGIDGRIARLLKATSSFGVQMDSLAD

A. fulgidus

PS Synthase
CDP-alcohol
phosphotransferase
AF2299

Sohlenkamp
et al., 2003;
KEGG
Sinorhizobiu
m meliloti
1021

DGCDGEIARLKFMESKYGAWLDGVLD

Sciara et al.,
2014

A. fulgidus

IPCT-DIPPS

AYYDGWIAREINRKVSLRISRL—LAD

Nogly et al.,
2014

S. meliloti

* gray highlighted residues represent the conserved amino acids
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CAPT motif of multiple enzymes shown in Table 4.4 were important for catalysis
in the Candida albicans PS synthase using alanine site directed mutagenesis.
We generated an HAx3-tagged version of the CaCHO1 on a SAT1
marked

plasmid

and

integrated

it

into

the

cho1∆∆

mutant

genome.

Transformants were screened for expression of Cho1-HAx3 by Western blot (Fig
4.1A) and the ability of a representative transformant expressing Cho1-HAx3
expression to complement cho1∆∆ for PS synthase enzyme activity was tested.
Cho1-HAx3 restored PS synthase activity to the cho1∆∆ strain (Fig. 4.1B). In
addition, the CHO1-HAx3 gene was able to at least partially restore growth to
cho1∆∆ on minimal medium lacking ethanolamine (data not shown).
It should be noted that several bands were observed that bound to an antiHA antibody, but none of these were present in the cho1∆∆ control (Fig. 4.1B).
We suspect that the band at 34 KDa is the full-length protein, which correlates
with the predicted molecular weight of 34.8 KDa. Proteolytic maturation of
enzymes is a well-documented phenomenon (Hartmann, et al. 2014) and
previous studies found similar findings with the PS synthase in S. cerevisiae
(Choi, et al. 2010, Dey, et al. 2017, Kinney and Carman 1988), showing a 30
KDa band and a 23 KDa band in western blot analysis. Although our band sizes
differ (36, 34, and 29 KDa), we do see a difference of 7 KDa between our largest
band and our smallest, which matches with what has been seen in S. cerevisiae.
These previous studies found that the 30 KDa band was likely proteolytically
degraded to produce the 23 KDa band, but that both forms of the protein were
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Figure 4. 1. Enzyme Activity and Expression of Cho1p-HAx3
(A) Western blot showing expression of Cho1p-HAx3 (HA1) as compared to a
negative control. Several bands are present, possibly indicating degradation (29
KDa) or phosphorylation of Cho1p (36 KDa). (B) Protein was collected from
cho1ΔΔ, cho1ΔΔ::CHO1-HA, cho1ΔΔ::CHO1-HAx3 and used in an in vitro PS
synthase assay. A small, but statistically significant decrease is seen in the HAx3
tagged version of Cho1p. * p = 0.0013
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active (Kinney and Carman 1988, Kohlwein, et al. 1988).

Confirmation of the CAPT-Motif’s Importance in Enzyme Activity
We performed site-directed mutagenesis of the non-alanine residues in the
CAPT motif. Each residue was mutated to alanine within the CHO1-HAx3 in the
pCDC4 plasmid as described in materials and methods. The mutant plasmids
were transformed into cho1ΔΔ, checked for correct reintegration by PCR and
then colonies representing each mutation were screened for those that showed
expression of Cho1-HAx3 similar to wild-type by western blot (Fig. 4.2, Table
4.5). Membranes were isolated from each of the amino acid substitution mutants,
along with cho1∆∆::CHO1-HAx3 and cho1∆∆ controls, to assess activity of each
mutant protein by the in vitro PS synthase assay. In contrast to the findings in the
CAPT domain from S. cerevisiae Cpt1p (Williams and McMaster 1998), the
D125A, D128A, G142A, and D146A from the Cho1 PS synthase CAPT motif
showed 0% of Cho1p-HAx3 activity. G129A and D150A showed 4% and 67.5%
of the Cho1p-HAx3 activity, respectively (Fig. 4.3). The R133A mutant originally
showed decreased activity, however this reintegrated plasmid also showed lower
expression levels by western blot, so, we performed another enzyme assay on a
highly expressed R133A mutant and found that activity correlated with
expression, leading us to believe that R133A does not significantly impact the
activity of Cho1p-HAx3 (Fig. 4.3, data not shown).
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Figure 4. 2. Expression of Cho1p-HAx3 CAPT Motif Mutants
Protein was collected from cho1ΔΔ, cho1ΔΔ::CHO1-HAx3 (HA1) and each CAPT
motif point mutant used in a western blot to assess expression. Expression from
two western blots per mutant were quantified against tubulin standards using
Image J and the average was taken to determine approximate expression values
(shown in Table 4.5).
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Table 4. 5. Average (AVG) expression via
western blotting (WB) CAPT motif (top) and
predicted serine binding motif (bottom)
mutants
Strain
cho1ΔΔ
HA1
D125A
D128A
G129A
R133A
G142A
D146A
D150A

WB#1
1.724
31.685
36.884
67.666
131.73
16.29
20.758
14.069
26.714

WB#2
0.887
28.325
18.863
27.896
53.005
20.702
13.762
35.931
24.955

AVG
1.3055
30.005
27.874
47.781
92.368
18.496
17.26
25
25.835

% WT
4.3
100
93
159
308
62
58
83
86

cho1ΔΔ
HA1
R186A
L187A
R189A
F190A4

0.061
3.1951
3.4295
2.1733
1.7103
1.3978

0.1421
20.359
14.435
12.09
19.024
17.989

0.1015
11.777
8.9324
7.1315
10.367
9.6934

0.9
100
81
65
95
88
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Figure 4. 3. Enzyme Activity of Cho1p-HAx3 CAPT-Motif Mutants
Protein was collected from cho1ΔΔ, cho1ΔΔ::CHO1-HA, cho1ΔΔ::CHO1-HAx3
and each of the CAPT motif point mutants and used in an in vitro PS synthase
assay. All mutants show statistically significant decrease or abolishment of
activity. * p = 0.0046, ** p = 0.0016, all other = p < 0.0003
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Assessment of Predicted Serine Binding Motif’s Role in Enzyme Activity
In addition to CDP-DAG, Cho1 also binds serine as a substrate, and we were
interested in determining the serine binding site of Cho1. The serine binding site
is of particular interest in this study as CDP-DAG binding is common to several
enzymes that bind CDP-alcohols, whereas the serine binding site is more
specific to this enzyme.
However, unlike the CAPT motif, there is little known, to our knowledge,
about where serine binds in Cho1. Previous work on the mammalian PS
synthase, PSS1, identified an asparagine (Asn-209) residue as likely playing a
role in serine binding or recognition (Ohsawa, et al. 2004). However, as the Cho1
protein from C. albicans shares little amino acid similarity with mammalian PSS1,
and in sequence alignment, a corresponding Asn-209 residue is entirely absent
within CHO1, this informed our search relatively little.
We took a two-pronged approach to identify where serine might bind in
Cho1. PI synthase and PS synthase from yeast are similar enzymes in that both
bind CDP-DAG and a small molecule as substrates to generate their respective
phospholipids. Candida albicans Pis1 shares 28.5% amino acid similarity with
Cho1 and only differs enzymatically in binding inositol instead of serine. We
hypothesized that alignment and comparison of sequences between the two
genes might reveal a conserved serine binding site in Cho1. We aligned the Pis1
amino acid sequences from C. albicans, Saccharomyces cerevisiae, and
Schizosaccharomyces pombe with the Cho1 amino acid sequence from the
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same organisms (Fig. 4.4). From this alignment, we found a highly conserved
sequence in all of the PS synthase linear sequences that was entirely absent
from the Pis1 linear sequences (X-V-L-C-G-L-X-R-L-A-R-F). We predicted that
this might be part of the serine binding motif. Site directed mutagenesis of the
latter portion of the motif was performed as described previously for the CAPT
motif. We screened for colonies with roughly equal average expression of mutant
forms of CHO1-HAx3 compared to the cho1ΔΔ::CHO1-HAx3 background strain
(Fig. 4.5A, Table 4). We isolated membranes from each mutant and the control
(wild-type and cho1∆∆) strains and performed an in vitro PS synthase assay to
compare them. Each mutated residue in the latter portion of this motif
demonstrated a complete abolishment of activity as assayed in our in vitro
enzyme experiment with the exception of F190A which showed 59% of the
background activity (Fig. 4.5B).

Homology Model Predicting Cho1p Structure
Cho1 is a membrane protein that has not yet been crystalized. However, there
are several CDP-alcohol binding phospholipid biosynthetic proteins that have
been crystalized recently. Using Molecular Operating Environment software, we
threaded the sequence of CHO1 onto the solved crystal structures of these
proteins: two archeal and one bacterial membrane-bound proteins with CAPT
motifs (Clarke, et al. 2015, Nogly, et al. 2014, Sciara, et al. 2014). This
experiment produced a homology model that demonstrates the close proximity of
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Figure 4. 4. Sequence Alignment Reveals Possible Serine Binding Motif
Alignment of a portion of the PS synthases and PI synthases from C. albicans, S.
cerevisiae, and S. pombe. Highly conserved sequence, hypothesized to be
serine binding site in PS synthases, is highlighted in yellow.
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Figure 4. 5. Expression and Enzyme Activity of Cho1p-HAx3 Predicted
Serine Binding Motif Mutants
(A) Protein was collected from cho1ΔΔ, cho1ΔΔ::CHO1-HAx3 (HA1) and each
predicted serine binding motif point mutant used in a western blot to assess
expression. Expression from two western blots per mutant were quantified
against tubulin standards using Image J and the average was taken to determine
approximate expression values (shown in Table 4.5). (B) Protein was collected
from cho1ΔΔ, cho1ΔΔ::CHO1-HA, cho1ΔΔ::CHO1-HAx3 and each of the
predicted serine motif point mutants and used in an in vitro PS synthase assay.
All mutants show statistically significant decrease or abolishment of activity. * p =
0.0032, all other = p < 0.0001
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the serine binding site (yellow) with the CAPT motif (cyan) (Fig 4.6). These data
further support the findings in our experimental work.

Discussion
In this study we found that most of the amino acids in the predicted CAPT
motif in C. albicans Cho1-HAx3 are necessary for PS synthesis. However, there
were some differences from what has been observed in the CAPT motifs from
some other enzymes. For example, as opposed to the findings in S. cerevisiae
Cpt1 (Williams and McMaster 1998), only mutations of Asp125, Asp128, Gly142,
and Asp146 caused loss of activity, while mutations of Gly129 and Asp150
showed a severe to modest decrease in activity, and Arg133 showed nearly wildtype level activity (Fig. 4.3). In the Cpt1 enzyme from S. cerevisiae, Williams et
al., published that replacing Gly114, Gly127, Asp131, and Asp135 with alanine
abolished enzyme activity, while Ala117 and Arg118 mutants displayed
decreased activity and mutation of Asp113 had no detectable effect on enzyme
function (Williams and McMaster 1998). Williams and McMaster noted that,
because the amino acid glycine does not have a functional group, it is possible
that the importance of the glycine residues could be steric and control binding or
positioning of the substrates. Further, the alanine and arginine residues within
the Cpt1 CAPT motif were predicted to be important in binding and positioning of
the CDP-alcohol substrate (Williams and McMaster 1998).
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Figure 4. 6. Predicted Structure of Cho1p Based on Homology Modeling
(A) Cho1p amino acid sequence was threaded onto the crystal structure of the
AF2299 CDP-alcohol phosphotransferase (PDB accession number 4O6N via
Clarke et al., 2014) using Molecular Operating Environment 2015.1 software. The
CAPT motif is shown in cyan and the predicted serine binding motif is shown in
yellow. (B) Shows a closer view of the proximity of the CAPT motif to four amino
acids of the predicted serine binding site.
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A

Figure 4.6 continued
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B

Figure 4.6 continued
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Last, the final two aspartic acid residues within the yeast Cpt1 were
identified as probable catalytic residues (Williams and McMaster 1998). Within C.
albicans Cho1p-HAx3, we did not see a severe loss of activity for the D150A
mutation, which was the case for the second aspartic acid in the motif in yeast
CPT1. As a result, we suspect the catalytic residue in C. albicans Cho1p is one
of the three remaining aspartic acids: D125, D128, or D146. Despite the slight
differences between our findings and those of the yeast CPT1, which is not
totally unexpected given the difference in substrate and organism, our data
supports and confirms the importance of the CAPT motif in proper enzyme
function of Cho1p in C. albicans (Williams and McMaster 1998).
In addition to confirming the importance of the predicted CAPT motif in
Cho1, we predicted a possible serine-binding motif based on sequence
alignment from three different yeasts. This motif, X-V-L-C-G-L-X-R-L-A-R-F, is
highly conserved across PS synthase orthologs in these organisms, while it is
entirely absent from the Pis1p enzymes of the same three organisms (Fig. 4.4).
Site directed mutagenesis of the latter four residues in the motif produced an
almost complete abolition of activity. The only exception was the F190A mutation
which statistically significantly decreased activity, but only to 59% that of the
background strain (Fig. 4.5B). Although from these results we cannot say for
certain whether our mutations are affecting substrate binding, catalysis, or
protein stability/folding, it is clear that this sequence is critical for enzyme
function.
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In order to gain some insight into how these motifs might be arranged
relative to one another, we produced a homology model of Cho1. This homology
model, created by threading Cho1 sequence on the solved structures of other
membrane-bound CAPT-motif-containing proteins (Clarke, et al. 2015, Nogly, et
al. 2014, Sciara, et al. 2014), has provided at least a preliminary view of what
Cho1 might look like. The model predicts a six-transmembrane domain protein
structure with relatively close proximity of the predicted substrate binding sites.
Many of the residues within the CAPT motif are charged and have been found to
be part of a hydrophilic face of the 2nd and 3rd transmembrane domains of this
protein (Saha, et al. 1996). This correlates well with the homology model which
shows the CAPT motif spanning TM (2/3). The predicted serine-binding motif
(yellow) is located deep within the hypothesized membrane-bound portion, but it
is possible that there is a hydrophilic core that might allow substrate entry into
this site. This correlates well with the hypothesis that C. albicans Cho1 has a
cytosolic-facing hydrophilic core where substrates bind, which has been
demonstrated in PIS1 in yeast (Bochud and Conzelmann 2015). There is a long,
unstructured N-terminus that is predicted to be soluble and is likely important for
proper membrane insertion, although this has yet to be confirmed in C. albicans
(Sperka-Gottlieb, et al. 1990).
We have demonstrated here, for the first time, the importance of the CAPT
motif within the PS synthase from a medically-relevant, pathogenic fungus.
Further, we have begun efforts to identify binding location of the second
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substrate in this reaction, an area that is still relatively unstudied. We have
produced a homology model of Cho1p that places both of the substrate binding
sites in close proximity. These findings contribute not only to the general
understanding of phospholipid synthesizing enzymes, but also provide crucial
information on candidate locations of this protein where binding of small
molecules may inhibit activity. Because Cho1p represents such a promising drug
target, this data may lead to a more refined approach for discovering inhibitors.
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The findings from the projects in this dissertation have not always returned
expected results; however, they have provided some interesting and beneficial
data nonetheless. The primary goal of this work began as a search for small
molecules that inhibit the phosphatidylserine (PS) synthase enzyme in Candida
albicans. The secondary goal, which became equally as important as the
primary, was the characterization of the PS synthase protein itself.
One of the first projects undertaken in this work was to describe the PS
synthase’s contribution in the phospholipidome of C. albicans. Previous studies
described the phospholipid content of C. albicans, or showed PL mutant’s
phospholipid profile via TLC, but the work described in chapter two is the first
time mass spectrometry was used to define the lipid profiles of certain PL
mutants. In this study, we were able to identify that specific species of PS were
preferentially used to produce PE. In addition, we found that, in the event that
ethanolamine and choline are readily available within the medium, the Kennedy
pathway is able to compensate for the de novo loss of PE and PC production.
We were also able to describe the enzyme kinetics for the PS synthase, the
values

of

which

correspond

well

with

previously

published

data

for

Saccharomyces cerevisiae. These data helped to inform our screening
approaches described next.
In chapter three, the use of cho1ΔΔ mutant phenotypic traits as indicators
that compounds inhibit the PS synthase is discussed. This project looked for
compounds that could counteract Papuamide A, which is toxic to cells containing
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PS in their membranes. Thus, by counteracting Pap-A toxicity, hit compounds
were hypothesized to inhibit PS production by inhibiting PS synthase activity.
We identified a compound, SB-224289, which showed reproducible Pap-A
resistance. After further characterization, we concluded that SB-224289 did not
behave as we hypothesized, indicating that this trait of providing Pap-A
resistance was not specific enough for use in large scale screens. Indeed, at the
end of this chapter, we concluded that SB-224289 likely physically interacted with
Pap-A to abrogate the negative effects of the toxin.
Interestingly, as described in chapter four we found that when we
continued experimentation on SB-224289 in S. cerevisiae, it seemed to disrupt
proper localization of PS and another phospholipid PI54P. Thus, SB-224289 did
not behave by inhibiting the PS synthase enzyme, but instead controlled some
facet of phospholipid trafficking. Further investigation showed that SB-224289
treatment also caused a disruption in proper localization of Pma1p, a membrane
bound ATPase. Based on this, it seemed that SB-224289 activity acted more
generally by disrupting some component of cellular trafficking, possibly
endocytosis. We performed a screen on yeast homozygous mutants to determine
the intracellular target of SB-224289. In this assay, although it is as yet
incomplete, we identified Rho5p as a possible target for SB-224289. The direct
mechanism is unclear at the current time, but as Rho5p is active in many
pathways, it is conceivable that SB-224289 could interfere with one branch
pathway that controls endocytosis within yeast. However, this is speculation at
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the current time and further research will be conducted to either confirm or refute
these hypotheses. While unexpected given our initial goals of the Pap-A toxicity
screen, it still produced interesting results as a compound that induces largescale endocytosis could be useful in laboratory work.
In addition, as described in appendix three we performed a second Pap-A
toxicity screen, this time on plant extract fractions. It is well known that many
plants have innate defenses against fungal pathogens. Thus, we hypothesized
that there might be PS synthase inhibitors in the secondary metabolite milieu
produced by plants. We performed another screen and identified a fraction from
the leaf extract of the rain tree that allowed C. albicans to survive in the presence
of Pap-A. As described for SB-224289, we found that the rain tree extract did not
inhibit PS synthase as we hypothesized. We continued characterization of this
plant extract in an attempt to identify the bioactive component, but found that the
complexity of molecules within the plant extract precluded our ability to isolate
the single molecule producing our phenotypic trait.
Because of the difficulties encountered with our Pap-A toxicity screening,
we tried to take a more direct approach to identify compounds that inhibit the
fungal PS synthase. To do this, we used a phenotypic trait of cho1ΔΔ as an
indicator that the PS synthase had been inhibited. As described in appendix one,
this phenotypic trait was ethanolamine auxotrophy. Ethanolamine auxotrophy
describes cells that must have ethanolamine provided in the medium to survive.
This is a trait of cho1ΔΔ because PS is a precursor to the de novo production of
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PE, which is an essential phospholipid. Without PE, the cells cannot grow.
However, there is a secondary, scavenging pathway called the Kennedy pathway
that produces PE without the requirement for PS first. We hypothesized that PS
synthase inhibitors would cause the cells to become ethanolamine auxotrophs,
and thus unable to grow in minimal medium deplete of ethanolamine. We
performed a screen on small molecules, looking to identify ones that might cause
ethanolamine auxotrophy in minimal medium. Any positive hits that were
identified in this initial screen were then further confirmed by adding
ethanolamine back to the medium and looking for a recovery of growth (via the
Kennedy pathway of producing PE from exogenous ethanolamine).
Although we found positive hits in our initial screen, we never identified a
compound that showed a reproducible return of growth when ethanolamine was
returned to the medium. However, although we did not find compounds that
induced ethanolamine auxotrophy, and thus inhibit the PS synthase, we did
identify a compound that showed effective inhibition of growth of C. albicans.
This compound, called Lee-3664, showed effective killing of C. albicans at low
concentrations, while also showing relatively low cytotoxicity against mammalian
cells. Based on this, further characterization of this compound, as well as
chemical modification of its structure, is underway with collaborators at St. Jude.
Because of the difficulties we faced with the high-throughput screening
approaches with small molecules, we became interested in taking a different
approach for identifying PS synthase inhibitors. We hypothesized that, by
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identifying the important functional locations on PS synthase, we might be better
able to target those in a rational manner. Thus, in order to do this, we performed
various site-directed mutagenesis experiments to identify substrate binding sites
on the protein.
As described in chapter five, the fungal PS synthase is known to bind to
CDP-DAG and serine. Previously published data has shown a well-conserved
motif for many enzymes that bind CDP- molecules. We performed site-directed
mutagenesis on this sequence within the PS synthase and found that indeed
there was a significant decrease in enzymatic activity upon loss of many of these
amino acids. In addition to the CDP-DAG binding site, we were interested,
perhaps more so, in determining where serine binds the protein. Unlike CDPDAG, there is little in the literature known about where serine binds in any
protein. Thus, we performed sequence alignments of fungal PS synthase and PI
synthases to guide our hypothesis of where serine binds. We identified an amino
acid sequence that was well conserved across several fungal PS synthases but
absent in PI synthases. When the amino acids in this sequence were mutated
individually to alanines, the enzyme showed a complete abolishment of activity.
Although at this point we cannot say for certain whether this is the true binding
site of serine or these amino acids are important in another way for the enzyme
function, this characterization has revealed another location on the protein where
inhibition may be beneficial in stopping the function of the enzyme.
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Last, there is little known about PS trafficking and dynamics within any
organism. Because of this, we were interested in determining how long PS
remains at the plasma membrane of S. cerevisiae. As described in appendix two,
we produced several yeast strains carrying fluorescent molecules to demonstrate
localization of PS. We also wished to put the PS synthase under a repressible
promoter whereby we could control the production of PS and follow its
movement, appearance, or disappearance within the cell. Unfortunately, all
attempts at producing repressible PS synthase in this yeast were not entirely
successful at producing a clean shut off of PS expression. As a result, we used
lyso-PS treatment in a cho1Δ to measure PS duration at the membrane. This
lyso-PS was added exogenously into the medium of cho1Δ cells which took up
the lyso-PS, modified it in the ER, and then returned it to the plasma membrane.
We observed an appearance of PS at the membrane within fifteen to thirty
minutes that remained up to 300 minutes after removal of exogenous lyso-PS,
although diffusion began to occur at later time points. These findings, although
not exactly as occurs naturally, demonstrate the potential for PS to remain in the
membrane for extended periods of time.
The last project we worked on was crystallization of Cho1p as described in
appendix four. Although this project was begun too late for a structure to be
solved, we did take the first important steps for protein crystallization. Strains of
S. cerevisiae were produced where both the S. cerevisiae and C. albicans PS
synthase were highly expressed and tagged with Hisx6. These strains will allow
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isolation and purification of the protein in future experiments using affinity
chromatography. Although it may be a daunting task, once a crystal structure is
solved, it will greatly advance our understanding of the protein in general, and as
a drug target. In fact, modern technology allows for computational screening with
solved protein structures whereby small molecules can be docked within the
proposed active site of the protein. These identified molecules that “fit” well into
the active site would then further be tested in in vitro and in vivo assays to
determine efficacy. As described in chapter five, a homology model was
produced that predicted the structure of the PS synthase, but it is well
documented that homology models are not always accurate. We attempted to
use the homology model of Cho1p in the computational screen, but the
parameters determining “hit” compounds were too loose, allowing too many hits
to be identified. Thus, it is our intention to perform another computational screen
with increased confidence once a crystal structure is solved.
In addition to the future computational screen, another screening
approach is underway. This approach utilizes three different expression profiles
of the drug target in genetically altered C. albicans. First is an overexpressed
version of the protein, second is a wild-type version, and third is an under- or
non-expressed protein. Each of these strains also expresses a unique
fluorescent marker that differentiates it from the other strains. These strains are
pooled in 96-well plates and treated with the compound of interest. After
incubation, fluorescence is monitored to determine if there has been an effect on
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the strains. If the target itself is being specifically inhibited, there should be a
dose-response of efficacy. For instance, the overexpressed strain should be
completely inhibited as there is more target for the compound to inhibit. The wildtype should also be susceptible, but perhaps to a lesser degree. And last, the
deletion or under-expressed protein strain should grow relatively well since the
drug target is present in decreased levels. Thus, this method allows
differentiation of compounds that are outright toxic (i.e. kill all of the strains) and
those that are selectively toxic based on the drug target.
This approach is in the beginning stages with Glen Palmer and
collaborators from the UT Health Science Center. Strains have been constructed
and large scale screens are slated to go forward. This methodology seems
promising and will hopefully reduce much of the nonspecific activity of drugs that
we have seen in our previous screening approaches.
In conclusion, the work in this dissertation has described an entirely new
physiological behavior for the compound SB-224289. Although a clear answer for
its exact mechanism is not known, a molecule that disrupts proper trafficking of
cellular material (i.e. endocytosis) could be useful in labs that study of these
processes in yeast.
Further, the findings of this dissertation have provided a greater general
understanding of Cho1p and its importance and activity within the pathogenic C.
albicans. Research is still underway to more-confidently describe the substratebinding sites of Cho1p, but our findings demonstrate two motifs that may play
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important roles in enzyme function. Because of the highly conserved nature of
the CAPT motif residues, it seems likely that decreases in activity in the CAPTmotif mutant versions of Cho1p are likely a result of disruption of CDP-DAG
binding or catalytic activity of the enzyme. To further confirm this, Km and Vmax
analysis would need to be performed on some of the still-functional mutant
versions of Cho1p to determine where the true disruption lies.
Second, although there is little evidence to confidently demonstrate that
our predicted serine-binding motif is truly important in serine binding, three of the
four residues within this motif were shown to abolish activity of the protein,
indicating at least that they are important in some way to enzyme function.
Because of the questions that still remain regarding this motif, and the possibility
that it is not involved in serine-binding as hypothesized, it will be even more
important that future experiments include active site labeling which can more
definitively identify residues important in serine binding.
Last, this research has made possible many Cho1p inhibitor screening
approaches that were not possible before its completion. Although there are
clearly difficulties in screening for inhibitors of Cho1p, this research has provided
an excellent path forward in further screening approaches to identifyi inhibitors.
Plus, it has lended credence to the hypothesis that Cho1p represents an
excellent drug target. Because Cho1p is crucial to the de novo production of
several major phospholipids (PS, PE, and PC), its disruption renders this
organism unable to grow and cause infection in the host. In addition, although it
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is not required that a drug target be absent within the host organism for
specificity, the fact that Cho1p is absent within mammals may remove the added
possibility of toxicity to the host, as it is an issue in some antifungal drugs on the
market today.These reasons alone support the usefulness of pursuing Cho1p as
a drug target; however, there are also many tools that allow for the study of
Cho1p as well as PS levels, localization, and biosynthesis. These tools include
the in vitro PS synthase assay, microscopy of GFP-Lact-C2-expressing strains of
S. cerevisiae, lipidomics, and more. Further, there are excellent phenotypic traits
that can be used in secondary screens to confirm the activity of possible Cho1p
inhibitors

(i.e.

Papuamide-A

assay,

ethanolamine

auxotrophy,

β-glucan

unmasking in the cell wall). These tools and secondary screening traits have
been developed, utilized, or optimized within this dissertation work. This array of
tools and secondary screens available for use in studying Cho1p support its
excellent potential as a drug target.
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APPENDIX I
SCREEN FOR COMPOUNDS INDUCING ETHANOLAMINE
AUXOTROPHY IN CANDIDA ALBICANS

191

Contributing authors to this work include: Chelsi D. Cassilly, 1 Martin Cheramie,
Robin B. Lee,

2

Dinesh M. Fernando.,

2

Miranda J. Crouch,

1

Richard E. Lee,

2
2

Todd B. Reynolds 1
University of Tennessee, Knoxville

1

St. Jude Children’s Research Hospital 2

This article has not been published elsewhere at this time, nor will it be before
completion of this ETD. The Abstract is a modified version of one submitted for
presentation at the Comparative and Experimental Medicine and Public Health
Research Symposium at the University of Tennessee, Knoxville, in 2015. The
author contributions are as follows: Conceived and designed the experiments:
CDC MC RBL REL TBR. Performed the experiments: CDC MC RBL DMF MJC
TBR. Analyzed the data: CDC MC RBL DMF REL TBR. Contributed
reagents/materials/analysis tools: TBR REL. Wrote the paper: CDC DMF

Abstract
The pathogenic fungus Candida albicans is the leading cause of hospitalacquired

fungal

infections

in

immunocompromised

individuals.

Invasive

bloodstream infections have a 30% mortality rate. Three antifungal classes are
used to treat invasive fungal infections including azoles, echinocandins, and
polyenes. Rising drug resistance and drug toxicity have made these compounds
less effective and new drugs are needed. The fungal phosphatidylserine (PS)
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synthase (Cho1p) has been suggested as a drug target because it is: 1) required
for C. albicans virulence, 2) conserved among fungi, and 3) absent from
mammals. Thus, Cho1p inhibitors could be broad-range antifungals with few
detrimental side effects. To identify Cho1p inhibitors, we have taken a novel
compound screening approach. Cells lacking Cho1p cannot survive without
supplemented

ethanolamine

because

de

novo

biosynthesis

of

phosphatidylethanolamine (PE), a vital phospholipid, is downstream of PS
production.

Thus, these cells only survive by making PE from imported

ethanolamine by an alternative pathway. We screened compounds for their
ability to inhibit growth of wildtype C. albicans in media lacking ethanolamine, but
not in media containing ethanolamine, thus indicating ethanolamine auxotrophy.
A set of three large-scale, high-throughput screens were performed. Although we
did not succeed in identifying PS synthase inhibitors from these screens, we
were able to identify a compound of interest, named Lee-3664, that seems highly
toxic to fungi. Further compound modifications and testing are underway on this
compound.

Introduction
In addition to the drug screen performed with Papuamide A (Cassilly, et al.
2016), we also screened compounds for their ability to phenocopy the cho1∆∆
mutant. One particularly useful phenotypic trait is ethanolamine auxotrophy (i.e.
the inability to survive without ethanolamine supplemented in the medium). In the
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de novo pathway, PS is a precursor for synthesis of PE, so PE synthesis is also
blocked when PS synthesis is disrupted, as in the case of the cho1∆∆ mutant
(Chen, et al. 2010). PE is an essential phospholipid, and without it C. albicans is
unable to survive. The cho1∆∆ can circumvent this blockage of the de novo
pathway by using the alternative Kennedy Pathway to import exogenous
ethanolamine for the production of PE (Cassilly, et al. 2017). However, this only
works in culture media as there is insufficient ethanolamine in the mouse host to
support PE synthesis during an infection, which likely contributes to avirulence in
the cho1∆∆ mutant (Davis et al., in preparation). We hypothesized that
compounds that cause wild-type C. albicans to become an ethanolamine
auxotroph could be inhibiting an enzyme within the PS synthesis pathway.
In order to test this hypothesis, we developed a screen where we grew the
wild-type organism in ethanolamine deplete synthetic medium. The organism
was then treated with compounds from a selected library and allowed to incubate
overnight. Wells that contained actively growing cells, like the wild-type DMSO
negative control, were considered negative hits (because they are not
ethanolamine auxotrophs) while wells that contained no growth were considered
initial hits.
To eliminate false positives, specifically compounds that are inherently
toxic to the cells, we developed a secondary screen that supplemented 1 mM
ethanolamine to the medium. This exogenous ethanolamine would be substrate
for the Kennedy Pathway to circumvent the need for PS, and thus allow growth of
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the cho1∆∆ mutant. As a result, in this secondary screen, compounds that
inhibited growth in the ethanolamine negative screen, but not in the presence of
ethanolamine, were considered true hits. True hits were then further screened
more stringently to determine the lowest concentration at which the compounds
were effective.
We performed three different small-scale but high-throughput screens for
compounds that caused a loss of growth in minimal medium. These compounds
were then tested in a minimum inhibitory concentration (MIC) curve in duplicate
with media +/- ethanolamine to find the minimum concentration that caused
ethanolamine auxotrophy. Unfortunately, we were unable to identify any hits that
induced ethanolamine auxotrophy in the wild-type organism reproducibly.
However, one beneficial aspect of our screening approach was the alternative
ability to identify compounds that are fungicidal (i.e. compounds that inhibited
growth in both +/-ethanolamine conditions, indicating that they might be toxic to
fungi instead of simply inhibitory to a particular pathway). Although we were
unable to identify PS synthase inhibitors through this screen, we did identify one
compound in particular with promise as a fungicidal drug.
Materials and Materials
Strains and culture methods
The strains used in this study were wild-type (SC5314), cho1Δ, cho1ΔΔ
(YLC337), and psd1Δ/Δpsd2Δ/Δ::PMet3-PSD1 (YLC331). Strains were previously
published and described (Chen, et al. 2010) and can be found in Table A1.1.
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Minimal medium (0.67% yeast nitrogen base without amino acids (Difco), 2%
dextrose (ThermoFisher Scientific)) and YPD rich medium (1% yeast extract, 2%
peptone, 2% dextrose) were used where indicated (Guthrie 2002).

Genetics and Cloning
The plasmid pYLC314 which contains an ACT1 promoter and nourseothricin
resistance gene (SAT1) followed by PMET3 was isolated from E. coli. To insert this
sequence in front of the CHO1 gene in cho1Δ, we designed one primer
containing the sequence upstream of CHO1 followed by the ACT1 promoter
beginning (CCO14) and a second, reverse primer containing the 3’ portion of
PMET3 followed by sequence just before the start codon of CHO1 (CCO15) (Table
A1.1) This portion was amplified using PCR, then purified and transformed into
cho1Δ. Selection was performed on YPD-nourseothricin plates. This produced
cho1Δ PMET3-CHO1.

Secondary Screens for Ethanolamine Auxotrophy
Further screening of transformants was performed using serial dilution on
minimal medium agar plates supplemented with: 1) nothing, 2) 2.5 mM cysteine/
2.5 mM methionine, 3) 1 mM ethanolamine, or 2.5 mM cysteine/ 2.5 mM
methionine 1 mM ethanolamine. A starting culture of 0.1 OD600/ml was diluted
1:10 five times and then spotted on each plate. Positive and negative growth
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Table A1. 1. Strains, Plasmids, and Primers Used or Produced in this Study
Name
SC5314
(Ca157)
Ca159
(YLC337)

C. albicans
C. albicans

cho1ΔΔ

YLC331

C. albicans

psd1Δ/Δpsd2Δ/Δ::pMet3-PSD1

CDCS11

S. cerevisiae

cho1Δ PMET3-CHO1

Source
Lab
Strain
Chen et
al., 2010
Joseph
Chen
Becker
Lab

pYLC314

E. coli

PMET3, AmpR, SAT1

Joseph
Chen

CCO14

CCO15

Organism

Genotype

TTCAAACAAGCATTTTGTTATATATAA
CGGTTTTCTTTTTTTCATCTCGTTTTA
TTTATTTACACATTTTTTCGTCAAAAC
TAGAGAATAATAAAG
TTCTGAATCTGATACAATTGCTGATTC
TTGGTGCTTGGAGAACCCGGTAGCT
GATGAGTCTGTCATGAATAGGTTTTC
TGGGGAGGGTATTT

This
Study

This
Study
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controls included the wild-type and cho1ΔΔ. Plates were allowed to dry and
incubated at 30°C overnight before pictures were taken.
Additionally, a form of the above assay was performed in 96-well plates
with liquid medium instead. Appropriate cell cultures were grown overnight in 5
ml to stationary phase in 5 ml YPD shaking at 30°C. Cultures were pelleted and
washed with sterile water 2x. Cells were resuspended in minimal medium and
diluted to an OD600/ml of 0.1. Cells were then counted on a hemocytometer twice
and diluted to 2.5 x 103 cells/ml. 50 μl of the dilutions were pipetted into a 96-well
plate, then additional medium was added containing either 1) nothing, 2) 5 mM
cysteine/ 5 mM methionine, 3) 2 mM ethanolamine, or 5 mM cysteine/ 5 mM
methionine 2 mM ethanolamine. Plates were incubated at 30°C overnight. The
following day, Alamar Blue was added according to the manufacturer’s protocol
and (Cassilly, et al. 2016), then fluorescence was read in a plate reader as a
proxy of growth.

Ethanolamine auxotrophy screening
Wild-type and cho1ΔΔ were grown overnight in 5 ml of YPD shaking at 30°C.
The following day cultures were transferred to 15 ml conical tubes and
centrifuged at 3,000 rpm for 3 minutes. Supernatant was decanted and cells
were washed 2x with sterile water. On the last wash, cells were resuspended in
minimal medium and the OD600/ml was taken using a spectrophotometer.
Cultures were diluted to an OD600/ml of 0.1 in 5 ml of minimal medium. Using a
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hemocytometer, cells were counted for each strain twice then diluted to 1.6 x 10 6
cells/ml. These dilutions were pipetted into either a 96- (100 μl/well) or 384- (40
μl/well) well plate and incubated at 30°C overnight. Compounds from each library
used were added to a concentration of ~10 μM using a automated pintool as
described in (Cassilly, et al. 2016).
The

following

day,

CellTiter

Glo

was

added

according

to

the

manufacturer’s protocol and luminescence was measured to assess growth of
the organism. To define positive hits, all data was copied from BMG Pherastar
software

into

an

Excel

spreadsheet.

Before

proceeding

raw

Relative

Luminescence Units (RLU) were normalized to each other (0<n<1, 0 = positive
control, 1 = negative control). Data analysis proceeded using normalized RLU
(nRLU). DMSO negative control wells were averaged and Fluconazole positive
control wells were averaged. These averages provided our experimental maxima
and minima of nRLU for each plate. A fungicidal index (FI) was developed by
dividing the nRLU in the experimental well by the average of the plate’s DMSO
negative control wells’ nRLU in EA- plates (0<FI<1, lower the FI, the more
fungicidal the compound). To investigate recovery between EA+ and EA- wells, a
Recovery Index (RI) was developed by dividing the nRLU of corresponding wells
from the EA+ plate by the nRLU from the EA- plate. Therefore, a larger value
indicated greater recovery in the EA enriched media. To determine a hit in our
screen, the RI was divided by the FI (RI/FI). Therefore, the larger number, the
more recovery from adding EA in the presence of a compound active against C.
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ablicans. Data was then graphed, with each compound along the x-axis and
nRLU along y-axis. We followed up on the top 20 hits (top 20 highest numbers
from RI/FI). Hits were follow upon by MIC determination in 96 well format in EA/EA+ conditions. MIC was determined using Alamar Blue.

Mammalian Cytotoxicity
Vero (Kidney epithelial cells; ATCC CCL-81) and HEPG2 ( Liver Hepatocellular
Carcinoma cells; ATCC HB-8065) monolayers were trypsinized (ATCC 30-2101)
and quantified using disposable SD100 cell counting chambers and Cellometer
Auto T4 (Nexcelom Bioscience, MA). Cells were seeded at 5000 cells/well (10-15
%

confluency)

into

white,

flat

bottom

96-well

plates

(Nunc

136101,

ThermoFisher) using enriched Dulbecco’s Modified Eagle’s Medium (Hyclone:
DMEM/ High Glucose) for Vero cells and Eagle’s Minimum Essential Medium (
EMEM; ATCC 30-2003) for HEPG2 cells, each containing 10 % Fetal Bovine
Serum (ATCC-30-2020). Plates were incubated overnight at 37°C in the
presence of 5% CO2. All compounds were solubilized in DMSO and serially
diluted in respective media for each cell line. A serial dilution of DMSO only was
made to monitor for diluent toxicity against HEPG2 and Vero. Equal volume of
media containing compound dilutions was transferred to plates containing
seeded cells using Biomek FXP liquid handling robot (Beckman Coulter,CA). The
plates were briefly spun and incubated for 72 hours. After 72 hours of
incubation,

viability

was

indirectly

measured

using

the

CellTiter-Glo®
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Luminescent Cell Viability (G7572 Promega) assay. Assay plates were read at
peak emission wavelength of 590 nm on a PHERAstar FS Multilabel reader
(BMG, Cary,NC). The raw data was normalized to no drug (DMSO only) wells as
100% viability standard. The concentration of test compounds that inhibited
growth by 50% (IC50 value) was computed using nonlinear regression based
fitting of inhibition curves using log [inhibitor] vs. Response-variable slope (four
parameters) - symmetrical equation, in GraphPad Prism version 7 (GraphPad
Software, La Jolla California USA, www.graphpad.com).

Results
Initially we wanted to set strong positive and negative controls for our screen. In
previous work, we found that the cho1∆∆ mutant showed relatively poor growth
return in the presence of ethanolamine (Chen, et al. 2010). Because of this,
detection of recovered growth of the cho1ΔΔ mutant in our screen presented a
possible challenge in using cho1ΔΔ mutant as the positive control for identifying
hits.
We were interested in producing a strain of C. albicans with CHO1 under
the repressible promoter PMET3. In this case, PMET3-CHO1 should produce Cho1p
when grown in conditions where methionine and cysteine are absent, but not
produce the protein when grown in the presence of methionine and cysteine
(Care, et al. 1999). This would give us a way of controlling Cho1p expression via
the action of compounds (i.e. cysteine and methionine) which is a close analog of
201

what we were screening for (i.e. small molecules that inhibit Cho1p). We used
PCR to amplify PMET3 from pYLC314 (Joseph Chen) with overhangs matching to
the upstream region of CHO1. We made many attempts to integrate the
construct into the genome of a heterozygous cho1Δ mutant. We isolated one
positive colony where PMET3-CHO1 appeared to have integrated (CDCS11). As
shown in Figure A1.A, cho1ΔΔ cannot grow on minimal medium due to
ethanolamine auxotrophy while cho1Δ::PMET3-CHO1 grows because it is
expressing Cho1p under these conditions. In Figure A1.1B, cho1ΔΔ grows in 1
mM ethanolamine supplemented medium because it can produce PE via the
Kennedy Pathway. The cho1Δ:: PMET3-CHO1 strain grows equally as well in
minimal medium containing ethanolamine as in medium unsupplemented with
ethanolamine. In Figure A1.1C, cho1ΔΔ cannot grow on minimal media with 2.5
mM cysteine and 2.5 mM methionine because it has to have ethanolamine to
grow. In addition, cho1Δ:: PMET3-CHO1 strain does not grow when 2.5 mM
cysteine and 2.5 mM methionine are supplemented because the presence of
these components shut off the PMET3 which is controls expression of Cho1p and
thus, the organism becomes an ethanolamine auxotroph under these conditions.
Last, in Figure A1.1D, the cho1 ΔΔ mutant has a modest return of growth on
minimal medium supplemented with 2.5 mM cysteine and 2.5 mM methionine
and 1 mM ethanolamine because it is able to produce PE via the Kennedy
Pathway. The cho1Δ::PMET3-CHO1 strain also has a modest return of growth
when ethanolamine is added due to the same reason. Although these results
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Figure A1. 1. Growth Phenotype of the cho1Δ::PMET3-CHO1 Strain
The cho1ΔΔ and cho1Δ::PMET3-CHO1 strains were compared for growth
phenotype on minimal medium supplemented with (A) nothing, (B) 1 mM
ethanolamine, (C) 2.5 mM cysteine and 2.5 mM methionine, (D) 1 mM
ethanolamine and 2.5 mM cysteine and 2.5 mM methionine.

203

were precisely as expected, this phenotype unfortunately seemed to disappear
over time and we could never replicate this data in new transformations. Thus,
the project to produce cho1Δ::PMET3-CHO1 was abandoned.
Despite this problem we continued efforts to produce an adequate positive
control for our screen. Previously in the Reynolds Lab, a strain had been
produced

where

the

PSD1

psd1Δ/Δpsd2Δ/Δ::PMET3-PSD1

gene

(Joseph

was

Chen).

under
This

PMET3

strain

is

control:
also

an

ethanolamine auxotroph under certain circumstances because, even though it
can produce PS, it can only convert that PS to PE in medium lacking cysteine or
methionine (i.e. when the Psd1p enzyme is produced). To confirm that this strain
behaved as expected, we tested the ability of psd1Δ/Δpsd2Δ/Δ::PMET3-PSD1 to
respond to methionine, cytsteine, and ethanolamine. We found that this strain
showed no growth in the presence of cysteine and methionine alone, but that
upon the addition of 1 mM ethanolamine, was recovered for growth (Fig. A1.2).
This was an excellent proxy of what we expected to see with small molecule
inhibitors in our screening approach. However, while psd1Δ/Δpsd2Δ/Δ::PMET3PSD1

showed

excellent

ethanolamine

auxotrophy

recovery

at

UTK,

reproducibility of this phenotype was never secured at St. Jude, and thus the
cho1ΔΔ mutant was included as a positive control in our high-throughput screens
instead of psd1Δ/Δpsd2Δ/Δ::PMET3-PSD1.
At UTK we performed several assays to determine the appropriate
conditions for use of cho1ΔΔ mutant as a positive control (Table A1.2, Fig.
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Figure A1. 2. Use of PMET3-PSD1 as a positive control
When grown without 1 mM ethanolamine (A) the cho1ΔΔ strain
cannot grow under any circumstance and the psd1ΔΔpsd2ΔΔ::PMET3PSD1 can grow only without the presence of met/cys. However, when
1 mM ethanolamine is added to the medium (B) there is a return of
growth to both cho1ΔΔ and psd1ΔΔpsd2ΔΔ::PMET3-PSD1 nearly to
wild-type levels in the presence of met/cys*. Medium also contained
50 mM Hepes to allow for measurement with Alamar Blue.*Too high
concentrations of met/cys appear toxic (>/= 0.63 mM). Abbreviations:
met/cys = methionine and cysteine.

205

A1.3). While the cho1ΔΔ mutant was sufficient as a positive control at UTK,
detectable growth of this control was never observed at St. Jude for any of the
screens performed.
In a pilot study at St. Jude Children’s Research Hospital (St. Jude), we
assessed

1,831

bioactive,

FDA-approved

compounds

(http://www.selleckchem.com/screening/chemical-library.html) to identify those
which produce ethanolamine auxotrophy in wild-type C. albicans growing in
medium lacking ethanolamine (i.e. phenocopy the cho1ΔΔ mutant). This initial
screen revealed 13 initial hits (0.7% hit rate). The Z-scores for most of the plates
were above 0.5, indicating a reliable screen by standard HTS statistical appraisal
(Zhang, et al. 1999). Each of the 13 hits was rescreened in triplicate under a
dose-response curve in media +/-ethanolamine using controls of compounds that
had no effect or were toxic. Unfortunately, this revealed that none of the
bioactives induced ethanolamine auxotrophy, although several were directly
inhibitory to growth.
We performed a second screen with a 510-compound library subset from
the Medicines for Malaria Venture (https://www.mmv.org/).

Due to the

effectiveness against the eukaryotic organism Plasmodium, we were interested
to see if these compounds were also effective against C. albicans. From this
screen, we obtained no compounds that induced reproducible ethanolamine
auxotrophy in wild-type C. albicans.
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Table A1. 2. UTK-Determined Parameters for Ethanolamine Auxotrophy
Screening

Primary
Screen

Counter
Screen

Cell
Concentration
(cells/ml)

Incubation
Temperature
(°C)

Viability
Indicator

Plate

Medium

384well

0.67% yeast
nitrogen base,
2% dextrose

1 x 10

4

30

CellTiter
Glo

96well

0.67% yeast
nitrogen base,
2% dextrose,
50 mM
HEPES, 1 mM
Ethanolamine

1 x 104

30

Alamar
Blue
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Figure A1. 3. Use of cho1ΔΔ as a positive control
(A) When grown without 1 mM ethanolamine the cho1ΔΔ and psd1ΔΔpsd2ΔΔ
strains cannot grow due to ethanolamine auxotrophy. The psd1ΔΔ strain shows a
severe growth defect at the highest cell concentration and is undetectable at the
lower cell concentrations. The only cell growth is seen in wild-type and
cho1ΔΔ::CHO1 which can synthesize PE de novo. (B) When the medium is
supplemented with 1 mM ethanolamine, cho1ΔΔ, psd1ΔΔ, and psd1ΔΔpsd2ΔΔ
show a return of growth nearly equal to the wild-type and cho1ΔΔ::CHO1 strains
at the highest cell concentration.
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The last library screened was the Maybridge Collection of 1,342 fragments
(http://www.maybridge.com/portal/alias__Rainbow/lang__en/tabID__230/Deskto
pDefault.aspx). These fragments are increasingly useful due to their diversity in
structure as well as their high potential to be combined or modified to improve
efficacy. On average, these compounds were within the size range of 200 to 300
Da and soluble in water. From this screen we identified 20 true hits that produced
ethanolamine

auxotrophy;

however,

upon

performing

dose

response

experiments, none reproducibly retained this phenotype.
Although we saw no compounds from any screen that produced
ethanolamine auxotrophy, we did find 18 total initial hits that appeared to be
fungicidal. These hits thus became of primary interest and were screened further
for minimum inhibitory concentration (MIC) against fungi and tested for
mammalian cytotoxicity. After cytotoxicity testing against HepG and VERO cells,
we identified two promising compounds. One had a fungal MIC of less than 0.57
μM and a cytotoxicity index of 27.5 μM. The second had a fungal MIC of 4.6 μM
and a cytotoxicity index of greater than 109 μM. Because of the excellent
cytotoxicity index of the second compound, we began to focus on this compound,
now named Lee-3664.
Unfortunately, while this compound showed great promise at St. Jude, the
fungal MIC experiments could not be reproduced at UTK. This seems to indicate
that conditions must be completely uniform to produce desired phenotypes.
However, despite the issues in reproducibility, work is currently underway at St.
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Jude to further characterize Lee-3664 mechanism of action by screening a
heterozygote deletion collection of C. albicans. Further, chemists at St. Jude are
modifying the structure of Lee-3664 to produce analogs with the expectation that
some of them may be more effective antifungals with lower MICs.

Discussion
It was our expectation to perform the three described small-scale, highthroughput screens and then ramp up the approach to include the 520,000 onsite compound library (Chen 2008) at St. Jude, but because of the challenges
associated with this work, this goal was abandoned. Indeed, we began this
screening approach in order to avoid the complexity associated with the
Papuamide A screen. As these results show, using ethanolamine auxotrophy as
a screening trait has its own unique set of challenges. However, although this
work has been met with problems, from finding adequate controls to issues with
reproducibility across work sites, there is still the potential that interesting
information may come of this screen in future studies at St. Jude.

210

References
Care RS, Trevethick J, Binley KM et al. The MET3 promoter: a new tool for
Candida albicans molecular genetics. Mol Microbiol 1999;34: 792-8.
Cassilly CD, Farmer AT, Montedonico AE et al. Role of phosphatidylserine
synthase in shaping the phospholipidome of Candida albicans. FEMS
Yeast Res 2017;17.
Cassilly CD, Maddox MM, Cherian PT et al. SB-224289 Antagonizes the
Antifungal Mechanism of the Marine Depsipeptide Papuamide A. PLoS
One 2016;11: e0154932.
Chen T, Guy, R. K. HIGH-THROUGHPUT SCREENING AND DRUG
DISCOVERY AT ST. JUDE CHILDREN’S RESEARCH HOSPITAL. Cell
Notes 2008: 3 - 4.
Chen YL, Montedonico AE, Kauffman S et al. Phosphatidylserine synthase and
phosphatidylserine decarboxylase are essential for cell wall integrity and
virulence in Candida albicans. Mol Microbiol 2010;75: 1112-32.
Guthrie C, Fink, G. R. (ed.) Methods in Enzymology volume 350: Academic
Press, 2002.
Zhang JH, Chung TD, Oldenburg KR. A Simple Statistical Parameter for Use in
Evaluation and Validation of High Throughput Screening Assays. J Biomol
Screen 1999;4: 67-73.

211

APPENDIX II
TRAFFICKING AND STABILITY OF PHOSPHATIDYLSERINE IN
THE PLASMA MEMBRANE OF YEAST
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Abstract
Phosphatidylserine (PS) is a phospholipid that is commonly enriched in the inner
leaflet of the plasma membrane of yeast and other eukaryotes. PS is produced in
the endoplasmic reticulum and is trafficked to the mitochondria where it can be
used to produce other phospholipids or to the plasma membrane. Although there
have been some advances in understanding PS trafficking, little is known about
the duration of PS at the plasma membrane. Previous studies involving
extracellular addition of lyso-PS (i.e. PS where one fatty acid tail has been
removed) suggested a rapid conversion of Lyso-PS into PS, followed by
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incorporation into the plasma membrane. To further study this, we engineered a
strain of Saccharomyces cerevisiae where the PS synthase gene (CHO1) is
controlled by the repressible galactose promoter (PGAL1). In the presence of
galactose, Cho1p enzyme is expressed, and thus PS is synthesized. However,
when glucose is present in the medium instead of galactose, PGAL1 represses
CHO1 and therefore PS production. In addition, we introduced a fluorescent, PSspecific probe to S. cerevisiae in order to visualize PS via fluorescent
microscopy. We found that glucose repression of CHO1 via PGAL1 caused a
diffusion of the fluorescent probe away from the plasma membrane, indicating a
decrease in PS levels. However, PGAL1 did not completely shut off Cho1p
production, and thus the results were variable. In addition, we tested the effects
of membrane-perturbing agents on PS localization and found that some
compounds cause redistribution of PS within yeast.

Introduction
Phosphatidylserine (PS) is a glycerophospholipid and is considered a major
phospholipid in eukaryotic organisms. Within most eukaryotes, PS is enriched in
the inner leaflet of the plasma membrane and can have significant roles in
membrane structure and cell signaling (Carman and Han 2011, Lagace and
Ridgway 2013, Levin 2005, Mioka, et al. 2014). PS is produced in the
endoplasmic reticulum (ER) by the PS synthase enzyme Cho1p (Carman and
Han 2011, Cassilly, et al. 2017, Chen, et al. 2010, Osman, et al. 2011). After
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production, PS can either be trafficked to the plasma membrane or used to make
phosphatidylethanolamine (PE) in the mitochondria or endosome (Yeung, et al.
2008). Several studies have been conducted to study trafficking of PS to the
mitochondria and plasma membrane. These studies describe the mitochondrial
associated membrane (MAM) and the plasma membrane associated membrane
(PAM) which are portions of the ER that are closely associated with the
mitochondria or the plasma membrane, respectively. The MAM and the PAM are
where the majority of phosphatidylserine synthesis and trafficking are predicted
to occur (Achleitner, et al. 1999, Kuchler, et al. 1986a, Maeda, et al. 2013, Moser
von Filseck, et al. 2015, Natarajan, et al. 2004, Osman, et al. 2011, Pichler, et al.
2001, Pomorski, et al. 2003, Sleight and Pagano 1983, Tamura, et al. 2012,
Voelker 2003). Despite these studies, little is known about the dynamics of PS
once it reaches the plasma membrane.
Previous work by (Maeda, et al. 2013, Moser von Filseck, et al. 2015)
described a rapid (within 10 minutes) incorporation of Lyso-PS into PS in the ER,
and subsequent relocation to the plasma membrane. Although this describes the
movement of newly formed PS to the membrane, it is through an unnatural
mechanism whereby Lyso-PS is the starting material that is converted into PS,
then trafficked back to the plasma membrane (Maeda, et al. 2013). While this is
informative, it does not describe the natural process of PS trafficking whereby PS
is produced from CDP-DAG and serine. Understanding this natural trafficking
and dynamics of PS was the goal of the present study.
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In order to observe the movement of PS, we constructed a version of the
ScCHO1 gene which is under the control of a repressible promoter. The
galactose promoter (PGAL1) allows expression of a particular gene in the
presence of galactose and represses the expression of the gene in the presence
of glucose. By inserting PGAL1 in place of the native CHO1 promoter (PGAL1CHO1), we are able to control the expression of Cho1p, and thus the production
of PS in the cell. Thus, when grown in medium containing galactose, CHO1
transcribed and translated into protein, allowing the production of PS.
Alternatively, when in the presence of glucose, CHO1 is shut off, halting the
production of PS.
In order to visualize changes in PS localization as a result of the above
experimentation, we utilized two fluorescent, PS-specific probes GFP-Lact-C2
and mCherry-Lact-C2. Fluorescent molecules GFP and mCherry were fused to
the C2 domain of Lactadherin, a bovine protein that binds specifically to PS, to
create useful PS-specific probes (Fairn, et al. 2011a, Fairn, et al. 2011b).
Together with the repressible production of Cho1p (PGAL1-CHO1), these tools in
theory should allow not only control of PS production, but also visualization of PS
overtime. However, we found that the PGAL1-CHO1 strain was leaky, and even
when grown in the presence of glucose, produced a small amount of PS. This
concentration, though low, was still enough to support growth and show
localization of PS, which precluded our ability to obtain total CHO1 shut off.
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As a result, we began efforts to utilize a new method using a plant system
of controlled protein degradation. This system is a naturally occurring process in
plants where the plant hormone auxin induces the degradation of anything
bearing a particular sequence. Recently, this auxin-based degradation has been
developed into a tool to control the proteolysis of specified proteins in other
systems like yeast (Nishimura, et al. 2009). We wished to utilize this system to
control degradation of Cho1p in yeast. Although final results were never obtained
showing auxin-repressible degradation of Cho1p, strains were developed within
this study, allowing this system to be usable in the future.
Last, because PS has been shown to be important for virulence of some
fungi (Chen, et al. 2010, Vale-Silva, et al. 2016), we wished to utilize these tools
in C. albicans and C. glabrata, but as a result of cloning and expression issues,
were unable to adapt these techniques for the pathogenic fungi. Findings from
our experiments, although incomplete, are excellent beginning steps in
developing a greater understanding of PS dynamics.

Materials and Methods
Strains Used
Wild-type Σ S. cerevisiae (TRY181) and the cho1Δ deletion mutant (BMY2),
which is unable to produce PS, were used. These strains contain auxotrophies
for uracil and histidine (Table A2.1). All other strains were produced as described
below. Details on particular strains can be found in Table A2.1.
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Table A2. 1. Strains Produced or Used in this Study
Strain
Σ (TRY
181)

Organism

Genotype

Source

S. cerevisiae ura3Δ his3Δ

Lab Strain

BMY2

S. cerevisiae ura3Δ his3Δ cho1 Δ

Lab Strain

RF01

S. cerevisiae ura3Δ his3Δ pGFP-Lact-C2

This study

RF04

This study

RF09

S. cerevisiae ura3Δ his3Δ cho1Δ pGFP-Lact-C2
ura3Δ his3Δ pGPD416-mCherryS. cerevisiae Lact-C2

RF10

ura3Δ his3Δ cho1 Δ pGPD416S. cerevisiae mCherry-Lact-C2

This study
This study

RF18

ura3Δ his3Δ pGPD416-mCherryS. cerevisiae Lact-C2 pRS426GFP-2×PH(PLCδ)
ura3Δ his3Δ cho1Δ pGPD416mCherry-Lact-C2 pRS426GFPS. cerevisiae 2×PH(PLCδ)

RF25

ura3Δ his3Δ cho1Δ::PGAL1-CHO1
S. cerevisiae G418R

This study

RF26

ura3Δ his3Δ cho1Δ::PGAL1-CHO1
S. cerevisiae G418R pGFP-Lact-C2

This study

RF21

This study
This study

CDCS67

MATaura3-1::ADH1-AtTIR19Myc(URA3) ade2-1 his3-11, 15
S. cerevisiae leu2-3, 112 trp1-1 can1-100
MATaura3-1::ADH1-AtTIR19Myc(URA3) ade2-1 his3-11, 15
leu2-3, 112 trp1-1 can1-100
S. cerevisiae cho1::CHO1-Deg-KanR

MG1655

E. coli

CDCS12

E. coli

LactC2-GFP-AmpR

This study

CDCS16

E. coli

AmpR

This study

Cg 27

C. glabrata

ura3Δ his3Δ leu2Δ tryp1Δ

Lab Strain

C. glabrata

ura3Δ his3Δ leu2Δ tryp1Δ pGFPLact-C2

This study

BY25594

RF29

From
Minetaka
Sugiyama

This study
Gift from
Fozo Lab
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Table A2. 2. Continued.
Strain
SC5314
(Ca157)

Organism

Genotype

Source

C. albicans

Ca159

C. albicans

cho1ΔΔ

Lab Strain
Chen et
al., 2010

CDCS18

C. albicans

PENO1::PENO1-GFP-Lact-C2-SAT1

This study

CDCS24

C. albicans

cho1ΔΔ PENO1::PENO1-GFP-LactC2-SAT1

This study
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Strain Production
We used a standard lithium acetate transformation method to construct the S.
cerevisiae strains in this study (Gietz and Woods 2002). All strain and plasmid
information can be found in Tables A2.1 and A2.2, respectively. Transformation
of GFP-Lact-C2 into WT and cho1Δ S. cerevisiae: GFP-Lact-C2 (pGFP-Lact-C2)
was transformed into wild-type and cho1Δ using the URA3 marker to produce
ura3Δ his3Δ pGFP-Lact-C2 and ura3Δ his3Δ cho1Δ pGFP-Lact-C2, respectively.
Transformation of mCherry-Lact-C2 into WT and cho1Δ S. cerevisiae: mCherryLact-C2 (pGPD416-mCherry-Lact-C2) was transformed into wild-type and cho1Δ
using the URA3 marker to produce ura3Δ his3Δ pGPD416-mCherry-Lact-C2 and
ura3Δ his3Δ cho1Δ pGPD416-mCherry-Lact-C2, respectively. Transformation of
GFP-2x Ph(PLCδ) into ura3Δ his3Δ pGPD416-mCherry-Lact-C2and ura3Δ his3Δ
cho1Δ pGPD416-mCherry-Lact-C2S. cerevisiae: The GFP-2xPh(PLCδ) was cut
from pRS426GFP-2×PH(PLCδ) and ligated into pRS423 to produce pRF1 (Table
A2.2). pRS426GFP-2×PH(PLCδ) (pRF1) was transformed into ura3Δ his3Δ
pGPD416-mCherry-Lact-C2 and ura3Δ his3Δ cho1Δ pGPD416-mCherry-LactC2using the HIS3 marker to produce ura3Δ his3Δ pGPD416-mCherry-Lact-C2
pRS426GFP-2×PH(PLCδ) and ura3Δ his3Δ cho1Δ pGPD416-mCherry-Lact-C2
pRS426GFP-2×PH(PLCδ), respectively. Transformation of PGAL1 into WT and

cho1Δ S. cerevisiae: PGAL1 was amplified from p73 with primers adapted from
(Longtine, et al. 1998) (CCO49 and CCO50) containing overhangs of the native
CHO1 promoter. The PCR product was transformed into wild-type and cho1Δ
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Table A2. 3. Plasmids Used in this Study
Plasmid
p200 (pGFPLact-C2)

GFP-Lact-C2, URA3, Cen/Ars, AmpR

pBS34

mCherry, URA3, AmpR

Source
Yeung et al.,
2008
Shaner et al.,
2004

pGPD416mCherryLact-C2

mCherry-Lact-C2, URA3, AmpR

Fairn et al.,
2011

pRS423

HIS3, AmpR

Lab Strain

pRS426GFP2×PH(PLCδ)

GFP-2x Ph(PLCδ), URA3, AmpR

Addgene
plasmid #
36092

pRF1

GFP-2x Ph(PLCδ), HIS3, AmpR

This study

p73

Inserts

R

PGAL1, G418 , Amp
R

R

R

Lab Strain

EBp42
BYP 6740
(Pmk43)
BYP 6742
(Pmk76)

NAT , Amp

URA3, AmpR

Lab Strain
Nishimura et
al., 2009
Nishimura et
al., 2009

pCDC2

eGFP-Lact-C2, NATR, AmpR

This study

pRI1

ApR

Fozo Lab,
Opdyke et al.,
2006

pCDC5

GFP-Lact-C2, AmpR

This study

pRS423
pUC57

HIS3, AmpR

Lab Strain
Lab Strain

pCDC4

GFP-Lact-C2, NATR, AmpR

This study

pCDC2

eGFP-Lact-C2, NATR, AmpR

This study

AmpR, KAN
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using the G418/Kanamycin resistance marker to produce ura3Δ his3Δ
cho1Δ::PGAL1-CHO1 G418/KanR. Primer sequences can be found in Table A2.3.
Transformation

of

GFP-Lact-C2

into

ura3Δ

his3Δ

cho1Δ::PGAL1-CHO1

G418/KanR S. cerevisiae: GFP-Lact-C2 (pGFP-Lact-C2) was transformed into
ura3Δ his3Δ cho1Δ::PGAL1-CHO1 G418/KanR using the URA3 marker to produce
ura3Δ his3Δ cho1Δ::PGAL1-CHO1 G418/KanR GFP-Lact-C2. Cloning of AuxinRepressible Degron System: For inserting the “degron sequence” at the Cterminus of ScCHO1, we adapted the primers from (Nishimura, et al. 2009). First
we made CCO120 and CCO121 based on pYM3/6_F and pYM3/6_R with
overhangs matching the ScCHO1 gene just before the stop codon and just after
the stop codon, respectively. However, because we had no success with these
oligonucleotides, we ordered a second reverse primer to replace CCO121, called
CCO143. This primer in combination with CCO120 resulted in a band ~2.4 Kb in
length when used in PCR of BYP 6740 (Pmk43) (plasmid from Minetaka
Sugiyama). This PCR product was then transformed into BY25594 (from
Minetaka Sugiyama). Correct orientation of the insertion was confirmed using
CCO108 in combination with either CCO144 (3.3 Kb band) or CCO145 (2.1 Kb
band). Sequencing to confirm the correct sequence insertion was performed
using CCO140.
The strain already contained the E3 ligase with a uracil marker (BYP 6742
(Pmk76)), but to include the GFP-Lact-C2 probe, we had to move GFP-Lact-C2
into a plasmid with an alternative marker (pGFP-Lact-C2 contains a uracil marker
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Table A2. 4. Primers Used in this Study
Primer

Sequence

Source

CCO49

AAGAGAGATACACCTATTTTTTTCA Adapted from
TTTTGTGGGTGATTGTCATTTTTAG Longtine et al.,
GAATTCGAGCTCGTTTAAAC
1998

CCO50

TCCGTGTGTGGGAATTCTTGAGGT
GCGAAATCTTCATCTGATTCAACC
ATTTTCATTTTGAGATCCGGGTTTT

Adapted from
Longtine et al.,
1998

TTATCCATGGGTGTGGAATGATTTC
GAAGAGCTTGAAAATTCCAAAGCCA
AGCTTCGTACGCTGCAGGTCG
AAAAGTTATATGTACAAATTTTTTTT
GACGCCAGGCATGAACAAAAACTA
GGTAAGATCTCTTGAATGATCGTTC
CACTTTTTAGC
AAAAGTTATATGTACAAATTTTTTTT
GACGCCAGGCATGAACAAAAACTA
CGAGTCAGTGAGCGAGGAAGC
ATGGTTGAATCAGATGAA
GAATGTCGTGTGAAGCTG
GTGAGAACTGTATCCTAGC
CAGCTGGCAAGAATTGAG
AAAAgcggccgcCCTAACAGCCCAGC
AGC
AAAAgagctcATGGTGAGCAAGGGCG
GGAATATTACAACCATGGCTGATCC
ATGTCTAAAGGTG
TACAATCATGACTGATCCATGTCTA
AAGGTG

Adapted from
Nishimura et al.,
2009

CCO120

CCO121
CCO143
CCO108
CCO144
CCO145
CCO140
CCO147
CCO148
CCO32
CCO33

Adapted from
Nishimura et al.,
2009
This study
This study
This study
This study
This study
This study
This study
This study
This study
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(parent plasmid is pRS416)). Thus, we selected pRS423 which contains a HIS3
marker. pRS423 was digested with NotI-HF and SacI, then purified. GFP-Lact-C2
was amplified from pGFP-Lact-C2 using CCO147 which contained a NotI cut site
3’ of the GFP sequence and CCO148 which contained a SacI cut site 5’ of the
Lact-C2 sequence.

Candida glabrata
C. glabrata was transformed with pGFP-Lact-C2 using the same lithium acetate
transformation method as S. cerevisiae. The produced strain, RF29 can be found
in Table A2.1 and the plasmid in Table A2.2.

Candida albicans
Because of the special CTG codon usage in C. albicans, we could not utilize the
same plasmids for S. cerevisiae or C. glabrata. After several attempts to perform
multiple tandem site-directed mutagenesis procedures we used Genescript to
synthesize the plasmid pCDC6 which contains a codon-optimized GFP-Lact-C2
in pUC57. Unfortunately, no fluorescence was seen upon transformation into C.
albicans, and thus a new GFP gene (eGFP) was used. The present GFP gene
was removed from pCDC4 using NcoI and SspI. eGFP was amplified using
CCO32 which contained a 3’ SspI cut site and CCO33 which contained a BspHI
cut site (matched up with NcoI cut site), producing pCDC2. This plasmid was
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digested in the promoter and transformed into both wild-type (CDCS18) and
cho1ΔΔ (CDCS24).

Escherichia coli
E. coli strain MG1655 was used for this study. GFP-Lact-C2 was amplified from
pGFP-Lact-C2 using primers TRO 938 and TRO939 which contain EcoRI and
HinDIII cut sites respectively. pRI plasmid was then digested using EcoRI and
HinDIII and gel purified. The digested GFP-Lact-C2 fragment was ligated into
plasmid pRI to produce pCDC5. This plasmid and the empty vector were
transformed simultaneously into chemically competent MG1655 to produce
CDCS12 and CDCS16, respectively.
For the transformation, MG1655 was streaked on an LB plate and
inoculated in 3 ml of LB overnight at 37°C, shaking. The following morning the
cells were diluted 1:500 in LB and shaken at 37°C until the OD 600 reached
approximately 0.4 to 0.6 (~3 hours). The cells were pelleted at 3600 rpm at 4°C
for 10 minutes. Pellets were resuspended in water and spun again. The pellet
was then resuspended in 800 μl of ice cold water then spun down at 13,000 rpm
at 4°C for 3 minutes. The supernatant was aspirated and then the pellet was
resuspended in 100 μl of ice cold water. Gene Pulse cuvettes were placed on
ice, then 40-50 μl of the cells were mixed with 1.5 μl of the ligation or with 0.5 – 1
μl of pRI empty vector. The cuvettes were electroporated at 25 μF with a
resistance of 200 Ω and a voltage of 2.5 V. The cuvettes were then immediately
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placed on ice and 500 μl of SOC medium was added to rescue for 1 hour at 37°C
shaking. After the rescue, cells were plated on LB-Ampicillin plates and
incubated at 37°C overnight.

Fluorescent Microscopy
To confirm the successful transformation of fluorescent probes into our yeast
strains, overnight cultures were diluted back to 0.1 or 0.2 OD600 and allowed to
grow for 2-4 hours shaking at 30°C or until early log phase was reached. Cells
were then imaged via fluorescent microscopy (Leica). For quantification of
localized, partially localized, and diffuse GFP-Lact-C2, 80 total frames were
assessed. The percentages of each category in each frame was calculated and
then averaged with the rest of the frames for both galactose- and glucose-grown
strains. All images were analyzed using Leica Application Suite 4.4.

Serial Dilution Plating
To test the effectiveness of our repressible promoter, ura3Δ his3Δ cho1Δ::PGAL1CHO1 G418/KanR were grown overnight, then diluted to 0.1, 0.2, 4 x 10 -3, 8 x 10, and 1.6 x 10-6 OD600. 10 μl aliquots were spotted onto minimal medium agar

4

plates supplemented with galactose or glucose, +/- 1 mM ethanolamine. Plates
were incubated at 30°C then viewed the following day for growth.
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Lipid Extraction and Thin Layer Chromatography
The ura3Δ his3Δ cho1Δ::PGAL1-CHO1 G418/KanR strain was grown in 5 ml
minimal medium supplemented with either glucose or galactose overnight,
shaking at 30°C. Lipids were extracted using a standard hot ethanol extraction
(Hanson and Lester 1980). Isolated lipids and lipid standards (Avanti) were
spotted on thin layer chromatography plates (Millipore) and separated with
chloroform:ethanol:water:trimethylamine (35:30:7:35) solvent system (Chen, et
al. 2010). Lipids were imaged using primulin dye and UV-light exposure.

Lyso PS Uptake Experiment
The Lyso-PS protocols from (Maeda, et al. 2013, Moser von Filseck, et al. 2015)
were adapted for this experiment. Overnight cultures of cho1Δ pGFP-Lact-C2
were either used directly (stationary phase study) or diluted to 0.1 and allowed to
grow for 2 hours (log phase study). Cells were washed with cold water, followed
by lyso-PS (Avanti) addition and a 10 minute incubation on ice. Tubes were then
incubated at 30˚C and at select time points a 10 μL sample of cells was removed
and mounted onto slides. For some experiments where time was constraining,
Prolong Gold (Life Technologies) was used to preserve samples until microscopy
could be performed. Stationary phase time points: 0, 15, 30, and 60 minutes. Log
phase time points: 0, 1, 2, and 3 hours.
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Compound Treatment
The ura3Δ his3Δ pGFP-Lact-C2 and ura3Δ his3Δ cho1Δ pGFP-Lact-C2 strains
were used to test the effects of Papuamide-A (Pap-A) (Flintbox), SB-224289
(Tocris), and Staurosporine (CGP 41251) (SelleckChem) on PS localization.
Overnight cultures were diluted to 0.2 OD600 and allowed to grow for 3-4 hours.
Cultures were then diluted to 0.1 OD600 and 200 μL of the ura3Δ his3Δ pGFPLact-C2 were either treated with 50 μg/mL Pap-A, 4.5μg/mL staurosporine, 250
μM SB-224289, or the solvent (water:methanol (2:1)) for Pap-A and DMSO for
SB-224289 and staurosporine) as negative controls. ura3Δ his3Δ cho1Δ pGFPLact-C2 was used as a positive control for PS mislocalization. All samples were
then incubated at 30˚C for 1 hour and 20 minutes followed by fluorescent
microscopy. A second trial was performed with a decreased concentration of SB224289 (100 μM) and cell plating for viability.

Results
Phosphatidylserine is produced in the endoplasmic reticulum in yeast and can
either be trafficked to the plasma membrane or the mitochondria where it is used
to produce phosphatidylethanolamine (PE). Some studies have provided a
greater understanding of PS trafficking to these areas; however, the duration of
PS at the plasma membrane is currently unknown. In this work, we undertook
experimentation to determine the length of time that PS remains at the
membrane in the model yeast Saccharomyces cerevisiae.
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In order to perform these studies, we began by creating strains harboring
GFP-Lact-C2 (Yeung, et al. 2008). GFP-Lact-C2 binds to PS in the cell and emits
a green fluorescence, allowing us to visualize PS localization within cells.

GFP-Lact-C2 (pGFP-Lact-C2) in wild-type and cho1Δ S. cerevisiae
Figure A2.1A shows micrographs of wildtype and cho1Δ S. cerevisiae lab strains
carrying pGFP-Lact-C2. GFP-Lact-C2 localizes to the membrane in wild-tyep
where PS is enriched. In cho1Δ, which has no PS, GFP-Lact-C2 is diffuse
throughout the cell.

mCherry-Lact-C2 (pGPD416-mCherry-Lact-C2) in wild-type and cho1Δ S.
cerevisiae
We further wanted to determine if the probe bound to the fluorophore mCherry
might offer even clearer signal. Figure A2.1B shows micrographs of of wildtype
and cho1Δ S. cerevisiae lab strains carrying pGPD416-mCherry-Lact-C2 grown
to log phase. As was shown with GFP-Lact-C2, we see localization of mCherryLact-C2 at the membrane in wild-type whereas diffuse signal in cho1Δ. However,
although overall we saw diffusion in cho1Δ, we did see some cells with slight
localization at the membrane, which was not ideal and prompted us to focus on
GFP-Lact-C2 as our fluorescent probe for PS-localization.
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Figure A2. 1. Localization of PS in Wildtype and cho1Δ Yeast
Fluorescent microscopy of (A) wild-type and cho1Δ carrying pGFP-Lact-C2 and
(B) pGPD416-mCherry-Lact-C2. Images were taken during log phase of growth.
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GFP-2x Ph(PLCδ) (pRS426GFP-2×PH(PLCδ)) in wild-type and cho1Δ S.
cerevisiae
In order to better create a distinction between membrane-bound and diffuse
GFP-Lact-C2 probe (i.e. PS localization), we wished to incorporate a second,
plasma membrane positive marker. The Plekstrin homology domain (PH domain)
is a domain of approximately 120 amino acids that binds to PI4,5P2 in the
membrane of S. cerevisiae (Lemmon 2007). We hypothesized that localization of
the PH domain fused with GFP (GFP-2x Ph(PLCδ)) to PI4,5P2 could be used as
a positive marker for the plasma membrane. This, combined with mCherry-LactC2 would allow us to monitor the precise location of PS in the cell.
Under this model, mCherry-Lact-C2 and GFP-2x Ph(PLCδ) would overlap
(forming a yellow signal) in the wild-type organism. In the cho1Δ, the membrane
would be green (GFP-2x Ph(PLCδ)) and the cytoplasm would appear red (diffuse
mCherry-Lact-C2 signal) as a result of absence of PS. We further hypothesized
that, should this tool be useful, we could add a third component to control PS
production (place CHO1 under a repressible promoter). Thus, PS should start out
located at the membrane, but upon the shut off of PS production via our
repressible promoter, it should visibly diffuse into the cytoplasm. Resulting
overlay images of the red and green fluorescence under normal conditions
should show a yellow color around the membrane. When the expression of
CHO1 is turned off, there should be a separation of colors as the red begins to
diffuse into the cytoplasm, while the green stays at the membrane.
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pRS426GFP-2×PH(PLCδ) was transformed into wildtype and cho1Δ S.
cerevisiae already carrying pGPD416-mCherry-Lact-C2. As expected, in wildtype
there is localization of the fluorescence under both green and red fluorescence
(Fig A2.2). In addition cho1Δ displayed green fluorescence (GFP-2x Ph(PLCδ))
localized at the plasma membrane. When under the red fluorescence, the
mCherry-Lact-C2 signal is diffuse throughout the cell. However, the results were
inconsistent throughout experiments with some showing localization of mCherryLact-C2 in cho1Δ, and still others showing low mCherry-Lact-C2 signal all
together (Fig A2.2). As a result, we began to focus efforts on the use of GFPLact-C2 alone.

Transformation of PGAL1, G418R, AmpR (p73) into WT S. cerevisiae
Next, in order to study the length of time that PS remains at the membrane, we
wished to create a strain where the PS synthase gene (CHO1) was under a
repressible promoter. We engineered the strain cho1Δ::PGAL1-CHO1 which allows
PS production when the strain is grown in galactose medium, and inhibits PS
production when the strain is grown in glucose (Eckert and Muhlschlegel 2009,
Longtine, et al. 1998).
We performed two experiments to validate cho1Δ::PGAL1-CHO1. First, the
strain was grown on minimal medium with: 1) histidine and uracil to account for
the auxotrophies of the parent strain, 2) galactose or glucose to either repress or
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Figure A2. 2. Localization of PS and PI4,5P2 in Wild-type
and cho1Δ Yeast
Fluorescent microscopy of (A) and (B) cho1Δ and (C) wild-type
S. cerevisiae with the PH domain GFP and Lact-C2 mCherry
under red and green fluorescence in stationary phase.
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allow PS production, and 3) +/- 1 mM ethanolamine to account for any
auxotrophy produced by PS decreases (Chen, et al. 2010).
As shown in Figure A2.3, in the presence of galactose, PGAL1 is turned on,
allowing expression of CHO1 and hence the production of PS (Fig. A2.3A). In the
presence of glucose PGAL1 is shut off, turning off expression of CHO1 and
preventing PS from being made (Fig. A2.3B). Addition of ethanolamine allows for
production of PE in the absence of PS via the alternative Kennedy Pathway
(Cassilly, et al. 2017, Chen, et al. 2010), and allows growth (Fig. A2.3D).
However, in the presence of glucose without ethanolamine, the organism should
be unable to grow. Unfortunately, though there is a decrease in growth, the fact
that the organism is still able to grow (Fig. A2.3C) is an indication that there is an
incomplete shut off of PGAL1. In this case, we hypothesize that some PS is still
being produced via leaky repression of CHO1 to the extent that PE can be made
in the absence of PS.
In order to confirm our suspicions of an incomplete shut-off of CHO1, we
isolated lipids from strains grown in all conditions mentioned above. We then
performed thin layer chromatography to qualitatively measure PS levels within
each condition. As shown in Figure A2.4, PS is present in cho1Δ::PGAL1-CHO1
grown in galactose and wild-type negative control, because the CHO1 gene is
being expressed. Inversely, there is no PS in cho1Δ positive control. However, as
suggested by the growth of glucose-grown cho1Δ::PGAL1-CHO1 in Figure A2.4,
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Figure A2. 3. Phenotype of the cho1Δ::PGAL1CHO1 on Solid Medium
Serial dilutions of the cho1Δ::PGAL1-CHO1 strain
in medium supplemented with (A) galactose
(Gal) and (B) 1 mM ethanolamine (Etn) or (C)
glucose (Glu) and (D) 1 mM ethanolamine.
Results show decreased growth on medium +
Glu without Etn where both de novo and
Kennedy PE synthesis are inhibited.
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Figure A2. 4. cho1Δ::PGAL1-CHO1 TLC
cho1Δ::PGAL1-CHO1 shows decreased,
but not complete loss of, PS in presence
of glucose as compared to strain grown
in galactose, wild-type, and the cho1Δ
negative control. These results indicate
an incomplete shut off of the CHO1
gene.
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there is some PS in the strain grown in glucose, further displaying the incomplete
shut off of PGAL1.
Despite these data, we were interested in performing microscopy in an
effort to identify any GFP-Lact-C2 localization differences in this strain. We
inserted

GFP-Lact-C2

within

cho1Δ::PGAL1-CHO1.

We

then

performed

microscopy to determine the influence of growth in glucose or galactose on PS
localization. Figure A2.5A shows cho1Δ::PGAL1-CHO1 carrying pGFP-Lact-C2
grown in galactose. As expected, GFP-Lact-C2 localized around the cell
membrane. Figure A2.5B, cho1Δ::PGAL1-CHO1 carrying pGFP-Lact-C2 is grown
in glucose, shutting off PGAL1, and hence repressing the expression of the CHO1
gene. PS is not being produced, so the GFP-Lact-C2 is diffuse in the cytoplasm.
Unfortunately, these results were not consistent and we met with high
variability when viewing the cells under the fluorescent microscope. As shown in
Figure A2.5C, three localization signatures were seen: 1) distinct localization with
the PS localized mainly at the membrane, 2) diffuse with no signs of fluorescence
at the membrane, and 3) partial localization with some fluorescence diffuse and
localized at the membrane. This further indicated that PGAL1 produced an
incomplete shutoff of CHO1 and that PS was still being produced to some extent
in some cells.
To quantify these findings, we counted the cells falling into the three
signature fluorescence types. Figure A2.5D shows the quantification of 80 frames
of fluorescing cells (n=1669 fluorescing cells). Localized, partially localized, and
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Figure A2. 5. Localization of PS in cho1Δ::PGAL1-CHO1::GFP-Lact-C2 S.
cerevisiae
(A) Shows the cho1Δ::PGAL1-CHO1::GFP-Lact-C2 S. cerevisiae grown in
galactose medium, with localized PS at the membrane. (B) shows the strain
grown in glucose and the diffusion of Lact-C2-GFP into the cytoplasm. (C)
Examples of cells localized, partially localized, and diffuse. (D) Quantification of
GFP-Lact-C2 localization reveals that shut off of Cho1p (i.e. cells grown in
glucose) causes quantitative decreases in plasma membrane localization of the
probe, but that the result is not consistent. Galactose grown cells showed less
growth and weaker fluorescence due to the nature of the galactose carbon
source compared to glucose. Localized, partially localized, and diffuse
fluorescing cells are calculated as a percent of total cells counted. n = 1669
fluorescing cells.
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diffuse fluorescing cells were calculated as percentages of each frame, then
averaged to produce an overall percentage. Although there is a significant
increase in the mislocalization when the strain is grown in glucose, the frames
are not completely uniform, and the variability was judged as too high to continue
these experiments. Additionally, since galactose is not as preferable of a carbon
source as glucose, the cells showed less growth, and also a weaker fluorescence
signal.

Exogenous Addition of Lyso PS
Previous studies found that addition of lyso-PS (PS with one fatty acid chain) to
cho1Δ strain which produces no PS caused the cells to uptake the lyso-PS and
recycle it in the cell as PS. The lyso PS is converted to PS and transferred to the
membrane from the ER (Maeda, et al. 2013, Moser von Filseck, et al. 2015). We
wished to reproduce this result by adding lyso-PS to cho1Δ carrying pGFP-LactC2. Then we monitored the movement of PS through the cell over a time course
via fluorescent microscopy. We added lyso PS to cultures for 10 minutes at room
temperature to allow for uptake. Tubes were then placed in the 30˚C water bath
to allow for trafficking within the cells.
Under the green fluorescence, the cells showed diffuse GFP-Lact-C2
signal for the 0 and 15 minute time points (Fig A2.6). We hypothesize that lysoPS is taken up here, and in the process of being repackaged in the ER. The cells
began to show localization around the 30 minute time point where they have
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Figure A2. 6. Time Course of PS Localization in cho1Δ Upon Addition of
Lyso PS
cho1Δ S. cerevisiae carrying pGFP-Lact-C2 shows a plasma membrane
localization of PS within 30 minutes of incubation at 37°C.
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likely sent re-modeled PS to the plasma membrane. At 60 minutes, the PS is
more localized at the membrane. It remains localized at 120 and 180 minute time
points, though some of the signal begins to diffuse back in to the cytoplasm.

Compound Experiment
After having engineered the wildtype and cho1Δ carrying pGFP-Lact-C2 strains,
we were interested in using this tool (GFP-Lact-C2) to determine effects of
membrane-perturbing agents on PS localization. Papuamide-A, SB-224289, and
staurosporine were chosen because previous experiments have been performed
that indicate that these compounds either disrupt PS trafficking or plasma
membrane structure in Candida albicans (Andjelic, et al. 2008, Cassilly, et al.
2016, Cho, et al. 2013b, Cho, et al. 2012, Selkirk, et al. 1998a). Papuamide-A is
a compound that binds to PS in the plasma membrane and causes cell lysis and
death (Andjelic, et al. 2008, Cassilly, et al. 2016, Chen, et al. 2010).
Staurosporine blocks endosomal sorting and recycling of PS, and hence inhibits
the trafficking of PS to the membrane (Cho, et al. 2013b, Cho, et al. 2012). SB224289 is 5-HT1B receptor antagonist that has been shown to cause trafficking
problems in S. cerevisiae, and likely promotes massive endocytosis (Chapter 2
and 3) (Cassilly, et al. 2016, Selkirk, et al. 1998a).
To test the effects of these compounds on PS localization, we treated log
phase wild-type carrying pGFP-Lact-C2 with varying concentrations of each
compound and examined the GFP-Lact-C2 probe signal via fluorescent
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microscopy. All data was compared to an untreated control and cho1Δ (Fig
A2.7A). As shown in Figure A2.7C, when wild-type was treated with Pap-A,
accumulation of fluorescence inside the cells was observed, as well as a
decrease in cell size, indicating the process of cell death (compare to Fig A2.7B).
This was further demonstrated by plating the treated cell sample on solid
medium. Samples treated with Pap-A were not viable, whereas untreated cells
grew. When treated with staurosporine, which is supposed inhibit the trafficking
of PS to the membrane, PS was seen trapped in punctuate spots within the
cytoplasm (Fig A2.7E, compare with Fig A2.7D). Last, cells treated with SB224289 showed accumulation of GFP-Lact-C2 in the cytoplasm, and a decrease
in signal at the membrane (Fig A2.7G, H, compare with Fig A2.7F). Viability
plating of staurosporine and SB-224289-treated cells indicated no signs of cell
toxicity via a fungicidal mechanism.

Efforts to Adapt PS Trafficking Tools in Other Microbes
Because of the usefulness of these tools developed in S. cerevisiae, we wished
to move them into other systems, including pathogenic fungi (C. albicans and C.
glabrata) and bacteria (E. coli).
In C. albicans, we inserted the GFP-Lact-C2 gene into an ENO1 locus of
wild-type and cho1ΔΔ as described in materials and methods. Although
fluorescent signal was observed in both strains (Fig A2.8C and D), there seemed
to be a great deal of unexpected localization of GFP-Lact-C2 at the membrane in
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Figure A2. 7. Effect of Membrane-Perturbing Agents on Cells
(A) cho1Δ carrying pGFP-Lact-C2 control while (B) wild-type carrying pGFP-LactC2 untreated with a methanol:water solution, and (C) treated with 50 μg/mL PapA. (D) wild-type carrying pGFP-Lact-C2 treated with DMSO, while (E) shows the
strain treated with 4.5 μg/mL Staurosporine. (F) wild-type untreated with DMSO,
while (G) the strain treated with SB-224289 at 250 μM or (H) 100 μM.
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Figure A2. 8. Localization of PS E. coli and C.
albicans
Fluorescent microscopy of (A) empty vector (B)
GFP-Lact-C2 in E. coli. Fluorescence exposure =
3.5 sec and (C) cho1ΔΔ and (D) wild-type C.
albicans expressing GFP-Lact-C2.
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cho1ΔΔ. Because this strain produces no PS, this result was attributed to a high
concentration of GFP-Lact-C2 within the cells that may show localization or
accumulation as an artifact.
For C. glabrata, a strain bearing GFP-Lact-C2 was produced, however,
efforts to produce a cho1ΔΔ strain were not successful and thus abandoned.
Last, for E. coli, we also expressed GFP-Lact-C2 in a common lab strain.
However, because of the high concentration of the probe within the cells, high
auto-fluorescence in our empty vector control, as well as poor resolution on
microscopes available to us, no distinction or localization could be determined
and this project was discontinued (Fig A2.8A and B).

Discussion
In this project, we have introduced PS specific probes, GFP-Lact-C2 and
mCherry-Lact-C2 into wild-type and cho1Δ strains of S. cerevisiae. In both
instances, we observed probe localization to the membrane in wild-type cells
where PS is enriched. Alternatively, in cho1Δ strains, we saw diffuse signal as
PS is not present in these strains.
After introducing the mCherry-Lact-C2 probe into S. cerevisiae, we
decided utilize a second probe for another phospholipid, PI4,5P2, as a
membrane specific probe. We hypothesized that this would allow us to monitor
the movement of PS through the cell based on a separation of colors in
overlapped pictures of the two probes under either red or green fluorescence.
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The localization at the membrane under the green fluorescence demonstrated
the localization of GFP-PH-Domain bound to the membrane, while the low signal
under the red fluorescence demonstrates the diffusion of the mCherry-Lact-C2
probe into the cytoplasm. Upon the introduction of GFP-PH-domain, we found
inconsistencies in the cells when viewed under red fluorescence. Most of the
cells that showed clear localization around the membrane under the green
fluorescence showed low or undetectable signal under the red fluorescence. The
mCherry-Lact-C2 probe was diffuse in the cho1Δ, because PS is not being
produced. Although the cells might have shown diffuse red fluorescence as
predicted, the signal was bleached soon after the fluorescence was switched to
the red color. This would have presented a challenge in performing time-lapse
experiments with the two colors, because if the pictures are overlapped and the
mCherry-Lact-C2 does not fluoresce as brightly as the PH domain-GFP, we
would not be able to sufficiently observe a separation of colors. As a result,
although elegant in theory, this project proved insufficient for our purposes.
We next focused efforts on controlling PS synthesis in vivo. We utilized
the PGAL1 promoter which represses PGAL1 in the presence of glucose,
suppressing the PGAL1-CHO1 gene in our construct. We expected no growth on
minimal medium as a result of ethanolamine auxotrophy, but found that the strain
grown in glucose (i.e. PGAL1-CHO1 repressed) was able to grow, though at a
lesser degree than the strain grown in galactose (i.e. PGAL1-CHO1 expressed).
This finding was further supported by thin layer chromatography where PS was
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still present in the repressed strain, though at a lower degree. These findings
indicated that PGAL1-CHO1 was not fully repressed in our experiments, despite
what has been previously reported about PGAL1 providing a very tight shut off in
S. cerevisiae (Longtine, et al. 1998), thus confounding our efforts to control PS
production.
Despite this issue, we still wanted to determine if repressing PGAL1-CHO1
—albeit incompletely—might have an effect on PS localization intracellularly. We
transformed the GFP-Lact-C2 probe into the PGAL1 strain, then viewed it under a
fluorescent microscope. We saw an increase in mislocalization when the strain
was grown in glucose (i.e. PGAL1-CHO1 repressed), showing more diffuse signal
than when grown in galactose (i.e. PGAL1-CHO1 expressed). However, some
frames showed cells with localized GFP-Lact-C2 signal in cho1Δ, while some
showed more diffuse signal. In addition, there were many cells that showed
partial localization, indicating that some PS was still being made within the
population of cells. This inconsistency precluded our ability to fully take
advantage of these tools for controlling PS production. Thus, due to the
incomplete shutoff, the cho1Δ::PGAL1-CHO1 strain was deemed insufficient for
the time-lapse experiments in monitoring the trafficking of PS and its duration at
the plasma membrane.
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Lyso PS Experiment
Because of the issues with cho1Δ::PGAL1-CHO1, we decided to utilize the strains
produced in this study to determine the effects of specific treatments on probe
localization. First, we treated cho1Δ carrying pGFP-Lact-C2 with lyso-PS to
monitor the movement of PS into the cells. Results of these time course
experiments showed that at 30 minutes, PS localization around the plasma
membrane could be observed, because the lyso PS was being converted into
PS, and hence was being transported from the rough ER to the plasma
membrane. Once at the plasma membrane, the PS remained there until the 180
minutes, but eventually began to diffuse back into the cytoplasm. Although this
experiment showed that PS remains at the membrane for at relatively lengthy
period of time, it is not representative of the biological process whereby PS is
produced within cells. This experiment depends on the cell taking up extracellular
lyso-PS from the medium and using it to form PS, instead of producing PS in the
ER and trafficking it to the membrane. Experiments to assess PS production
within the cell using fluorescent, click-tagged serine analogs are underway in
collaborator Michael Best’s laboratory and, if successful, will reflect a more
accurate view of PS trafficking and dynamics.

Compound Experiments
Furthermore, we chose to test the effects of membrane-perturbing agents on
GFP-Lact-C2 localization. In Figure A2.7, cells treated with Pap-A, the PS248

specific toxin, showed signs of cell death with PS accumulating in the cytoplasm
in conjunction with loss of cell viability. Cells treated with staurosporine also had
an expected accumulation of PS in punctuate dots in the cytoplasm, although
cells remained viable when plated. Cells treated with SB-224289 at both 250 μM
and 100 μM, showed a similar accumulation of PS in the cytoplasm with no
concomitant loss of viability. Although the true mechanism of action of SB224289 is not currently known, SB-224289 likely causes a disruption in PS
trafficking by inducing large-scale endocytosis of the plasma membrane.
Last, based on the usefulness of the tools developed in this study, we
wished to translate them into other relevant systems including C. albicans, C.
glabrata, and E. coli. However, though strains containing GFP-Lact-C2 were
produced in each of these studies, difficulties were encountered for each,
prohibiting our ability to utilize these tools in secondary systems.
These findings, while not conclusive for our initial experimental goals,
provide some evidence that PS remains at the membrane for a relatively long
period (~180 minutes). In addition, although several difficulties were encountered
in these studies, several strains of excellent quality and importance were
produced that will be of great use in future studies on PS trafficking and
membrane dynamics.
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APPENDIX III
EXTRACT FROM SAMANEA SAMAN LEAF EXTRACT INHIBITS
THE TOXICITY OF MARINE DEPSIPEPTIDE PAPUAMIDE A
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Introduction
As reported previously (Cassilly, et al. 2016), a high-throughput screening
approach has been developed to identify compounds that affect the PSaccessibility of a PS-binding toxin called Papuamide-A (Pap-A). Pap-A is isolated
from sea sponges (Theonella spp.) and is known to lyse membranes containing
PS (Andjelic, et al. 2008, Parsons, et al. 2006, Uzair, et al. 2011). Thus, Pap-A is
toxic to wild-type C. albicans, but is non-toxic to a Cho1p mutant (cho1∆∆)
(Cassilly, et al. 2016). Our screening approach utilized Pap-A as a filter which
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would sort compounds by their ability to protect wild-type C. albicans from a toxic
dose of Pap-A. We hypothesized that compounds which inhibit PS synthesis or
PS availability at the plasma membrane, would render Pap-A unable to bind and
lyse the membranes of those cells, allowing survival of the organism in the
presence of Pap-A. Compounds that cause this trait would then be possible hits
for antifungal drug development.
It is a well known phenomenon that plants have natural antifungal
defenses (Cho, et al. 2013a). We thought it likely that some plants could produce
compounds which might inhibit the fungal Cho1p or affect PS distribution. We
screened 23,585 plant extract fractions (Natural Products Library from the
University of Mississippi) for their ability to abrogate the toxic effects of Pap-A
and identified one plant extract from the Rain Tree that we further characterized.
The fractions of this extract did not show signs of inhibiting Cho1p, however, we
identified that this extract has potent ability to inhibit the toxic effects of Pap-A.

Materials and Methods
Strains Used
All strains used in this study can be found in (Chen, et al. 2010). The wild-type
strain from which all mutants were made is SC5314 (Gillum, et al. 1984). This
study included both cho1∆∆ (YLC337) and cho1∆∆::CHO1 (YLC344) (Chen, et
al. 2010). YPD (1% Bacto yeast extract, 2% Bacto peptone, and 2% dextrose
(Thermo Fisher Scientific, San Jose, CA)) and minimal medium (0.67% Bacto257

yeast nitrogen base (without amino acids) 2% dextrose) were used to culture all
strains as indicated (Guthrie 2002) .

Papuamide A resistance assay
This assay was performed as previously described in (Cassilly, et al. 2016) in a
96-well plate format. Cultures were grown overnight, shaking, at 30°C and diluted
to 2 x 104 cells/ml in YPD. Plant extract fractions were diluted to twice the desired
μg/ml concentration in a volume of 37.5 μl of YPD. Then 37.5 μl of the previously
diluted cell suspension was added, diluting the final concentration of both cells
and plant extract by half. Plates were incubated at 37°C for 6 hours, then 75 μl of
YPD containing depsipeptide (Pap-A at 8 μg/ml) was added to each well, again
diluting this concentration by half. Plates were incubated overnight at 37°C.
The next day Alamar Blue (Invitrogen, Waltham, MA) was added at a
1:10 dilution and plates were incubated at 37°C for 30 minutes to 2 hours until
color change was visible. Fluorescence was then read at excitation 550 nm and
emission 590 nm on a Cytation3 BioTek plate reader using Gen 5 software.

High throughput screen for Pap-A resistance
23,585 compounds from the Natural Products Library from the University of
Mississippi were screened in a total of 93 384-well plates (Nunc). Using a
BioMek robot with pin tools, 0.173 μl of plant extract fractions at varying
concentrations were inoculated into 10 μl of YPD in each well (excluding columns
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1, 2, and 13) from stock plates. Wild-type and cho1∆∆ (positive control strain)
were grown in liquid YPD in a 30°C shaker overnight and diluted to 10 4 cells/ml in
YPD. 10 μl of wild-type were added to each well of the 384 well plates containing
the test compound using a Wellmate, except column 2 where 10 μl of cho1∆∆
was added. Plates were incubated for 6 hours at 37°C, and then 10 μl of YPD
containing 21 μg/ml Pap-A was added to give a final concentration of 7 μg/ml in
30 μl of YPD. Plates were then incubated for another 16 hours at 37°C to allow
selection for Pap-A resistance. The next day, cell survival was measured by
adding 10 μl of Alamar Blue (Invitrogen, Waltham, MA) at a 1:3 dilution using a
Wellmate. Plates were allowed to incubate again at 37°C for 1 hour. Plates
were sealed, then fluorescence was then read at excitation 550 nm and emission
590 nm on an EnVision plate reader (Perkin Elmer, Waltham, MA). In each
plate, three of the columns of wells were used as controls. Column one contained
50 μM SB-224289 as a positive control (Cassilly, et al. 2016). Column two
contained cho1ΔΔ plus Pap-A, as a second positive control. Column 13 was a
negative control containing wild-type cells with no compounds in the presence of
Pap-A.

Phosphatidylserine Synthase Assay
This procedure was amended from (Bae-Lee and Carman 1984, Matsuo, et al.
2007) as described previously in (Cassilly, et al. 2017, Cassilly, et al. 2016).
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Fractions of S. saman plant extract were added to the reaction mixture at varying
concentrations to test their ability to inhibit [ 3H]-PS production.

Ethanolamine Auxotrophy Assay
Wild-type and cho1∆∆ cultures were grown in YPD overnight shaking at 30°C.
The next day, cultures were washed with water and diluted to 2x10 4 cells/ml in
minimal medium containing 50 mM HEPES buffer. 50 μl of cell suspensions were
added to wells of a 96-well plate (Costar). Plant extract fractions were diluted into
minimal medium containing 50 mM HEPES buffer either with or without 1 mM
ethanolamine (one plate contained ethanolamine, the second did not), and 50 μl
were added to the wells, diluting the concentration to a final of 25 μg/ml. Wildtype with no fraction added served as the negative control and cho1∆∆ served as
the positive control. Plates were incubated at 37°C overnight. The next day,
Alamar Blue (Invitrogen) was added at a 1:10 dilution and plates were incubated
for another 2 hours. Following this incubation, fluorescence was read at
excitation 550 nm and emission 590 nm on a Cytation3 BioTek plate reader
using Gen 5 software.

β 1,3-glucan Unmasking Microscopy
β 1,3-glucan unmasking immunofluorescence experiments were performed as
described in (Davis, et al. 2014a). Wild-type and cho1∆∆ cultures were grown in
YPD overnight shaking at 30°C. The following day the cells were diluted to an
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OD600 of 0.1 and Fraction 2-1 or DMSO for a negative control was added to a
100 μg/ml concentration. This was incubated at 30°C shaking for 1 hour and then
cells were washed with 1X PBS. Cells were then pelleted and washed in 3% BSA
rocking for 1 hour at room temperature. Cells were pelleted and then incubated
with 1:800 anti-(1-3)-glucan antibody (Biosupplies Australia) and incubated on ice
for 1.5 hours. Afterwards, cells were washed with 1X PBS at least 3 times before
1:600 goat anti-mouse antibody conjugated to Cy3 (Jackson ImmunoResearch)
was added in 5% BSA. This was allowed to incubate for 20 minutes on ice before
washing again with 1X PBS at least 3 times. Cells were resuspended in 1X PBS,
added to a slide, and imaged on a fluorescent microscope at an exposure of 1
ms.

GFP-Lact-C2 Microscopy
Wild-type and cho1∆∆ strains expressing GFP-Lact-C2 were grown in YPD
overnight shaking at 30°C. The next day, cultures were diluted to 0.2 OD 600 in
YPD and allowed to grow shaking at 30°C for another 3 hours. Following this
incubation, cultures were diluted again to 0.1 OD600 in 1X PBS and 100 μg/ml
concentration of plant extract fraction 2-1 or DMSO negative control and
incubated again shaking at 30°C for 1 hour. Cells were then pelleted,
resuspended in a small volume of PBS, placed on a glass slide, and imaged via
fluorescent microscopy.
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Solid Phase Extraction
C18 Reverse Phase SPE was peformed to remove tannins and polyphenols, and
separate the extract into three fractions. First the fraction was applied to the C18
column and deionized water was passed through to create the first fraction.
Second 50% methanol was passed through to produce a second fraction. And
last 100% methanol was passed through the column to create the third fraction.

Statistical analysis
Graphs were made using GraphPad Prism version 6.04. Unpaired t-tests were
used to determine significance between results. RISE (Robust Investigation of
Screening Experiments) software was used to analyze data from the high
throughput screen and was used to calculate Z’-scores, identify 95th and 99th
quantile data, and identify compounds that yielded hits of greater than 90% of
positive control (cho1∆∆).

Results
We screened 23,585 plant extract fractions (Natural Products Library from the
University of Mississippi) for their ability to abrogate the toxic effects of Pap-A
(Fig. A3.1) (Tu, et al. 2010). From this screen, we identified 79 initial hits, which
is a 0.3% hit rate with hits considered as fractions that allow greater that 60% of
the growth of the positive control (cho1∆∆). We then performed a dose-response
assay to determine both the effective concentration range of the compounds, as
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Figure A3. 1. Natural Products Library Screened Against Papuamide-A
23,585 natural product fractions were screened for their ability to protect wildtype C. albicans (open black circles) against 7 μg/ml Pap-A. Fluorescence was
measured as a proxy of growth using Alamar Blue over approximately 1 hour at
37˚C. The untreated cho1∆∆ positive control’s growth in the presence of Pap-A
is represented by green circles. Natural product fractions that allowed wild-type
cells to display >60% (above the blue line) of the growth of cho1∆∆ control are
shown in blue circles. Around 95% of the tested natural products allowed growth
at levels closer to the negative control wells, which contained untreated wild-type
cells with Pap-A (open red circles). Horizontal lines indicate the 99th quantile
(purple) where 99% of the natural product fractions fell, and the 95th quantile
(yellow) where 95% of the natural product fractions lie. Vertical lines divide the
natural product fractions based on the 384-well plate in which they were
screened which correlate to plate numbers along the bottom. A full description of
the screening method can be found in the Materials and Methods.
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well as the reproducible hits (data not shown). From this dose-response, we
identified two compounds that reproducibly conferred Pap-A resistance to wildtype C. albicans, one from the bark extract of the white oak tree Quercus alba
and the second from leaf extract of the rain tree Samanea saman. The Q. alba
extract fraction showed an average of 42.3% survival (when compared to
cho1∆∆) in the presence of Pap-A at a concentration of 18.03 μg/ml (Table A3.1).
The S. saman extract fraction showed an average of 102% survival (when
compared to cho1∆∆) in the presence of Pap-A at a concentration of 41.55 μg/ml
(Table A3.1).
There have been several papers published that characterized the white
oak tree (Keller, et al. 2004, Walters, et al. 2001), whereas the rain tree is an
understudied plant (Staples 2006). This, in addition to the fact that the rain tree
extract showed higher levels of protection against Pap-A (Table A3.1), directed
us to focus our studies on the rain tree extract. As plant extracts are complex
mixtures of many compounds (Tu, et al. 2010), our goal was to identify which
compound(s) within this mixture were responsible for the marked Pap-A
protection.
Fractionation of S. saman Crude Leaf Extract
We obtained crude S. saman leaf extract from the University of Mississippi
and performed C18 Reverse Phase SPE: hydrophobic separation to remove
tannins and polyphenols, and separate the extract into three fractions. The first
fraction (F1) was all compounds dissolved in deionized water, the second (F2) in
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Table A3. 1. Two Natural Products Show Reproducible Resistance to Pap-A
Plate

Well

Final Conc
(ug/ml)
% Growth

Source

80004

A18

41.55

111

Samanea|saman|Fabaceae|LeaF|135

80005

A18

41.55

102

Samanea|saman|Fabaceae|LeaF|135

80006

A18

41.55

96

Samanea|saman|Fabaceae|LeaF|135

80004

B09

18.03

32

Quercus|alba|Fagaceae|BarK|139.7

80005

B09

18.03

83

Quercus|alba|Fagaceae|BarK|139.7

80006

B09

18.03

12

Quercus|alba|Fagaceae|BarK|139.7
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Figure A3. 2. Fraction F2 Retains the Highest Concentration of the
Bioactive Component
Cells were treated with three fractions of S. saman plant extract for 6 hours and
then treated with a lethal dose (4 μg/ml) of Pap-A. Protection is seen in all
fractions at the highest concentration (50 μg/ml). However, as the concentration
of the extract decreases to 3.125 μg/ml, the only fraction still able to protect wildtype cells from Pap-A is F2, indicating that the bioactive concentrates to this
fraction.
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50% methanol, and the third (F3) was 100% methanol. With these three
fractions, we performed our Pap-A assay again to determine which fraction
retained the Pap-A protective activity. This assay revealed that, while all of the
fractions seem to show some Pap-A protection at high concentrations (50 μg/ml)
Fraction F2 retained the Pap-A protective activity even at the lowest
concentrations tested (Fig. A3.2).
Our next step was to further fractionate F2 via high-performance liquid
chromatography (HPLC). For this experiment we used a C18 reverse phase
column to separate the fraction based on hydrophobicity. This separated F2 into
seven different portions (F2-1 through F2-7). These seven fractions were then
again tested for their ability to provide Pap-A resistance in order to allow us to
narrow the activity to one. Figure A3.3 shows that at the highest concentrations
of the fractions tested, we see Pap-A protection in all but F2-6 and F2-7.
However, as the concentration was decreased to 6.25 μg/ml, the Pap-A
protection activity dropped off to include only F2-1. This indicates that the
particular compound of interest was present in most fractions in residual
amounts, but seemed to be most concentrated in F2-1.

S. saman Leaf Extract Fractions Do Not Inhibit Cho1p
We were interested in determining if any of the fractions generated could inhibit
Cho1p in an in vitro PS synthase assay (Bae-Lee and Carman 1984, Cassilly, et
al. 2016, Matsuo, et al. 2007). We performed this assay first with the original
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Figure A3. 3. Fraction F2-2 Retains the Highest Concentration of the
Bioactive Component
Cells were treated with all fractions of S. saman plant extract fraction F2 for 6
hours and then treated with a lethal dose (4 μg/ml) of Pap-A. Protection is seen
in all fractions of F2 aside from F2-6 and F2-7 at the highest concentration (400
μg/ml). However, as the concentration of the extract decreases to 6.25 μg/ml, the
only fraction still able to protect wild-type cells from Pap-A is F2-1, indicating that
the bioactive concentrates to this fraction.
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Figure A3. 4. No S. saman Fractions Inhibit the PS Synthase
(A) An in vitro PS synthase assay was performed with 100 μg/ml concentrations
of each plant extract fraction. Activity is represented as counts per minute per
milligram of protein, quantifying the incorporation of 3H-l-serine incorporated into
PS. No inhibitory activity is seen when compared with the DMSO negative control
and the cho1ΔΔ positive control. (B) Ethanolamine auxotrophy tests were
performed to assess the ability of the plant extract fraction to inhibit Cho1p in
vivo. Cells were treated with 25 μg/ml concentration of the plant extracts and
then grown in minimal medium either without or with 1 mM ethanolamine. None
of the fractions produce ethanolamine auxotrophy in the wildtype when compared
with the cho1 ΔΔ positive control.
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three fractions provided by SPE (F1 and F3) and the seven fractions of F2 at a
100 μg/ml concentration of each extract fraction, well over the effective
concentrations shown in our assays. We found that no fraction showed a
statistically significant decrease in PS synthase activity when compared with a
non-treated control (Fig. A3.4A). Additionally, we wished to determine if the
fractions would inhibit Cho1p in vivo. To do this, we used a common trait shown
by the cho1∆∆ mutant, ethanolamine auxotrophy. Because PS is a precursor for
the biosynthesis of phosphatidylethanolamine (PE), a vital phospholipid, when
Cho1p is deleted—or as we suspect, inhibited—the organism will become an
ethanolamine auxotroph and can only grow if the medium is supplemented with
exogenous ethanolamine (Chen, et al. 2010). As a result, we used this trait to
test whether any of the S. saman fractions caused wild-type C. albicans to
become an ethanolamine auxotroph. We expected to see no growth in minimal
medium containing no ethanolamine if the fractions inhibited Cho1p, and a return
of growth in medium containing ethanolamine (indicating that the organism can
uptake the ethanolamine and circumvent the need for PS to make PE). As in our
in vitro assay, we found that no S. saman fractions caused the wild-type
organism to become an ethanolamine auxotroph (Fig. A3.4B).
Last, we wish to determine if Fraction F2-1 produced a disruption in the
cell wall organization, or PS localization, both of which might indicate a disruption
in PS production or localization (Davis, et al. 2014a). Wild-type cells were treated
with Fraction F2-1 at a 100 μg/ml concentration and tested for increased β (1,3)270

Figure A3. 5. S. saman Fraction 2-1 Does Not Cause B-1,3
Glucan Exposure or Disruption of PS Localization
(A) Microscopy was performed by treating wild-type and cho1 ΔΔ
cells with DMSO or 100 μg/ml of Fraction F2-1. Cells were then
washed and incubated with primary antibody for B-1,3, glucan.
Then treated with secondary antibody Cy3 for imaging as an
indication of disrupted cell wall structure. (B) Wild-type and cho1
ΔΔ cells expressing the GFP-Lact-C2 probe were treated with
DMSO or 100 μg/ml of Fraction F2-1 then assessed via
microscopy for mislocalization of the probe, indicating PS
mislocalization.
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glucan unmasking and GFP-Lact-C2 mislocalization as compared to a cho1ΔΔ
positive control. Under no circumstances did we see increased β (1,3)-glucan
unmasking or a changed in the localization of GFP-Lact-C2, indicating that
Fraction F2-1 does not inhibit PS production or cause a change in cell wall
organization as we originally hypothesized (Fig. A3.5). These results were
unexpected based on the reproducible Pap-A protection that Fraction F2-1
provides to wild-type C. albicans. We expect that it is likely that Pap-A and
molecules within Fraction F2-1 are interacting, causing Pap-A to be ineffective as
a toxin against C. albicans. As we previously published for the compound SB224289, a serotonin receptor antagonist that showed similar activity to Fraction
F2-1, this could be potentially useful for applications where toxins, like Pap-A,
need to be neutralized, but work should be continued to confirm these
predictions.
Despite the unexpected results, we decided to continue in the fractionation
of this extract in order to characterize some of the molecules that are found
within the rain tree leaf. HPLC was performed by collaborators at St. Jude,
however, HPLC fractionation failed to identify a discrete component responsible
for the observed activity.
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APPENDIX IV
CANDIDA ALBICANS PHOSPHATIDYLSERINE SYNTHASE
PURIFICATION FOR CRYSTALLIZATION
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Introduction
We were interested in using the data obtained in Chapter 4 to inform our search
for PS synthase inhibitors. We utilized the protein model produced using
Molecular Operating Environment (MOE) software (Fig. 4.6), to perform a
computational drug screen. The screen was performed using MOE, docking
compounds within the proposed active site. From this screen of 500 National
Cancer Institute diversity drug subset (https://cactus.nci.nih.gov/ncidb2.2/)
defining a hit based on the highest (or more negative) free energy. Following this
screen, we identified 57 possible PS synthase inhibitors. However, unfortunately
because of the loose specificity of the screen, this high number of hits was
unable to be screened via our complex and time-consuming PS synthase
secondary screen.
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The work in this appendix aimed to determine the structure of the
phosphatidylserine (PS) synthase enzyme within Candida albicans. As described
in the Introduction, there is a dire need for new antifungals as a result of rising
cases of fungal infections over the last several decades. This is mostly because
of the increasing number of people living in an immunocompromised state
(Mishra, et al. 2007) due to anti-cancer chemotherapeutics, diabetes, and HIV.
Nearly all the antifungal drugs used to treat life-threatening Candida infections
target a component of plasma membrane or lipid biosynthesis. The PS synthase,
Cho1p, plays an important role in this crucial process in C. albicans and
represents a novel target.
Thus, we aimed to determine the 3-dimensional structure of this protein
via protein crystallography methodology. This work is one of the first key steps
towards rational drug design to inhibit Cho1p, as well as provide greater
understanding of enzymes involved in phospholipid biosynthesis.

Methods and Materials
Strains
Genomic DNA was isolated from wildtype C. albicans SC5314 and wildtype S.
cerevisiae Σ (TRY181). Strains were grown using YPD media.
For expression studies, S. cerevisiae strain BJS21 was used (Becker Lab)
or for a vector control, BJ2164. These strains were grown in either YPD or Media
Lacking Tryptophan (MLT) for transformation selection.
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MOE Docking Computational Screen
The homology model from Chapter 4 was used in MOE. First the NCI Diversity
subset of 500 compounds (https://cactus.nci.nih.gov/ncidb2.2/) was downloaded
into MOE. Compounds were docked systematically based on entropy (rigidity in
binding) and enthalpy (ability to make H-bonds). The parameters “S” and
“LONDON” were used within MOE to assess free energy. Those compounds with
the most negative free energy were selected as hits. This work was done with the
assistance of the Baudry Lab on computer “Napoleon.” More information about
computational screens and compound docking can be found (Baudry, et al.
2003)

and

on

the

MOE

tutorials

(https://www.chemcomp.com/MOE-

Molecular_Operating_Environment.htm).
.
Genetics
In order to tag CaCHO1 and ScCHO1, we utilized the plasmid pBEC2 (7.8
Kb) which contained STE2 gene with a 3X FLAG and 6x His tag after a PGDP1
which is a high expressing promoter. This plasmid also contained TRP1 for use
in strains with tryptophan auxotrophy. This plasmid was digested with AatII and
HpaII to release a 400 bp fragment of STE2. The plasmid was then CIP treated
for 3 hr to remove phosphates at the end of the fragment. The fragment was then
gel extracted (Qiagen) to purify the digested plasmid from the STE2 fragment.
Next, using primer CCO74 which has 30 bp homology with PGDP1 and 20
bp homology with CaCHO1 beginning, and CCO75 which has 30 bp homology
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with the 3X FLAG tag and 20 bp homology with CaCHO1 end, we amplified
CaCHO1 which was approximately 800 bp in size. This fragment and the purified
plasmid (~7.5 Kb) were ligated in vivo when transformed together into S.
cerevisiae strain BJS21 using the LiOAc transformation procedure described in
(Gietz and Woods 2002). Transformants were selected on media lacking
tryptophan (MLT) for strains capable of growing in the absence of tryptophan.
Plasmids were then isolated from 6 transformants using the ZYMO yeast
plasmid extraction kit according to the manufacturer’s protocol. Isolated plasmids
were then transformed into DH5-α E. coli using ampicillin selection. Following
transformation, the plasmids were miniprepped (Qiagen) and then sequenced
using F1424GDP (Becker Lab) primer with homology to pBEC2. The resulting
plasmid was called pCDC13.
In order to address the CTG-codon issue between S. cerevisiae and C.
albicans, site-directed mutagenesis primers were produced, CCO78 and CCO79.
SDM was performed as described in Chapter 4 to make the mutation L246S.
Because CCO78 and CCO79 were not successful (there were repeats
introduced because the sequences contained a highly repetitive sequence in the
gene) new primers were made, CCO84 and CCO87. Further, a spurious
mutation was identified as T162. Because of the sensitivity of the project and the
importance of each amino acid, primers CCO113 and CCO114 were ordered to
correct the spurious mutation to T162A (correct sequence matches to CHO1
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allele A in the Candida Genome Database). The resulting plasmid, pCDC16, was
transformed into BJS21 to produce CDCS43.
For tagging ScCHO1, we performed a PCR to amplify ScCHO1using
primer CCO85 and CCO86 with the result of an 800 bp PCR product. In vivo
ligation of this PCR product and the cut plasmid pBEC2 (from above) was
performed in BJS21 using tryptophan auxotrophy. 6 transformants were selected
and plasmids were isolated, transformed into E. coli, miniprepped, and then
sequenced using F1424GDP (Becker Lab) primer. Mutations (particularly
premature stop codons) were present and thus a new reverse primer was
created, CCO98, and used. This new primer produced correct plasmids, although
the selected plasmid contained a spurious mutation, L236. Because of the
sensitivity of the project and the importance of each amino acid, primers CCO115
and CCO116 were ordered to correct the spurious mutation to L236F. Once
successful, the plasmid became known as pCDC20 and the strain CDCS47.
Site directed mutagenesis of all spurious mutations and hypothesized
phosphorylation sites was performed as described in Chapter 4. To produce the
S46AS47A mutation in ScCHO1, we produced primers CCO124 and CCO125.
For the S46DS47D in ScCHO1, we produced primers CCO126 and CCO127. For
the S43AS44A mutation in CaCHO1, we produced primers CCO132 and
CCO133. Last, for the S43DS44D mutation in CaCHO1, we produced primers
CCO134 and CCO135. One plasmid was produced, pCDC26, containing
ScCHO1S46S47D-FLAGx3-Hisx6.
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Last, a vector control strain was made containing the empty vector,
p424GDP which contained Ampicillin resistance and TRP1. p424GDP was
transformed into BJS21 to produce CDCS40. For primer, plasmid, and strain
lists, see Tables A4.1, A4.2, and A4.3, respectively.

Western Blots
Protein was isolated from CDCS43 as described in Chapter 4 and a western blot
was performed using BJS21 as a positive control and wildtype C. albicans as a
negative control. For detection, a rat anti-FLAG primary antibody (637301
BioLegend) was used, followed by a goat anti-rat secondary antibody (926-68076
LI-COR). The western blot showed adequate expression of CaCho1p-Flagx3Hisx6 and ScCho1p-Flagx3-Hisx6.

Phosphatase Treatment
Protein samples were treated with phosphatase as follows. 40 μg of protein was
treated with 1 μl. of λ-phosphatase, 3 μl. of phosphatase buffer, 3 μl. of Mn buffer
in a total volume of 30 μl. Samples were incubated at 30 C for 1 hour. Following
incubation, 1 μl of Laemmli Dye was added to each tube and the entire reaction
was boiled and loaded on an SDS PAGE. The western blot was then performed
as described above and in Chapter 4.
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Table A4. 1. Primers Used in this Study
Primer
CCO74
CDC75
F1424GDP
CCO78
CCO79
CCO84
CCO87
CCO115
CCO116
CCO85
CCO86
CCO98
CCO113
CCO114
CCO124
CCO125
CCO126
CCO127
CCO132
CCO133
CCO134
CCO135

Sequence
gtcttttttttagttttaaaacaccaagaacttagtttcgaCGGATCTAGAACAT
GTCAGACTCATCAGCT
GCTGCTGCCGCTGCCGCGCGGCACACCGGTCTTGTCAT
CGTCGTCCTTGTAGTCTGGTTTAGGAATTTTTAAAGAT

Source
This
study
This
study
Becker
Lab
GTATATAAAGACGGTAGGTATTG
This
GGAATAGTTTTCCAAGATACTTCATTTGAATTCCATTTGG study
This
CCAAATGGAATTCAAATGAAGTATCTTGGAAAACTATTCC study
GACAACTTACCATTTGGAATAGTTTTCCAAGATACTTCAT This
TTGAATTCCATTTGGTCACAATAG
study
CTATTGTGACCAAATGGAATTCAAATGAAGTATCTTGGAA This
AACTATTCCAAATGGTAAGTTGTC
study
This
GTGTCAGAAAGGGTTTCATTtTTGATAACATCCCATTCGG study
CCGAATGGGATGTTATCAAaAATGAAACCCTTTCTGACA
This
C
study
gtcttttttttagttttaaaacaccaagaacttagtttcgaCGGATCTAGAACAT This
GGTTGAATCAGATGAA
study
GCTGCTGCCGCTGCCGCGCGGCACACCGGTCTTGTCAT This
study
CGTCGTCCTTGTAGTCGAGCTTGAAAATTCCAAAGCCA
GCTGCTGCCGCTGCCGCGCGGCACACCGGTCTTGTCAT This
study
CGTCGTCCTTGTAGTCTGGCTTTGGAATTTTCAAG
This
GGGTATCTCCAGCAACAATTgCCTTTGCTATTGGATTCAG study
CTGAATCCAATAGCAAAGGCAATTGTTGCTGGAGATACC This
C
study
GAAGTTGGTGGCACATTAAGCAGAAGAGCCgCAgcTATA
This
TTTTCTATAAATACAACTCCATTGG
study
CCAATGGAGTTGTATTTATAGAAAATATAGCTGCGGCTC
This
TTCTGCTTAATGTGCCACCAACTTC
study
GAAGTTGGTGGCACATTAAGCAGAAGAGCCgatgaTATAT This
TTTCTATAAATACAACTCCATTGG
study
CCAATGGAGTTGTATTTATAGAAAATATATCATCGGCTCT This
TCTGCTTAATGTGCCACCAACTTC
study
GCCAACCCACCTTTATTGAGAAGATCAgCTgCATTATTCT This
CCTTATCCTCGAAAGATGACTTG
study
CAAGTCATCTTTCGAGGATAAGGAGAATAATGCAGCTGA This
TCTTCTCAATAAAGGTGGGTTGGC
study
GCCAACCCACCTTTATTGAGAAGATCAgaTgatTTATTCTC This
CTTATCCTCGAAAGATGACTTG
study
CAAGTCATCTTTCGAGGATAAGGAGAATAAATCATCTGA
This
TCTTCTCAATAAAGGTGGGTTGGC
study
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Table A4. 2. Plasmids Used in this Study
Plasmid
pBEC2
p424GDP
pCDC13

Inserts
Ste2p-FLAGx3-Hisx6, TRP1, Cen/Ars,
Amp
Amp, TRP1
CaCHO1-FLAGx3-Hisx6, TRP1, Cen/Ars,
Amp

pCDC20

CHO1L246S-FLAGx3-Hisx6, TRP1,
Cen/Ars, Amp
ScCHO1-FLAGx3-Hisx6, TRP1, Cen/Ars,
Amp

pCDC26

ScCHO1S46S47D-FLAGx3-Hisx6, TRP1,
Cen/Ars, Amp

pCDC16

Source
Becker Lab
Becker Lab
This study
This study
This study
This study
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Table A4. 3. Strains Used or Produced in this Study
Strain

Organism

Σ (TRY 181) S. cerevisiae
SC5314
(Ca157)

Genotype
ura3Δ his3Δ

Source
Lab Strain

C. albicans

Lab Strain

Ca159

C. albicans

BJ2168

S. cerevisiae

BJS21

S. cerevisiae

CDCS40

S. cerevisiae

cho1ΔΔ
MATa, prc1-407 prb1-1122
pep4-3 leu2 trp1 ura3-52
MATa, prc1-407 prb1-1122
pep4-3 leu2 trp1 ura3-52
ste2::KanR
MATa, prc1-407 prb1-1122
pep4-3 leu2 trp1 ura3-52
ste2::KanR p424GDP

Chen et al.,
2010

CDCS43

S. cerevisiae

pCDC16

This Study

CDCS47

S. cerevisiae

pCDC20

This Study

Becker Lab
Becker Lab
This Study
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Results
The preliminary steps involved in this project involved generating a “tagged”
version of Cho1p that can be expressed at high volumes and isolated via affinity
chromatography for further purification and characterization. 6xHis tags are ideal
for this because they are easily bound to Nickel columns for high
quality purification (Monk, et al. 2014). In order to do this, we utilized the plasmid
pBEC2 which contained STE2 gene with a triple FLAG tag and 6 His tag after a
PGDP1 which is a high expressing promoter. The resulting plasmid, pCDC16,
contained CaCHO1-Flagx3-Hisx6 under the PGDP1 promoter. This plasmid was
transformed into BJS21 S. cerevisiae to produce CDCS43. Expression of
CaCHO1-Flagx3-Hisx6 was confirmed via western blot (Fig. A4.1).
In addition to CaCHO1, we were interested in tagging ScCHO1 as well to
perform the crystallization of both proteins in tandem. This, we hypothesized,
would provide us with higher chances of success. Thus, we produced the
plasmid pCDC20 which contained ScCHO1-Flagx3-Hisx6 under the PGDP1
promoter. This was transformed into BJs21 to produce the strain CDCS47.
Following this, protein from CDCS47 was isolated and a western blot was
performed to confirm expression using the same parameters as for CDCS43
(Fig. A4.1).
Interestingly, we saw the presence of a doublet band around 34 and 36
KDa in both CaCHO1-Flagx3-Hisx6 and ScCHO1-Flagx3-Hisx6. Previous work
(as described in Chapter 4) demonstrated that Cho1p in S. cerevisiae is
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Figure A4. 1. Expression of CaCho1p-Flagx3-Hisx6 and ScCho1p-Flagx3Hisx6
Western blot analysis using an anti-FLAG antibody shows bands for CaCho1pFlagx3-Hisx6 and ScCho1p-Flagx3-Hisx6 around ~34 KDa. Ste2p-Flagx3Hisx6 is shown as a positive control and either wild-type C. albicans or a
BJS21 strain carrying a vector control plasmid as negative controls. The ladder
along the right side shows the band sizes in KDa.
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phosphorylated by protein kinase C (Choi, et al. 2010, Kinney and Carman
1988). In order to determine if this was the reason for the doublet band we
observed, we treated protein samples with λ-phosphatase. Indeed, we saw a
disappearance of the doublet band in ScCho1p-Flagx3-Hisx6 when treated with
λ-phosphatase (Fig. A4.2A). Unfortunately, these results were inconsistent for
CaCho1p-Flagx3-Hisx6 which showed only a slight disappearance of the band
sometimes and other times protein samples of CaCho1p-Flagx3-Hisx6 untreated
with λ-phosphatase, but incubated at 30°C for 1 hour showed a loss of the
doublet band. This variability may indicate that the phosphorylation of CaCho1pFlagx3-Hisx6 could be very transient (Fig. A4.2B).
Because

having

a

mixed

population

of

phosphorylated

and

unphosphorylated protein could cause serious issues with a crystallization
procedure, we made an effort to identify possible phosphorylation sites in both
CaCHO1 and ScCHO1. Based on previous studies in S. cerevisiae (Choi, et al.
2010), two serine residues were identified as phosphorylation sites, S46 and
S47. Homologous serine residues were identified in CaCHO1, S43 and S44.
Thus, we decided to mutate these residues to alanine and aspartic acid. Alanine
would served to completely abolish the phosphorylation site, while aspartic acid
would be a mimic of a phosphate group. Although SDM procedures were carried
out for all primer combinations in pCDC14 and pCDC20 respectively, due to time
constraint, the project was never completed.
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Figure A4. 2. Phosphatase Treatment of ScCho1p-Flagx3-Hisx6 and
CaCho1p-Flagx3-Hisx6
Protein samples were either 1) treated with λ-phosphatase for 30 minutes at
30°C, 2) incubated without the enzyme for 30 minutes at 30°C, or 3) untreated,
then analyzed via western blot using an anti-FLAG antibody. (A) ScCho1pFlagx3-Hisx6 and (B) CaCho1p-Flagx3-Hisx6. In A) the ~36 KDa band
disappears, leaving only the dephosphorylated 34 KDa band. In B) there is a
slight disappearance of the 36KDa band, but it is not as stark as the difference in
ScCho1p-Flagx3-Hisx6. The ladder along the right side shows the band sizes in
KDa.
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